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9Outline of the thesis
This thesis explores the use of fluorodeoxyglucose (FDG) positron emission 
tomography (PET) in infectious diseases. Early detection of metastatic infection in 
patients with Gram-positive bacteraemia is important as morbidity and mortality 
are higher in the presence of these foci, probably due to incomplete eradication of 
clinically silent foci during initial treatment. Focal infectious disease can be detected 
by computed tomography (CT), magnetic resonance imaging (MRI) and ultrasonog-
raphy. These techniques, however, are less suitable as a screening method when 
clues for specific sites of infection are absent. Scintigraphic imaging allows 
delineation of the localization of foci in all parts of the body, based on functional 
changes of tissues. Since activated inflammatory cells take up large amounts of 
glucose as a result of an increased metabolic rate, FDG-PET/CT represents a 
promising imaging technique in these patients.
Only recently FDG-PET/CT is emerging as a promising imaging technique in 
non-osseous infectious and inflammatory diseases, as an increasing number of 
reports are appearing in literature. In chapter 1, the literature on the use of FDG-PET/
CT in non-osseous infection is reviewed.
In literature complicating infectious foci by either haematogenous or local 
spreading of microorganisms are frequently seen, especially in Staphylococcus 
aureus bacteraemia (SAB) and Streptococcus species bacteraemia (SSB). In chapter 2, 
the extent of the problem, outcome and risk factors of complicating infectious 
disease in Gram-positive bacteraemia in our hospital were studied. 
In chapter 3, the results of a retrospective study on the possible value of FDG-PET/
CT in the detection of metastatic infectious complications are presented. The results 
from this study were promising. Therefore a large prospective observational study 
with a well matched historical control group was performed. It was studied whether 
FDG PET/CT enables early and accurate diagnosis of metastatic infectious 
complications in patients with Gram-positive bacteraemia and risk factors for 
complicating infectious foci and whether detection of metastatic foci influences 
clinical outcome by enabling early and more accurate diagnosis of those foci. 
Results of this study were presented in chapter 4.
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As costs of FDG PET/CT often are a major concern, a cost effectiveness analysis was 
performed alongside the prospective study in chapter 4. All healthcare associated 
costs were collected. Since the incidence of relapse of infection was expected 
to decrease costs, associated with an increase in incidence of clinical relevant 
metastatic foci still might be cost effective. Data are presented in chapter 5.
Due to the design of the prospective study in which the majority of patients had 
a thorough search for metastatic infectious complications we had an unique 
opportunity to update clinical knowledge on metastatic disease in Gram-positive 
bacteraemia. Data on this subject are presented in chapter 6. At the same time it 
was noticed in chapter 4 that significantly less patients in the historical control 
group underwent echocardiographic examination as compared to the prospective 
cohort in which echocardiography was routinely facilitated. In chapter 7, the 
consequences of both echocardiographic regimes were analysed.
In chapter 8, it was explored whether FDG PET/CT  could also be used in the absence 
of neutrophils in the peripheral blood. Fever frequently develops during the 
profound neutropenia induced by intensive chemotherapy, but is not always related 
to infection. The absence of neutrophils might have a negative impact on predictive 
values of FDG PET/CT regarding the detection of metastatic infectious foci. The 
ability of FDG PET/CT  to delineate focal foci of infection or inflammation during 
profound chemotherapy induced neutropenia was studied. 
In Chapter 9, a general discussion and future perspectives are provided. 
Outline of the thesis
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Abstract 
FDG-PET is emerging as a promising imaging technique in non-osseous infectious 
and inflammatory diseases, as an increasing number of reports are appearing in 
literature. In general, sensitivity of  FDG-PET in diagnosing non-osseous infections 
compares favourably to other diagnostic modalities. Lower specificity due to FDG 
accumulation in conditions involving leukocyte activation and malignancy may be 
overcome by implementing FDG-PET in a diagnostic protocol. In fever of unknown 
origin (FUO), FDG-PET appears to be of great advantage as malignancy, inflammation 
and infection can be detected. Studies on SUV ratios, uptake patterns and dynamics 
may be helpful to increase specificity. Image fusion combining PET and CT facilitates 
anatomical localization of increased FDG-uptake and better guiding for further 
diagnostic tests to achieve a final diagnosis. More data on the utility of FDG-PET to 
monitor the response to treatment will be available in near future. Early reports on 
FDG-PET during treatment follow-up in large vessel vasculitis already showed 
promising results. In conclusion, the body of evidence on the utility of FDG-PET in 
non-osseous infection and inflammation is growing and FDG-PET may become one 
of the preferred diagnostic procedures for these diseases.
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Introduction
In clinical practice, the indications for positron emission tomography (PET) with 
F-18-fluorodeoxyglucose (FDG) are rapidly expanding. FDG-PET has become an 
established  diagnostic tool in oncology. Despite modification, FDG still passes the 
cellular membrane via the normal glucose transporters (GLUT) [1,2]. After entering the 
cell, FDG is phosphorylated by hexokinase similar to glucose. FDG-6-phosphate, 
however, is not processed via the glycolytic path way, resulting in intra-cellular 
accumulation. In tumour cells, increased FDG uptake due to  increased expression of 
the insulin-independent GLUT transporters or by increased concentrations of 
hexokinase, is driven by their accelerated metabolic and/or hypoxic state [1,3,4]. 
Similarly, leukocytes, especially granulocytes and macrophages may also show an 
enhanced metabolism upon activation. Granulocytes and macrophages convert their 
energy supply from endogenic glycolysis in resting state to insulin-independent 
excess glucose uptake under various chemotaxic influences [5]. Thus, FDG is not a 
specific tracer for malignant lesions, as uptake depends on accumulation of FDG in 
cells with an increased glucose metabolism. In fact, accumulation of FDG in 
inflammatory and infectious lesions is considered the main source of error of FDG-PET 
in staging cancer patients as inflammation and infection may cause false-positive 
readings [4,6-10]. By exploiting FDG-accumulation in inflammation and infection, 
FDG-PET has entered the field of imaging infectious and inflammatory diseases in the 
past few years [11,12]. 
Although FDG-PET is not specific for cancer or inflammation, an accurate diagnosis is 
feasible by using PET in a strict protocol in which certain patient characteristics and 
other diagnostic modalities such as CT are incorporated [9,10,13]. FDG-PET proved to 
be a valuable tool in reducing diagnostic procedures and identifying patients at risk for 
treatment failure in various malignancies [14,15]. Lack of specificity of FDG-PET is not 
likely to be a major issue in infectious and inflammatory diseases by applying the same 
principles. Furthermore, FDG-PET has several advantages as compared to conventional 
scintigraphic techniques. FDG has low physiological uptake in normal organs (except 
for the brain, heart, kidneys, and bladder) and provides relatively high target to 
background ratios. Low normal organ uptake is best assured by injecting FDG during a 
normoglycaemic, hypo-insulinaemic state created by a 6 hours fasting period [2,16]. 
FDG-PET provides high-resolution, three dimensional images of the whole body. Early 
imaging after one hour  is possible, resulting in early reporting. Furthermore, the 
dosimetry of FDG compares favourably to conventional radiopharmaceuticals.
FDG-PET/CT for imaging of non-osseous infection and inflammation 1
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Although increased glucose metabolism may correlate with structural anatomical 
damage as depicted by conventional radiological techniques, FDG-PET depicts 
functional changes in tissue which may often precede anatomical changes [17]. E.g. 
it may be difficult to detect active disease in scar tissue using conventional 
radiological techniques while one of the strongholds of FDG-PET is the delineation 
of disease activity [18,19]. Co-registration of PET and computed tomography (CT) in 
combined PET-CT scanners, improves the interpretation of the PET findings by 
exact localisation of lesions [20]. 
The relatively high costs and limited availability of FDG-PET may be considered 
drawbacks. However, the number of PET-scanners and especially integrated PET-CT 
scanners is expanding rapidly. Although a PET-procedure as such is relatively expensive, 
this will not be a major issue if FDG-PET proves to be cost-effective by providing a 
high diagnostic yield. An increasing number of reports exploring the use of FDG-PET 
in infectious and inflammatory diseases are appearing in literature. This review will 
focus on the use of PET in non-osseous infectious and inflammatory diseases.
Search of the literature
For the period 1980-2005, the National Library of Medicine (PubMed) was searched 
using the basic search terms for FDG-PET studies as proposed by Mijnhout et al [21]. 
Subsequently, the above string was combined with infection, inflammation, fever of 
unknown origin, or pyrexia of unknown origin. Additional search terms ‘bacteraemia’, 
‘bacterial infection’ were subsequently used, but did not reveal studies not already 
retrieved. A search in the Cochrane database only resulted in reviews focussing on 
the use of PET in various malignant diseases. No studies were found in the current 
controlled trials database.
A total number of 341 publications were retrieved. First, all publications addressing 
other topics than non-osseous infection and inflammation were excluded. The 
remaining publications (n=158) were divided into case reports, reviews and 
editorials (n=85), studies primarily aiming at diagnosing infection and inflammation 
(n=59), and studies not primarily aiming at diagnosing infection and inflammation 
(n=14). Finally, the publications were arranged according to organ system or 
localisation (Table I).
Chapter 1
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FDG-PET in infection of the abdomen and chest
In 1989, Tahara first reported high FDG uptake in a human abdominal abscess [22]. 
Since then, there have been numerous reports about FDG uptake in infection and 
inflammation, many arising from false positive results in studies on use of FDG-PET 
in oncology. 
Several prospective studies on use of FDG-PET in diagnosing  infection have been 
published. In 1998, Sugawara correctly diagnosed various active infections in 10 out 
of 11 patients [11]. Ichiva reported a 92% (23 of 25) sensitivity in a prospective study 
on FDG-PET in detecting various infectious lesions [23]. Okazuni reported pathologic 
FDG uptake in 11 of 39 patients with benign abdominal disease [24]. FDG-PET was 
positive in 6 patients with abdominal abscesses, 2 cases of pancreatitis, 1 pancreatic 
tumour and 2 benign tumours. Increased inflammatory activity resulted in the same 
degree of FDG uptake as malignant lesions.
Overall sensitivity of FDG-PET in detecting localized infections seems to be high. 
Negative predictive values reach 90-100% with regard to the exclusion of localized 
infection. Chacko described 167 FDG-PET scans to evaluate presence of infection in 
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 Table I  Type of infection in 35 trials primarily dealing with infection.
Anatomical site of infection Reference number
Endovascular 12, 17, 25, 32, 42, 50, 56, 59
Respiratory tract 10, 12, 17, 27-32, 59, 81
Skin and soft tissue (CGD, diabetic ulcer, post-
                         operative wound, muscle abscess)
11, 12, 17, 19, 25, 32, 35, 57, 59, 81, 86
Intra abdominal (abscess, liver cysts, cholangitis) 11, 12, 17, 18, 24, 32, 59, 81
Digestive tract 59, 74
Urogenital tract (renal cysts, prostatitis, adnexitis) 26, 32, 81
Central nervous system 60-63
Eye 17, 32
Osseous 11, 12, 17, 25, 32, 59, 81
Animal model (soft tissue, respiratory tract) 36, 85, 87, 88, 89
· References 23, 80  no detailed information about anatomical localisation of infection.
· CGD= chronic granulomatous disease
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175 different anatomic sites [25]. However, most referred to osseous and prosthetic 
joint infection (n=153). In 49 patients with clinically apparent soft tissue infection, 
FDG-PET was able to detect or exclude underlying osteomyelitis with an accuracy of 
92%. FDG-PET also delineated infection in organs, such as kidneys, liver and lungs 
even in the presence of pre-existent anatomical abnormalities. 
FDG-PET in 7 episodes of suspected renal or hepatic cyst infection correctly pointed 
out the infected cysts [26]. A follow-up PET scan showed complete normalisation 
after 6 weeks of treatment and ruled out re-infection in a subsequent episode of 
fever. In a prospective study in 23 patients with echinococcosis, FDG uptake 
discriminated active from inactive lesions. Furthermore, FDG-uptake corresponded 
with lesion activity during treatment and treatment interruption [18]. In chronic 
granulomatous disease (CGD), FDG-PET was compared to CT [19]. In contrast to CT, 
FDG-PET could discriminate between active and inactive lesions. Identification of 
causative infective organisms indicating the need for antibiotic treatment is more 
successful when cultures are taken from active lesions in patients with CGD. Jones 
et al stated that neutrophil activation was the distinguishing factor between 
rejection of lung transplants and infection regarding to FDG uptake [27]. Rejection 
did not lead to increased FDG uptake. This non-invasive and repeatable test could 
reduce the number of transbronchial biopsies required to exclude rejection during 
episodes of breathlessness after lung transplantation.
When underlying patient conditions involve leukocyte activation or malignancy, 
differentiation may be difficult. Several authors tried to differentiate between 
malignant and benign pulmonary masses with FDG-PET [10,28-30]. FDG uptake in 
chest masses did not differ between 79 patients with proven lung cancer and 14 
patients with known active tuberculosis [28]. In case of central lung carcinoma it 
was suggested to treat potential obstructive pneumonia first before FDG-PET was 
performed for staging of malignant disease [31].  Obviously, a known malignancy 
increases the likelihood of masses being malignant. Fifty-four patients with 
pulmonary masses detected on CT scanning or plain chest radiography were 
categorized according to the presence of malignancy in their medical history [10]. 
The positive predictive value for malignancy increased dramatically in case of 
history of primary lung carcinoma. Others tried to improve differentiation between 
malignant and infectious lesions by investigating uptake characteristics. Standardized 
uptake values (SUV) and uptake dynamics using dual time scanning have been 
Chapter 1
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subject of investigation [32]. In contrast to animal models, it has been reported that 
FDG-uptake increases with time in malignant lesions, while uptake in inflammatory 
and infectious conditions decreases due to higher levels of activity of glucose-
6-phosphatase in leukocytes as compared to that in cancer cells [33-36]. Evaluating 
studies applying dual time imaging in a diagnostic protocol should be awaited.
FDG-PET in bloodstream and vascular infections
Secondary metastatic infection complicating bloodstream infections is a well 
known condition, not limited to staphylococcal bacteraemia. Metastatic infection 
should be ruled out when consecutive blood cultures remain positive, treatment 
delay was suspected or clinical improvement does not occur within a certain time 
span [37]. Figure 1 shows an example of spondylodiscitis, complicating a Streptococcus 
pneumoniae bacteraemia. Starting empirical treatment without having a final 
diagnosis may lead to unnecessary prolongation of treatment or recurrence of 
infection when metastatic infection was missed. Especially endovascular infections 
often require prolonged treatment. Endovascular foci were successfully diagnosed 
FDG-PET/CT for imaging of non-osseous infection and inflammation 1
Figure 1  A 68-year-old female with a one week history of chills and fever complaining of 
left sided sight loss and lower back pain. Blood cultures showed growth of Streptococcus 
pneumoniae. FDG-PET correctly showed multiple meta static infectious lesions compatible 
with spondylodiscitis (arrows).
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in several case reports [38-41]. Stumpe et al correctly diagnosed septic thrombo-
phlebitis and septic arteritis correctly [12]. Of great importance, septic aortitis was 
correctly excluded in two patients in whom a mycotic aneurysm was suspected. 
Figure 2 shows an infected vascular graft and infectious lesions in both lungs in the 
course of haemolytic group C streptococci bacteraemia.
 
Myocardial FDG uptake shows variable intra and inter-individual uptake patterns 
among other things depending on blood glucose levels [16]. FDG-PET therefore is 
not likely to become the preferred diagnostic technique to identify infectious 
endocarditis. Focal myocardial FDG uptake however corresponded with echocardi-
ographic localisation of infection in 6 patients with proven endocarditis [42]. 
Although sometimes suggested, acute thrombosis did not lead to increased FDG 
uptake in a retrospective study on 27 patients with proven acute or chronic thrombosis. 
FDG-PET correctly detected septic thrombophlebitis in 9 patients in this study [43]. 
In only two publications, FDG uptake corresponded with acute thrombosis: FDG 
uptake was seen in the right calf in a patient with active lymphoma [44] and jugular 
vein thrombosis was detected while searching for malignancy in another patient 
Chapter 1
Figure 2  A 51-year-old male, admitted with a 5 days history of fever and chills. He under- 
went percutaneous embolectomy and stenting of a 2 year old right sided iliaco-femoral 
arterial graft one month before admission. He developed multiple septic emboli  at his right 
foot, dyspnoea and cough during the first days of admission. Blood cultures showed 
growth of haemolytic group C streptococci. FDG-PET-CT was compatible with both 
infection of the arterial graft (A) and metastatic pulmonary infection (B).
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[45].  On the other hand, FDG could distinguish between tumour and blood thrombosis 
in several other case reports [46-48]. Stumpe et al. also described FDG uptake in 
septic pulmonary embolism [12]. 
FDG uptake in the presence of intravascular devices like pacemaker leads or central 
venous catheters has been described. Figure 3 is an example of an infected 
pacemaker lead. Bhargava described 4 patients with catheter related pronounced 
FDG uptake located at the catheter tip [49]. In 2 patients incidental infection was 
treated. Catheter related infection was suspected in 1 and could not be ruled out in 
the other patient. Infection was not clinically suspected in the remaining 2 patients. 
It was stated that catheter related endovascular injury leading to catheter related 
thrombosis caused intense FDG activity. Catheter related deep vein FDG uptake 
proved to be complicated by septic thrombophlebitis in 6 patients in a preliminary 
report by Miceli et al [50]. At present no studies evaluating sensitivity and specificity 
of catheter related FDG-uptake regarding septic thrombophlebitis are found. Septic 
thrombophlebitis however should be considered. Further data confirming these 
findings should be awaited.
Fatal outcome in vascular graft infection due to massive bleeding is often preceded 
by low grade infection, lacking guiding signs and symptoms. Very little is known on 
success rates of prolonged antibiotic treatment in vascular graft infection. Surgery 
is probably more successful although morbidity and mortality rates are high. 
Stumpe et al. described vascular graft infection in 2 patients correctly identified on 
FDG-PET/CT for imaging of non-osseous infection and inflammation 1
Figure 3  A 17-year-old female with corrected coarctation of the aorta, ventricular septum 
defect and pacemaker dependency was admitted  with recurrent Haemophillus parainfluenzae 
bacteraemia. PET-CT showed irregular FDG-uptake on both the transmission corrected and 
uncorrected images (arrows), compatible with pacemaker lead infection. Transesophageal 
echocardiography did not reveal signs of endocarditis.
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FDG-PET [12]. Of equal importance are the true negative PET scans in 6 patients with 
uninfected vascular grafts in this study. Six earlier reports using combined PET/CT 
imaging also mentioned true positive FDG-PET results in the presence of vascular 
graft infection [32,51-55]. Like FDG uptake on intravascular devices, aseptic 
inflammation in vascular grafts leading to non-pathological FDG uptake is of 
concern. In a recent prospective study, Fukuchi et al presented more evidence on 
the use of FDG-PET in the detection of vascular graft infection [56]. FDG-PET and 
helical CT scanning were performed in 33 consecutive patients with suspected 
arterial graft infection. Clinical follow-up, surgical and microbiological results 
proved graft infection in 11 patients. As expected, sensitivity of FDG-PET was 
significantly higher than that of CT (91 vs. 64%). However, specificity was not 
significantly higher than in CT. A second analysis was performed in which only focal 
and not diffuse FDG uptake was set as the criterion for positivity. Using these 
adjusted criteria for evaluation of FDG-PET results, FDG-PET showed better 
sensitivity and specificity than CT. Positive predictive value increased from 56 to 
91%, as compared to 70% in CT. Also the negative predictive value of FDG-PET 
compared favourable to CT (95 vs 83%). Because many of the false positive PET 
results occurred in patients with recent graft implantation, it is to be expected that 
specificity and positive predictive value are even better after a certain period after 
surgery. 
FDG uptake in physiological wound healing is expected to diminish over time. In 
one study exploring the value of FDG-PET in patients suspected of postoperative 
infections (n=18), sensitivity and specificity of infection imaging in areas outside the 
region of surgical trauma were 86 and 100% [57]. Sensitivity of infection imaging in 
the area the surgical wound was 100%, while specificity was only 56%. The interval 
between surgery and FDG-PET was significantly shorter in patients with false 
positive results (34 vs. 54 days). Further studies on the degree, pattern and duration 
of physiological FDG uptake after surgery is warranted.
Bleeker-Rovers et al. reported 3 patients with Candida lung abscesses following 
candidemia identified on FDG-PET leading to successful prolonged treatment [58]. 
In a large retrospective study on use of FDG-PET in detecting metastatic infectious 
foci, 30 of 40 FDG-PET scans ordered because of suspected infectious metastatic 
foci revealed metastatic complications [17]. Although a median number of 4 imaging 
procedures had been performed before FDG-PET was requested, clinically relevant 
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metastatic foci were first detected by FDG-PET in 18 episodes. FDG-PET appears to 
have a promising role in detecting metastatic infectious foci in patients with high 
level of clinical suspicion. A prospective study is currently ongoing.
FDG-PET in immunocompromised hosts
Mahfouz et al retrospectively studied 248 PET scans ordered in patients with 
multiple myeloma either for staging disease progression or infection work-up [59]. 
In these patients, 165 infections were identified. FDG-PET identified infection even 
in patients with severe neutropenia. In 46 patients, infection was not identified by a 
regular diagnostic work-up. In this study, FDG-PET contributed to patient care in 76 
(46%) of all patients.
In human immunodeficiency virus (HIV) positive patients, intracerebral lesions are 
frequently found in advanced immune deficiency. The differential diagnosis contains 
a great variety of secondary infections and malignancy, especially lymphoma. In 3 
publications dealing with 11 to 18 HIV positive patients diagnosed with cerebral 
masses on CT or MRI, FDG uptake was significantly higher in lymphoma compared to 
infection, most often caused by toxoplasma [60-62]. Thus, FDG-PET can be of great 
value when biopsy of intracerebral lesions is not possible, given the importance of the 
differential diagnosis for the choice of therapy.  Chemotherapy can be withheld or 
postponed when the presence of lymphoma is small. O’Doherty et al arrived at the 
same conclusion in their prospective study among 57 febrile HIV patients [63]. Using 
FDG-PET, whole body scanning correctly located various other pathologic lesions, 
guiding the clinician in their diagnostic workup. Cryptococcus neoformans, Pseudo- 
monas aeroginosa, Mycobacterium tuberculosis, atypical mycobacteria and lymphoma 
were correctly localized. Sensitivity and specificity were 92 and 94% in this study. Two 
cases of progressive multifocal leukoencephalopathy (PML) could however not be 
differentiated from lymphoma in the largest study [60].
FDG-PET in sterile inflammatory disease
In a prospective study in 26 consecutive patients with large vessel arteritis, the use 
of FDG-PET in diagnosing vasculitis was investigated [64]. No false positive PET 
results were reported in a age and gender matched reference group. Overall 
FDG-PET/CT for imaging of non-osseous infection and inflammation 1
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sensitivity was 60% but increased to 95% with high CRP levels. Specificity was high 
(99.8%) and the positive predictive value reached 99.7%. in a large retrospective 
study concerning patients with suspected large vessel vasculitis, 10 true positive, 14 
true negative and 3 false negative FDG-PET results were collected [65]. Positive 
predictive value was 100% and the negative predictive value reached 82%. Eight 
other studies in 5 to 15 patients described the use of FDG-PET in large vessel 
vasculitis [66-73]. In 3 of these studies a matched reference group was included 
[66,67,69].  By dividing the  vascular system into different anatomical sides, adequate 
comparison between PET and MRI or angiography regarding disease extension was 
possible in 4 studies [68,70-72]. FDG-PET identified more  vascular regions involved 
in the inflammatory process than MRI. Furthermore, the estimated extent of disease 
as determined by MRI had to be upgraded from limited to extended disease after 
FDG-PET in 8 of 20 patients in the largest study [64]. These data are confirming the 
potential use of FDG-PET in diagnosing large vessel vasculitis as has been suggested 
in earlier case reports and studies describing the use of FDG-PET in FUO. 
Endovascular FDG uptake should be an alarming symptom as infectious or sterile 
arteritis is likely. 
Although physiological FDG uptake in the bowel is sometimes interfering with PET 
interpretation, Kresnik et al were able to detect colitis in an early stage on FDG-PET 
in 5 patients while colonoscopy did not yet reveal macroscopic lesions in these 
patients [74].  Endoscopic and radiologic studies are frequently required in 
inflammatory bowel disease (IBD) to determine disease activity. In a large study 
among 65 children with IBD, use of FDG-PET was compared to conventional 
endoscopic and radiologic studies [75]. FDG-PET correctly identified active 
inflammation in 80% and ruled out bowel involvement in children with recurrent 
abdominal pain without signs of IBD (n=10). It was stated that PET offers a 
non-invasive tool for identifying and localizing active IBD. Neurath et al studied 
non-invasive assessment of Crohn’s disease activity [76]. Of the 127 pathological 
FDG-PET findings, only 45 were accessible for endoscopic verification. Correlation 
of the foci with endoscopic findings showed a 89% specificity and a 85.4% sensitivity. 
FDG-PET may be useful when conventional studies cannot be performed to asses 
disease activity, localization and extension in inflammatory bowel disease, but 
should not replace conventional studies at the present time.
Chapter 1
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FDG-PET in fever of unknown origin 
Infection and inflammatory processes, but also malignancies are major causes of FUO. 
FDG being a non specific tracer seems to have great advantages in these patients as 
malignancy, non infectious inflammatory disease and infection all accumulate FDG. 
By identifying foci of increased FDG uptake, FDG-PET can guide additional 
investigations that lead to a final diagnosis. Six studies on the use of FDG-PET in FUO 
were identified dealing with 16 to 74 patients [32,77-81]. FDG-PET was useful in 37% of 
all PET scans made in a retrospective study [32]. The positive predictive value was 
87%. The negative predictive value was 95%. Although the retrospective nature of the 
study may have led to bias, follow-up of minimal 6 month minimised the chances for 
false negative PET results. In 3 prospective studies PET was helpful in 41 to 67%. 
FDG-PET compared favourable to Gallium-67 scintigraphy in 2 studies [77,81]. Gallium 
scintigraphy was helpful in only 25% in a subgroup of the same study. In a small study, 
FDG-PET appeared less useful than Indium-111 granulocyte scintigraphy [78]. 
However, selection bias may have influenced these results as only patients referred 
for Indium-111 granulocyte scintigraphy were recruited. The results of a large 
prospective multicenter study will be become available in the near future. 
FDG-PET during follow-up
FDG-PET is used for follow-up of the effect of treatment in various malignancies. 
First publications on use of FDG-PET in follow-up of large vessel vasculitis show 
promising results. In a prospective study in 26 consecutive patients with large vessel 
arteritis, follow-up FDG-PET scans were performed in 4 patients [64]. All of them 
received glucocorticosteroid treatment resulting in clinical improvement and 
normalisation of ESR and C-reactive protein. FDG-PET confirmed the reduction of 
both disease activity and extension. In another study FDG uptake during treatment 
follow-up normalised in all patients and was stable only in a non-responding patient 
[72]. Compared to MRI, FDG-PET also appears to be superior regarding treatment 
follow-up in large vessel vasculitis. FDG-PET showed normalisation in 80% of the 
identified vascular regions [70]. On MRI 15 of 17 affected regions remained 
unchanged. However, timing of FDG-PET was not standardized in these studies. 
First reports successfully correlating the degree of FDG uptake to disease activity in 
rheumatic arthritis recently appeared [82-84].
FDG-PET/CT for imaging of non-osseous infection and inflammation 1
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In a rat model the influence of antibiotic treatment on experimental soft tissue on 
FDG uptake over time was determined [85]. FDG PET however was not able to 
monitor therapy effects on soft tissue infection. Follow-up however only lasted 9 
days. Use of FDG-PET in follow-up of human infectious diseases was only studied by 
Reuter in human alveolar echinococcosis [18]. Due to the multilocular character of 
cysts, optimal surgical drainage of cysts often is not possible. Relapse rates are high, 
even after prolonged and consecutive chemotherapeutical treatment. In these 
cases, human alveolar echinococcosis is a chronic condition, interruption of 
treatment during dormant stages is part of clinical practice. This study showed  that 
residual disease after treatment discontinuation was not picked up by FDG-PET. 
Several case reports do mention normalisation of FDG uptake after treatment for 
various infectious diseases [26,58]. At present, very little is known about the 
correlation of response rates to a decrease in FDG uptake over time. Follow-up 
FDG-PET in human infection was only performed in a non-structured manner. Until 
further data become available, modification of treatment regimens solely on the 
basis of follow-up FDG-PET scans is not justified. A future role for FDG-PET in therapy 
monitoring however is not unlikely.
Conclusions and future directions
FDG-PET is a promising imaging technique in diagnosing non-osseous infectious 
and inflammatory diseases and FUO. Given the generally high negative predictive 
value for excluding focal disease, FDG-PET offers a useful contribution to a 
structured diagnostic workup, especially in case of FUO and suspected large vessel 
vasculitis, diminishing the number of redundant investigations. Further prospective 
clinical studies are warranted in patients suspected of infected vascular catheters or 
infected vascular grafts to enable definite conclusions on the usefulness of FDG-PET 
in these patients. Furthermore, the potential usefulness of FDG-PET in patients 
suspected of metastatic infectious disease should be confirmed in a prospective 
study. 
As FDG uptake can be quantified, it is possible to evaluate its use in therapy 
monitoring. Patients with infectious diseases at risk for treatment failure can 
potentially be identified. However, at present a negative follow-up FDG-PET scan 
should not be decisive in premature discontinuation of treatment as there is 
insufficient evidence on the clinical implications of monitoring residual infection 
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with repetitive FDG-PET scans. Further clinical studies are needed before the role of 
FDG-PET in follow-up of treatment for infectious diseases can be determined with 
more certainty.
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Abstract
Complicating infectious foci by either haematogenous or local spreading of 
microorganisms are frequently seen in  Staphylococcus aureus bacteraemia (SAB) 
and Streptococcus species bacteraemia (SSB). The aim of this study was to compare 
the epidemiology of complicating infectious foci during SAB and SSB in a university 
hospital in the Netherlands. The charts of all adult patients diagnosed with SAB or 
SSB (except for Streptococcus pneumoniae) from July 2002 until December 2004 
were retrospectively reviewed. Overall, 127 immunocompetent patients with SAB 
and 53 with SSB were identified. The percentage of complicating  infectious foci 
(39% of SAB patients, 25% of SSB patients) did not differ significantly. Endocarditis 
and cerebral involvement, however, were significantly more common in SSB. Of all 
complicating infectious foci, 32% did not have guiding signs or symptoms and 10% 
were only diagnosed at autopsy. Risk factors for developing complicating infectious 
foci were delayed treatment for more than 48h after the onset of symptoms, 
community acquisition, persistently positive blood cultures, presence of foreign 
bodies, prosthetic valves, or congenital heart disease. Infection-related mortality 
was 18% in SAB patients and 11% in SSB patients and was significantly higher in 
patients with complicating infectious foci (29 vs. 9%). In conclusion, complicating 
infectious foci are present in approximately one third of all patients with SAB and 
SSB. An active approach, searching for complicating infectious foci, is warranted in 
these patients, because only two thirds of complicated infectious foci have guiding 
symptoms or signs, and infection-related mortality is significantly increased in 
patients with complicating infectious foci compared to patients without these 
infections. 
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Introduction
Infection beyond the primary focus of infection is an important complication of 
Staphylococcus aureus bacteraemia (SAB) or bacteraemia with Streptococcus species 
(SSB), due to local spreading or haematological dissemination. Metastatic infection 
can occur at almost any site of the body and greatly influences morbidity and 
mortality [1-3]. Most studies on metastatic infection or complications of bacteraemia 
focus on SAB. In the Netherlands, only one retrospective study has been performed, 
including 75 patients with SAB [4]. In 35% of these patients, SAB was complicated by 
metastatic infection, relapse of infection occurred in 9 patients (12%), and the 
overall mortality rate was 23%. In other recent studies, the reported incidences of 
complicating infectious foci varied between 16 and 35%, with mortality rates 
between 16 and 34%, and recurrence rates of SAB between 8 and 23% [1,3,5,6]. 
Complications of SSB have been described in only a few clinical studies [7-10] that 
did not include all patients with SSB, but focused on specific subgroups of 
Streptococcus species [7,8,10]. Also, most studies did not specifically investigate 
metastatic infection [7-9]. One prospective study among 100 patients with Group A 
Streptococcus, including 62 IV drugs users and 52 HIV-positive patients, found 
metastatic complications in 37% of all patients: 5 patients with endocarditis, 20 
patients with septic pulmonary embolism and 12 patients with arthritis or 
osteomyelitis [10]. However, no information on mortality, relapse or incidence of 
complicating infectious foci is available for patients with SSB in general.
Diagnosis of complicating infectious foci is often difficult. In a Danish study, for 
example, endocarditis was not clinically suspected but was first detected at autopsy 
in 55% of 119 patients [11]. Standardization of diagnostic procedures is therefore 
desirable in patients with SAB and SSB, but so far, protocols or guidelines addressing 
the diagnostic search for complicating infectious foci are not available. To develop 
guidelines, information about current diagnostic procedures and the incidence and 
risk factors for complicated infection is needed. Risk factors for metastatic infection 
or high mortality after SAB defined in previous studies are community acquisition 
[6,12], unknown portal of entry [1], persistently positive blood culture results [6,13], 
persistent fever [6], foreign bodies [6,14,15] and underlying conditions such as im-
munosuppression and malignancy [12,16]. It is unknown whether these risk factors 
also apply to patients with SSB. 
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The aim of the present study was to describe and compare the epidemiology of SAB 
and SSB in a university hospital in the Netherlands and to identify risk factors for 
developing complicating infectious foci. 
Materials and Methods
Patients
All patients diagnosed with SAB and SSB (except for Streptococcus pneumoniae) 
between July 2002 and December 2004 at the Radboud University Nijmegen 
Medical Centre were identified through the microbiology laboratory database. 
Patients under 18 years of age, neutropenic patients (leukocyte count <1.0*109/L 
and/or granulocyte count <0.5*109/L) and patients with polymicrobial infection 
were excluded. Of all patients, epidemiological data, results of diagnostic tests, final 
diagnosis, treatment and follow up data were recorded.
Clinical features
Portal of entry was defined as a localised focus of infection preceding bacteraemia. A 
central venous catheter was considered as portal of entry if there was evidence of 
inflammation at the insertion site or culture of the catheter tip grew the same 
microorganism as the blood culture in the absence of evidence of another source. 
Respiratory or urinary tract infections were diagnosed as portal of entry only when 
specific symptoms and signs were present in addition to positive culture results. 
Bacteraemia was considered to be community-acquired if blood cultures taken within 
48 hours after admission were positive or signs of blood stream infection had been 
present before admission. Both metastatic infection and direct extension of the 
infection beyond the primary focus were defined as complicating infectious foci, e.g. 
deep tissue infection and abscess formation after surgery were classified as 
complicated infection. Endocarditis was defined according to the Duke criteria [17]. 
Prednisone ≥10 mg/day or other glucocorticoids in equivalent doses were considered 
as immunosuppressive treatment. 
Follow-up
The minimum duration of follow-up was 3 months. Patients were considered to 
be cured when cultures were negative and signs of infection were absent after 
 discontinuation of antibiotic therapy. Infection-related death included all patients 
who died with persistent signs of infection or positive blood cultures results in the 
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absence of another explanation for death. Recurrence of infection was defined as a 
second episode of bacteraemia with the same microorganism within 3 months 
after the first positive blood culture. 
Statistical analysis
Descriptive statistics for continuous variables are represented as mean ± standard 
deviations. In case of normal distribution of continuous variables medians and 
ranges are represented. Differences between the group of patients with SAB and 
SSB were tested with unpaired Student’s t-tests or Mann-Whitney U tests for 
continuous variables and with Fisher’s exact tests for categorical variables. 
Differences were considered to be statistically significant at p<0.05. Relative risks 
were calculated with a confidence interval of 95%.
Results
Epidemiology
Between July 2002 and December 2004, 160 adult patients had at least one positive 
blood culture with Staphylococcus aureus and 164 with Streptococcus species. 
Altogether, 33 patients with SAB and 111 patients with SSB were excluded: 24 SAB 
and 26 SSB patients had a polymicrobial infection, 7 patients with SAB and 84  with 
SSB were neutropenic and 3 medical charts were missing. Finally, the results of 127 
patients with SAB and 53 patients with SSB were studied. Of all 127 patients with 
SAB, only 2% had a bacteraemia caused by methicillin-resistant S. aureus. In SSB 
patients viridans streptococci were cultured in 38 cases, Streptococcus pyogenes in 
4 cases, Streptococcus agalactiae in 5 cases, β-haemolytic Streptococcus group C in 
4 patients and  Streptococcus bovis  bacteraemia was cultured in the remaining 
2 cases. Except for 3 patients whose positive blood cultures were not considered 
clinically relevant by their physician, all patients were hospitalised. The patients 
with SAB and SSB were comparable for most characteristics (Table 1). However, SSB 
was significantly more often community-acquired than SAB, and the duration of 
symptoms until presentation was also significantly longer. None of the patients 
used IV drugs or was HIV-positive. CVC infection was significantly more often the 
portal of entry in SAB than in SSB (Table 2). Of all CVC infections as portal of entry, 
12 CVC were untunnelled, 7 CVC were tunnelled and 4 were port-a-caths. Unknown 
portal of entry was significantly more common in patients with SSB than in those 
with SAB. 
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 Table 1  Patient characteristics of 180 patients with SAB and SSB.
Characteristics Total
(n=180)
SAB
(n=127)
SSB
(n=53)
Male sex 97 (54%) 70 (55%) 27 (51%)
Age (years) † 58±17 59±16 55±19
Community acquired 79 (44%) 47 (37%)‡ 32 (60%)‡
ICU admission prior to bacteraemia 41 (23%) 33 (26%) 8 (15%)
Chills 46 (26%) 29 (23%) 17 (32%)
Fever 155 (86%) 112 (88%) 42 (79%)
Duration of symptoms until presentation (days) ◊ 0 (0-111) 0 (0-39)‡ 0 (0-111)‡
CVC present 62 (34%) 47 (37%) 15 (28%)
 Total parenteral nutrition 17 11 6 
 Dialysis 7 7 0
 Other reasons 38 29 9
Foreign body present* 41 (23%) 30 (24%) 11 (21%)
 Prosthetic valve 8 5 3
 Prosthetic joint 12 10 2
 Other 21 15 6
Diabetes mellitus 31 (17%) 25 (20%) 6 (11%)
Haemodialysis 11 (6%) 10 (8%) 1 (2%)
Malignancy 35 (19%) 26 (20%) 9 (17%)
Congenital heart disease 7 (4%) 3 (2%) 4 (8%)
Immunosuppressive drugs 34 (19%) 27 (21%) 7 (13%)
IV drug use 0 (0%) 0 (0%) 0 (0%)
HIV infection 0 (0%) 0 (0%) 0 (0%)
† mean±SD ◊ median (range)
‡ p<0.05
* In 4 patients, more than one foreign body was present
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
ICU: Intensive Care Unit
CVC: central venous catheter 
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Development of complicating infectious foci
The percentage of patients developing complicating infectious foci was not 
significantly different between SAB and SSB (39 vs. 25%) (Table 3). In three patients 
metastatic infection was not diagnosed during the first period of hospitalization, 
but recurrence of SAB revealed  metastatic infection. Twenty-one patients, 16 with 
SAB and 5 with SSB, developed metastatic infections in more than one organ 
system. Endocarditis and cerebral involvement were significantly more common in 
SSB than in SAB. The localisation of other complicated infections was not significantly 
different between the two groups.
 
Risk factors for the development of complicating infectious foci
Risk factors for developing complicating infectious foci are shown in Table 4. 
Community acquisition and persistently positive blood cultures were risk factors for 
developing complicated infection in the SSB group. Delayed treatment for more 
than 48h after the onset of symptoms, however, was an important risk factor for 
developing complicating infectious foci in all groups. Complicating infectious foci 
were also significantly more common in patients with the presence of foreign 
bodies or congenital heart disease in all groups and prosthetic valves in the SAB 
group. Admission to ICU prior to developing bacteraemia appeared to be associated 
with fewer complicating infectious foci.
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 Table 2  Portal of entry of bacteraemia.
Diagnosis Total
(n=180)
SAB
(n=127)
SSB
(n=53)
CVC infection 23 (13%) 21 (17%)‡ 2 (4%)‡
Urinary tract infection 3 (2%) 3 (2%) 0 (0%)
Respiratory tract infection 4 (2%) 4 (3%) 0 (0%)
Skin and soft tissue infection 35 (18%) 25 (20%) 10 (19%)
Wound infection 20 (11%) 18 (14%) 2 (4%)
Endometritis 1 (1%) 0 (0%) 1 (2%)
Unknown 94 (52%) 56 (44%)‡ 38 (72%)‡
‡ p<0.05
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
CVC: central venous catheter 
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Diagnostic tests performed in patients with suspected complicating 
infectious foci
There was no significant difference between the total number and sort of diagnostic 
tests that were performed in patients with SAB or SSB in search for complicating 
infectious foci. Echocardiography was performed in 64 patients: transthoracic 
echocardiography in 42 patients, transesophageal echocardiography only in 7 
patients, and both in 15 patients. Patients were admitted to the infectious disease 
Chapter 2
 Table 3   Localisation and number of Complicating infectious foci in 62 patients 
with SAB and SSB.
Organ system Total
(n=91)
SAB
(n=72)
SSB
(n=19)
Endocarditis 15 6‡ 9‡
Pericarditis 1 1 0
Lung 8 6 2
Pleuritis 1 1 0
Mediastinum 5 5 0
Spondylodiscitis 11 10 1
Epidural abscess 4 4 0
Arthritis 8 8 0
Osteomyelitis 1 1 0
Liver 1 1 0
Spleen 1 1 0
Kidney 3 3 0
Brain 3 0‡ 3‡
Meningitis 1 0 1
Soft tissue 12 11 1
Vascular system 5 4 1
Foreign body 11 10 1
Total number of patients† 62/180 (34%) 49/127 (39%) 13/53 (25%)
‡ p<0.05
† In 21 patients, complicated infectious foci were found in more than one organ system.
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
CVC: central venous catheter 
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 Table 4   Percentage of patients and risk factors for developing complicating 
infectious foci in patients with SAB and SSB.
Risk factors Percentage of 
patients
Total SAB SSB
Complicated 
infection
Relative 
Risk  
[95%-CI]
Relative 
Risk  
[95%-CI]
Relative 
Risk  
[95%-CI]Present Absent
Community acquisition 53 39 1.5‡
[1.0-2.2]
1.4
[0.9-2.1]
5.3‡
[1.3-20.9]
Unknown portal of entry 58 48 1.3
[0.9-2.0]
1.4
[0.9-2.1]
2.2
[0.5-8.7]
Delayed treatment◊ 44 24 1.8‡
[1.2-2.6]
1.7‡
[1.1-2.5]
2.6‡
[1.0-7.0]
Positive blood culture after 48h* 23 10 1.8‡
[1.1-2.7]
1.4
[0.8-2.3]
4.0‡
[1.8-9.1]
Persistent fever after 72h 48 39 1.3
[0.9-1.9]
1.1
[0.7-1.6]
2.3
[0.9-5.8]
CVC not removed within 48h# 60 22 3.4
[0.7-16.2]
3.8
[0.8-17.1]
-
Foreign body 37 14 2.1‡
[1.4-3.0]
1.9
‡[1.2-2.8]
2.5‡
[1.0-6.2]
Prosthetic valve 8 3 1.9‡
[1.1-3.4]
2.2‡
[1.3-3.6]
1.4
[0.3-7.4]
ICU admission prior to 
bacteraemia
13 28 0.5
[0.3-1.0]
0.6
[0.3-1.1]
-
Diabetes mellitus 19 16 1.1
[0.7-1.9]
1.2
[0.7-2.0]
0.7
[0.1-4.2]
Malignancy 18 20 0.9
[0.5-1.5]
0.9
[0.5-1.6]
0.9
[0.2-3.3]
Immunosuppressive drugs 11 23 0.5
[0.3-1.1]
0.5
[0.2-1.1]
0.5
[0.1-3.6]
Haemodialysis 3 8 0.5
[0.1-1.8]
0.5
[0.1-1.8]
-
Congenital heart disease 10 1 3.0‡
[2.1-4.5]
2.7‡
[2.1-3.4]
3.7‡
[1.7-8.1]
Age > 60 years 48 47 1.0
[0.7-1.6]
1.2
[0.8-1.8]
0.6
[0.2-1.6]
‡ Relative Risk ≥ 1
◊ Delayed treatment for more than 48h after the onset of symptoms
* Positive blood culture after 48h after the first positive blood culture
# Only in case CVC infection was identified as portal of entry 
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
ICU: Intensive Care Unit
CVC: central venous catheter
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ward or infectious disease specialists were consulted in 43%. Permission for autopsy 
was obtained in 26% of 57 patients who died. Of the total number of 91 diagnosed 
complicated infectious foci, 29 (32%) did not present with signs that could have 
guided the physician to the diagnosis (Table 5). Radiology and scintigraphy were 
the most common techniques to detect complicating infectious foci (41% of all 
complicated infectious foci). In 7 complicated infectious foci with guiding signs 
(three cases of arthritis, two post-operative mediastinitis, one bursitis and one 
abscess), no investigation other than physical examination was performed to 
confirm these foci. A total of 15 patients were diagnosed with endocarditis: 12 
patients were diagnosed by the Duke criteria and in 3 patients, endocarditis was 
first diagnosed at autopsy. Only 3 patients (20%) with endocarditis had guiding 
signs or symptoms, such as a new or changed cardiac murmur or endocarditis 
stigmata. Autopsy revealed 9 additional complicated infectious foci (10%) that were 
not diagnosed ante mortem. These foci had not led to localizing signs or symptoms, 
except in 2 patients with SAB: the first patient had back pain and a partial paraplegia 
and MRI of the spine and bone scintigraphy showed spondylodiscitis. At autopsy, an 
epidural abscess was found in addition to spondylodiscitis. The second patient, 
who developed local tenderness to spinal percussion during admission, a MRI of the 
spine had not shown specific signs of spondylodiscitis. At autopsy, however, spon-
dylodiscitis was diagnosed.
Clinical course and outcome 
The duration of fever, the number of days with positive blood cultures and the 
duration of admission were significantly longer in patients with complicating 
infectious foci than in patients without complicating infectious foci (Table 6). Also, 
the duration of antibiotic treatment was significantly longer in patients with 
complicating infectious foci than in patients without complicating infectious foci 
(median 34 vs. 14 days). Ten patients, 5 patients with SAB and 5 with SSB, did not 
receive antibiotic treatment, because their physician did not consider positive 
blood cultures clinically relevant. None of these patients developed complicating 
infectious foci. Five patients were lost to follow-up after 3 months. There was no 
significant difference between the group with and without complicating infectious 
foci regarding cure and mortality rates within 3 months of follow-up. The infection-
related mortality, however, was significantly higher in patients with complicating 
infectious foci than in patients without complicating infectious foci (29 vs. 9%). Nine 
patients (7% of SAB) had a recurrent bacteraemia. CVC infection was the portal of 
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entry in 7 of these patients. In 5 of these 7 patients, the CVC had been not removed 
during the first episode of bacteraemia. After recurrence of bacteraemia, metastatic 
foci were diagnosed in 4 of 9 patients.
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 Table 5   Presence of guiding signs or symptoms of 91 complicating infectious 
foci and method of first diagnosis*.
All complicated 
infections
complicated 
infection after 
SAB
complicated 
infection after SSB
Guiding signs or 
symptoms
Guiding signs or 
symptoms
Guiding signs or 
symptoms
Procedure
Present
(n=62)
Absent
(n=29)
Present 
(n=53)
Absent 
(n=19)
Present  
(n=9)
Absent 
(n=10)
Physical examinationa 7 (11%) 0 (0%) 7 (13%) 0 (0%) 0 (0%) 0 (0%)
Radiology / scintigraphy 33 (53%) 4 (14%) 27 (51%) 4 (21%) 6 (67%) 0 (0%)
Duke criteria 3 (5%) 9 (31%) 3 (6%) 1 (5%) 0 (0%) 8 (80%)
FDG-PET 4 (6%) 6 (21%) 3 (6%) 6 (32%) 1 (11%) 0 (0%)
Gastroscopy 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (11%) 0 (0%)
Surgery 10 (16%) 0 (0%) 10 (19%) 0 (0%) 0 (0%) 0 (0%)
Lumbar puncture 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (11%) 0 (0%)
Bacterial culture 1 (2%) 2 (7%) 1 (2%) 2 (11%) 0 (0%) 0 (0%)
Pathology 0 (0%) 1 (3%) 0 (0%) 1 (5%) 0 (0%) 0 (0%)
Autopsy 2 (3%) 7 (24%) 2 (4%) 5 (26%) 0 (0%) 2 (20%)
* 62 patients were diagnosed with complicated infectious foci in 91 different organ systems
a   In case no investigation other than physical examination was performed to confirm the complicated 
infection foci
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
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Discussion
To the best of our knowledge, this is the first study evaluating complicating infectious 
foci of  SSB and SAB in one hospital. Community acquisition was significantly more 
common in SSB than in SAB. Profound neutropenia as a result of chemotherapy is a 
well known risk factor for viridans streptococcal septicaemia [18,19]. It is to be 
expected that the proportion of hospital-acquired SSB cases decreases when patients 
with neutropenia are excluded as was done in this study. In other studies [1,3,5,6], the 
percentage of community-acquired SAB and the age of SAB patients were comparable 
to our findings. In contrast with other studies, which have shown up to 62% IV drug 
users [1,3,5,6,10] and up to 52% HIV-infected patients [1,4-6,10], our population was 
characterized by the total absence of IV drug users and HIV-positive patients. 
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 Table 6   Course and 3-month follow-up in 127 patients with SAB and 53 patients 
with SSB.
Total SAB SSB
Complicated 
infection
Complicated 
infection
Complicated 
infection
Parameters
Present
(n=62)
Absent
(n=118)
Present
(n=49)
Absent 
(n=78)
Present 
(n=13)
Absent 
(n=40)
Duration of fever (days)† 4 (0-27)‡ 3 (0-28) 3 (0-27) 3 (0-25) 4 (1-8) 2 (0-28)
Duration of positive BC (days)† 1 (1-7)‡ 1 (1-10) 1 (1-7) 1 (1-10) 2 (1-4)‡ 1 (1-3)
Duration of treatment (days)† 34  
(1-222)‡
14  
(0-49)
33  
(2-222)‡ 
15  
(0-49)
34  
(1-89)‡ 
10  
(0-44)
Duration of admission (days)† 28  
(2-80)‡
15  
(0-74)
28  
(3-80)‡
16  
(0-74)
28  
(2-57)‡
9  
(0-38)
Lost to follow-up 0 (0%) 3 (3%) 0 (0%) 2 (3%) 0 (0%) 1 (3%)
Cure 35 (56%) 75 (64%) 27 (55%) 46 (59%) 8 (62%) 29 (73%)
Death 21 (34%) 36 (31%) 16 (33%) 26 (33%) 5 (38%) 10 (25%)
      Infection-related death 18‡ (29%) 11 (9%) 14‡ (29%) 9 (12%) 4‡ (31%) 2 (5%)
Persisting infection 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
Recurrence 5 (8%) 4 (3%) 5 (10%) 4 (5%) 0 (0%) 0 (0%)
† median (range)
‡ p<0.05
SAB: Staphylococcus aureus bacteraemia
SSB: Streptococcus species bacteraemia
BC: blood culture
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An unknown portal of entry was significantly more common in SSB than SAB. The 
unknown portal of entry for SAB was even higher than described in previous studies 
[1,3,5,6,12]: 44% vs. 7-25%, which might be explained by underreporting of the 
portal of entry due to the retrospective character of this study. CVC infection was a 
significantly more common portal of entry in patients with SAB (17%) than in those 
with SSB (4%), in agreement with previous studies [1,3,4,12]. 
The incidence of complicating infectious foci in SAB (39%) is in agreement with 
other studies (16-35%) [1,3-6]. In our study, the incidence of endocarditis was lower 
in patients with SAB (5%) than has been described earlier (8-39%) [3-6]. There is no 
significant difference between the incidence of complicating infectious foci in SSB 
and in SAB, although in our study, endocarditis and involvement of the brain were 
more frequently observed in SSB than in SAB. This is in contrast with studies 
suggesting that Staphylococcus aureus had emerged as the dominant cause of 
infective endocarditis [20]. However, the low number of patients with endocarditis 
and the fact that our study did not specifically focus on the incidence of endocarditis 
may in part explain these differences.
Identification of risk factors for developing or presence of complicating infectious 
foci should guide the physician to perform additional diagnostic tests to identify 
these foci. In our study, community acquisition and unknown portal of entry were 
not identified as risk factors for developing complicating infectious foci in SAB, in 
contrast to previous studies [1,6,12]. Community acquisition however, was a risk 
factor for developing complicating infectious foci in SSB.  Delayed treatment for 
more than 48h after the first symptoms, on the other hand, was a risk factor for 
developing complicating infectious foci in both SAB and SSB. Viridans Streptococcal 
bacteraemia probably is more likely to cause less acute infections, leading to 
treatment delay. Community acquisition and an unknown portal of entry as risk 
factors may be confounders due to delayed  treatment as suggested before [1,21]. 
The presence of foreign bodies or prosthetic valves were significant risk factors for 
developing complicating infectious foci, as described in previous studies [6,14,15]. 
Repetitive blood cultures between 48 and 96 hours after start of treatment were 
taken in a minority of patients (SAB 25%, SSB 22%). Persistently positive blood 
cultures were found as a risk factor in SSB, but not in SAB. The number of serial 
blood cultures is probably too small to reach significant conclusions due to the 
retrospective nature of the study and the absence of a protocol requiring systematic 
performance of serial blood cultures. Persistent fever [6,13], underlying patient 
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conditions [12,16] and age above 60 years [6] were previously described as risk 
factors for complicated infections in patients with SAB, but were no significant risk 
factors in this study. In the present study, risk factors for complicating infectious foci 
after SAB and SSB are rather similar. Admission to ICU prior to the bacteraemia 
appeared to be associated with a lower risk of developing complicating infectious 
foci. A possible explanation could be that bacteraemia in the ICU often is hospital-
acquired and therefore diagnosed and treated rapidly. 
The incidence of endocarditis may have been underreported in the present study 
due to the low percentage of patients in whom echocardiography was performed 
(36%). This percentage, however, is comparable to the only other Dutch study by 
Verhagen et al. (31%) [4]. Transesophageal echocardiography, which is more 
sensitive [24], was performed in only 22 patients (12% of the total group).  Three 
patients were first diagnosed with endocarditis at autopsy, which corresponds with 
20% of the total number of endocarditis cases in our study. In 2 Danish studies, even 
more patients with endocarditis were first diagnosed at autopsy (30-55%) [11,22]. 
The low rate of signs or symptoms that could guide the physician towards the 
diagnosis may explain the high proportion of cases diagnosed at autopsy, as was 
also noted in other studies [22,23]. From the results of our study, it is clear that a 
more active search for all complicating infectious foci should be recommended, 
since 32% of complicating infectious foci did not have guiding signs and symptoms 
and 10% was first diagnosed at autopsy. Preferable, a structured diagnostic protocol 
should be developed based on the presence of risk factors for developing 
complicating infectious foci. The yield of such a protocol will increase when patients 
at risk for developing infectious complications can be selected. Furthermore it 
would not be preferable to expose every patient with SAB or SSB to an extensive 
diagnostic work-up, with respect to radiation exposure, physical burden and costs. 
The protocol should at least include serial blood cultures and diagnostic tests 
guided by symptoms and signs in all patients. Transesophageal echocardiography 
should be part of the early evaluation of patients with SAB or SSB with risk factors 
for developing complicating infectious foci, as was recommended by others for 
patients with SAB [22, 23]. Since guiding signs and symptoms are absent in many 
cases, advanced scintigraphic techniques suitable for total body scanning, like 
positron emission tomography with 18-F-fluorodeoxyglucose (FDG-PET), might 
also be part of such a protocol. In a retrospective study of 40 patients with blood 
stream infections and a high risk of complications, FDG-PET diagnosed a clinically 
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relevant new focus in 45% of cases while on average already 4 conventional 
diagnostic tests had been performed previously [28]. 
The 3-month mortality of SAB (33%) in this study is similar to that in previous studies 
(16-34%) [1,3-5], as was the infection-related mortality in this study (18%) [4-6]. 
Lautenschlager et al. [1] found that the mortality rate of patients with SAB and 
metastatic infections (49%) was significantly higher than that of those without 
metastatic infections (25%). This difference in infection-related mortality rate was 
also found in our study in both patients with SAB (29 vs. 12%) and with SSB (31 vs. 
5%). The overall mortality rate was not significantly higher among patients with 
complicating infectious foci than in those without, suggesting other differences 
between the patient groups. Indeed, more patients without complicating infectious 
foci were admitted to the ICU and were at high risk for death due to the underlying 
illness. The recurrence rate in the present study (3%) is lower than that reported 
from previous studies (8-23%) [1,3-6]. The limited use of vancomycin which is 
associated with high relapse rates [25-27] and the high percentage of CVC removal 
during treatment in the present study may explain the low relapse rate. Only 7 CVCs 
were not removed within 48 hours after the first positive blood culture. Five of these 
7 patients did have a recurrence of the bacteraemia. This finding underscores the 
need for CVC removal in patients with SAB. 
The most important limitation of the present study is its retrospective character 
because of the associated chance of information bias. The incidence of complicating 
infectious foci may also have been underestimated since no structured diagnostic 
protocol was used. However, due to the population-based design and follow-up of 
at least three months, the majority of clinically relevant infections likely have been 
identified.
In conclusion, complicating infectious focioccur in approximately one third of patients 
with SAB or SSB. A more active approach searching for complicating foci is warranted 
in these patients, because infection-related mortality is significantly higher among 
patients with complicating infectious foci and only two thirds of these foci have 
guiding symptoms or signs. A structured diagnostic protocol should be developed 
based on the known risk factors for complicating infectious foci. Since risk factors 
appear to be similar in SAB and SSB, one protocol could be developed for both patient 
groups.  Prospective studies should confirm the data from the present study, especially 
in case of SSB, and evaluate the usefulness of such a diagnostic protocol.
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Abstract
Timely identification of metastatic complications of blood stream infections due to 
spreading of the microorganisms to distant sites, although critical, is often difficult. 
As fluorodeoxyglucose (FDG) accumulates in activated leukocytes in infectious 
lesions, FDG-positron emission tomography (PET) represents a promising imaging 
technique in these patients. The aim of this study was to assess the value of FDG-PET 
in detecting infectious foci in patients at high risk of metastatic complications.
Methods: The results of all FDG-PET-scans ordered because of suspected metastatic 
infection from October 1998 to September 2004 were analysed retrospectively. 
These results were compared to conventional investigation techniques and the final 
clinical diagnosis. 
Results: The results of 40 FDG-PET-scans were evaluated. In 60% of all episodes, 
Gram-positive bacteria were cultured, in 18% Gram-negative bacteria, in 20% 
Candida spp., and in 3% the infection was polymicrobial. Metastatic complications 
were diagnosed in 75% of all episodes. A median number of four diagnostic 
procedures to search for metastatic infection had been performed before FDG-PET 
was ordered. FDG-PET diagnosed a clinically relevant new focus in 45% of cases and 
confirmed abnormalities already diagnosed in 30%. The positive predictive value of 
FDG-PET was 91% and the negative predictive value was 100%.
Conclusion: FDG-PET is a valuable imaging technique in patients at high risk of 
metastatic infectious disease even when the results of other diagnostic procedures 
are normal.
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Introduction
One of the main complications of blood stream infections, especially in case of S. 
aureus bacteraemia or candidemia, is secondary metastatic infection caused by 
spreading of the microorganisms to distant sites. The prevalence of metastatic 
infection in patients with S. aureus bacteraemia varies from approximately 2 to 30% 
[1,2]. In a retrospective study, 29% of patients who were treated for candidemia 
developed disseminated disease [3]. The frequency of metastatic complications 
after bacteremic episodes caused by other microorganisms is not known. Known 
risk factors for developing metastatic complications of S. aureus bacteraemia are 
community acquisition, unknown portal of entry, longer time span between first 
symptoms and initiation of antibiotic therapy, the presence of prosthetic devices, 
persistent fever after 72 hours, and positive follow-up blood cultures at 24 to 96 
hours [4-8]. An important consequence of metastatic infection is the need for 
prolonged antimicrobial therapy. Failure to identify metastatic complications may 
lead to early cessation of therapy and relapse of blood stream infection and 
unfavorable outcome. Timely identification of infectious lesions, however, is often 
difficult, especially in patients without signs pointing to a specific localization. 
Focal infectious disease can be detected by computed tomography (CT), magnetic 
resonance imaging (MRI) and ultrasonography. These techniques, however, are less 
suitable as a screening method when clues for specific sites of infection are absent. 
Scintigraphic imaging allows delineation of the localization of foci in all parts of the 
body, based on functional changes of tissues. Since activated inflammatory cells 
take up large amounts of glucose as a result of an increased metabolic rate [9], fluo-
rodeoxyglucose (FDG) positron emission tomography (PET) represents a promising 
imaging technique in these patients. The aim of this study was to assess the value of 
FDG-PET in detecting metastatic infectious foci in patients with bacteraemia or 
fungemia at high risk of metastatic infection.
Materials and methods
Patients 
The results of all FDG-PET-scans ordered because of suspected metastatic infectious 
disease from October 1998 to September 2004 at the Radboud University Nijmegen 
Medical Centre were analysed retrospectively. The suspicion of metastatic complications 
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was based on positive blood cultures and one or more of the following symptoms and 
signs: persisting fever or positive blood cultures for more than 48 hours after initiation 
of antibiotic therapy, clinical deterioration after initial improvement of symptoms, or 
metastatic infectious foci elsewhere. All patients were evaluated with other imaging 
modalities and laboratory tests as was considered clinically appropriate.
FDG-PET 
A full ring PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) was used for 
data acquisition. Prior to FDG-injection patients had fasted for at least 6 hours. 
Immediately prior to the procedure, the patients were hydrated with 500 ml of 
water. One hour after intravenous injection of 200-220 MBq FDG (Tyco Healthcare/
Mallinckrodt Medical, Petten, The Netherlands) and 10 to 15 mg furosemide, 
emission and transmission images of the area between the proximal femora and the 
base of the skull were acquired (10 minute per bed position). The images were 
corrected for attenuation and were reconstructed using the ordered subsets-ex-
pectation maximization (OSEM) algorithm. Reconstructed images were displayed in 
coronal, transverse and sagittal planes. FDG-PET results were judged to be abnormal 
if focal accumulation of the tracer was detected outside areas of physiological 
uptake.
Clinical Features
The portal of entry was defined as a localized focus of infection preceding 
bacteraemia or fungemia. Primary infection of the respiratory or urinary tract was 
diagnosed only when symptoms and signs typically associated with bacterial 
infections of those systems were present in addition to appropriate culture results. 
Other foci were considered to be secondary metastatic infection. Endocarditis, 
defined according to the Duke criteria [10], and spondylitis were always considered 
as secondary metastatic infection. An intravascular catheter was considered to be 
the portal of entry if there was evidence of inflammation at the insertion site and/or 
culture of the vascular catheter tip was positive for the same microorganism without 
clinical evidence of another source for infection. The infection was considered to be 
nosocomial if cultures obtained after >48 hours of hospitalization were positive and 
clinical signs of infection were absent at the time of admission. The infection was 
considered to be community-acquired if cultures were positive within 48 hours 
after admission and/or signs of blood stream infection were present before 
admission.  
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Clinical Assessment of Test Results and Diagnosis
The results of FDG-PET were evaluated for their diagnostic contribution. A normal 
FDG-PET-scan was called true negative when no metastatic complications or relapse 
of infection were diagnosed during clinical follow-up of at least three months. A 
normal FDG-PET scan was considered false negative when a focal infection was 
diagnosed except for infection in the brain, the heart, the kidneys or the bladder 
(sites known for low sensitivity of FDG-PET due to physiological uptake of FDG) or 
the legs (not routinely imaged). Results were considered to be true positive when 
abnormal FDG-uptake pointed to the organ or tissue where the cause of the 
symptoms was eventually found. FDG-uptake in the source of the infection as well 
as in metastatic infectious foci were considered as true positive results. True positive 
FDG-PET results were further categorized as “clinically relevant new finding” when 
the abnormality caused a change of treatment (longer duration of antibiotic 
therapy, switching to another antibiotic or combination of antibiotics, drainage of 
abscesses or surgical intervention), as “clinically irrelevant new finding” when the 
abnormality did not change treatment or as “already known” when FDG-PET only 
showed metastatic foci already diagnosed by other diagnostic techniques. 
Abnormal results were categorized as false positive when the abnormality could 
not be confirmed. The final or probable clinical diagnosis served as a standard of 
reference and was used for the assessment of the FDG-PET results.
Follow-up
Medical charts were reviewed for follow-up data. After a minimum follow-up of 
three months, the patient was considered to be cured when no symptoms or signs 
of infection were present after discontinuation of antibiotic therapy. Attributable 
mortality included all patients who died with persistent signs or symptoms of 
systemic infection, positive blood culture results or a persistent focus of infection in 
the absence of another explanation for death. Relapse was defined as a second 
episode of bacteraemia or fungemia with the same microorganism within 12 weeks 
of the initial episode.
Statistical analysis
Descriptive statistics for continuous variables are represented as medians ± 
standard deviations. Categorical variables are reported in terms of the number and 
percentage of patients affected. Differences between the group of patients 
eventually diagnosed with metastatic infection and the group of patients without 
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metastatic infection were tested with unpaired student t-tests for continuous 
variables and with Fisher’s exact tests for categorical variables. Differences were 
considered to be statistically significant at p<0.05.
Results
From October 1998 to September 2004, 40 FDG-PET-scans were performed because 
of suspected metastatic infection. In two patients, FDG-PET was performed during 
two separate episodes of central venous catheter (CVC)-related blood stream 
infection. Patient characteristics for the total number of infectious episodes and 
subdivided for patients eventually diagnosed with metastatic disease and patients 
without metastatic foci are shown in Table 1. Three-quarters of infections were 
community-acquired with a short duration of symptoms before presentation 
(median one day). All patients had at least one risk factor for developing complicated 
disease. None of the patients had neutropenia. The total number of positive blood 
cultures and the number of days for which blood cultures remained positive were 
significantly higher in patients with metastatic disease.
Culture results are shown in Table 2. S. aureus was the most common cause of 
bacteraemia (14 episodes, 35%). All patients with Gram-negative bacteraemia for 
whom an FDG-PET-scan was ordered were eventually diagnosed with metastatic 
complications. Metastatic infection was also found in 16 episodes of Gram-positive 
bacteraemia (64%) and 7 episodes of candidemia (78%). The portal of entry was 
known in 28 episodes (70%, Table 3). In all patients with CVC-related blood stream 
infections, the CVC was removed before FDG-PET was requested. In 30 cases (75%), 
metastatic infectious foci were eventually diagnosed by conventional diagnostic 
techniques, FDG-PET or both. Metastatic infection was most often diagnosed in the 
cardiovascular system, the lungs and in bones or joints (Table 4). Of those with 
metastatic infection, 11 (37%) were diagnosed with metastatic foci in more than one 
organ system.
A median number of four diagnostic procedures to search for metastatic 
complications was performed before FDG-PET was requested (range 1 to 10). Chest 
X-ray was performed in 34 patients (85%), chest CT in seven patients (18%), 
abdominal ultrasound in 25 patients (63%), abdominal CT in 18 patients (45%), 
doppler ultrasonography of the subclavian and internal jugular veins in six patients 
(50% of all patients with CVC-related infection), and echocardiography was 
performed in 21 patients (53%). 
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Results of FDG-PET were negative in six patients (Table 5). None of these patients 
was diagnosed with metastatic complications or relapse after a follow-up period of 
at least three months, so these results were considered true negative. FDG-PET 
results were true positive in 31 cases (78%). FDG-PET diagnosed a clinically relevant 
new focus (figure 1) in 18 cases (45%), a clinically irrelevant new focus in one patient 
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 Table 1   Patient characteristics of 40 patients suspected of infectious metastatic 
disease in whom FDG-PET was performed.
Characteristic Total Metastatic Foci
(n=40) Yes (n=30) No (n=10)
Male 23 (58%) 17 (57%) 6 (60%)
Female 17 (42%) 13 (43%) 4 (40%)
Age (years) 60±17 60±17 60±18
Community acquired infection 30 (75%) 23 (77%) 7 (70%)
Duration of symptoms until presentation (days)*† 1±8 1±7 1±9
Duration of symptoms until adequate therapy (days) *† 2±8 3±8 2±9
CVC present 13 (33%) 10 (33%) 3 (30%)
Duration of CVC present (weeks) † 12±62 14±69 1±9
Total parenteral nutrition 9 (23%) 7 (23%) 2 (20%)
Diabetes mellitus 4 (10%) 3 (10%) 1 (10%)
Peritoneal dialysis 2 (5%) 1 (3%) 1 (10%)
Hemodialysis 1 (3%) 0 1 (10%)
Pacemaker 3 (8%) 3 (10%) 0
Congenital heart disease 3 (8%) 3 (10%) 0
Mechanic heart valve 2 (5%) 2 (7%) 0
Malignancy 1 (3%) 1 (3%) 0
Immunosuppressive drugs 8 (20%) 7 (23%) 1 (10%)
I.V. drug use 0 0 0
Positive blood cultures (number/patient) † 3±3 4±3‡ 2±1‡
Duration of positive blood cultures (days) † 2±8 3±8‡ 1±1‡
CVC=central venous catheter 
* One patient was excluded from these calculations because she had suffered from lower back pain, 
periodic low-grade fever and fatigue for almost three years before she was diagnosed with a S. aureus 
psoas abscess and before FDG-PET was performed.
† median±SD
‡ p<0.05
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 Table 2   Culture results.
Category Species Total Metastatic foci
(n=40)
Yes 
(n=30)
No 
(n=10)
Gram-positive bacteria Staphylococcus aureus 14 7 7
Staphylococcus epidermidis 1 1 0
Streptococcus pneumoniae 3 3 0
Other Streptococcus spp. 5 4 1
Enterococcus spp.* 2 1 1
Gram-negative bacteria Escherichia coli 3 3 0
Proteus mirabilis 1 1 0
Enterobacter cloacae 1 1 0
Salmonella group D 1 1 0
Serratia marcescens 1 1 0
Yeasts Candida albicans 6 6 0
Candida parapsilosis 2 1 1
Candida tropicalis* 1 0 1
* In one patient blood cultures were positive for Enterococcus faecium as well as Candida tropicalis.
 Table 3   Portal of entry: source of the bacteraemia or fungemia.
Diagnosis Total Metastatic foci 
(n=40) Yes (n=30) No (n=10)
CVC-related blood stream infection 12 9 3
Soft tissue-/skin-infection 5 1 4
Pneumonia 1 1 0
Urinary tract infection 4 4 0
CAPD-peritonitis 2 1 1
Wound infection 1 0 1
Cholangitis 2 1 1
Meningitis 1 1 0
Not known 12 12 0
CVC=central venous catheter
CAPD=continuous ambulatory peritoneal dialysis
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 Table 4   Localization of metastatic infectious foci in 30 patients eventually 
diagnosed with metastatic disease.
Organ system Number
(n=30)
Endocarditis 5
Endovascular 10
Lungs 7
Liver/biliary tract 2
Spleen 2
Arthritis 4
Nonvertebral osteomyelitis 1
Vertebral osteomyelitis 3
Psoas abscess 1
Skin/soft tissue 5
Brain 2
Eye 1
In 11 patients, metastatic infectious foci were found in more than one organ system.
 Table 5   FDG-PET results in 40 patients suspected of metastatic infectious disease.
FDG-PET results Number Confirmation
(n=40) Total Partial Not
Negative
True-negative 6
False-negative 0
Positive
True-positive 31* 27 3 1
Clinically relevant 18 15 2 1
Clinically irrelevant 1 0 1 0
Already known 12* 12 0 0
False-positive 3 0 0 3
*  In one patient with Staphylococcus aureus bacteraemia without metastatic infection, FDG-uptake 
was seen in the abscess of his right arm, which was the source of his bacteraemia. FDG-PET was 
otherwise normal.
62
Chapter 3
 Table 6   Outcome of 40 patients suspected of metastatic infectious disease.
Characteristic Total Metastatic foci
(n=40) Yes (n=30) No (n=10)
Duration of fever (days)* 18±27 25±30 7±14
Duration of hospitalization (days)* 45±25 47±25† 23±18†
Duration of antibiotic therapy (days)* 50±266 75±299† 35±16†
Admission to ICU 7 (18%) 6 (20%) 1 (10%)
Duration of ICU stay (days)* 2±6 2±6 2
Cure 30 (75%) 20 (67%)† 10 (100%)†
Persisting infection 4 (10%) 4 (13%) 0
Relapse 1 (3%) 1 (3%) 0
Death 5 (13%) 5 (17%) 0
* median±SD
† p<0.05
Figure 1  A In a 45-year-old woman with Staphylococcus aureus septicemia and persistent 
fever during therapy, PET showed increased FDG-uptake in multiple lesions in both lungs, 
the mediastinum and in the upper abdomen (Figure 1A). Subsequently, chest CT also 
showed multiple lesions in both lungs and the mediastinum. Cholangitis caused by 
gallstones was confirmed by abdominal ultrasound and endoscopic retrograde cholangi-
opancreatography (ERCP). The fever disappeared within two days after ERCP. After three 
months, FDG-PET was normal (Figure 1B) and antibiotic therapy was discontinued.
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and confirmed already diagnosed abnormalities in 12 cases (30%). In 27 of these 31 
episodes, FDG-PET results were fully confirmed by conventional diagnostic 
techniques. Results were partially confirmed in three cases. In the first patient, PET 
demonstrated increased FDG-uptake in the right wrist and the left hip. Infection of 
the wrist was confirmed by ultrasound showing a small fluid collection and an 
infiltrate surrounding the ulnar artery, but no diagnostic procedure was performed 
to confirm arthritis of the left hip. In the second patient, PET showed increased 
FDG-uptake in the liver and both total hip prostheses. Abdominal CT and culture 
confirmed liver abscesses, but ultrasound only partially confirmed infection of both 
total hip prostheses by demonstrating a large fluid collection around the left hip 
prosthesis. In the third patient, PET demonstrated abnormal FDG-uptake in multiple 
foci in both lungs and the liver hilus and irregular uptake in the spleen. Pulmonary 
abscesses and cholangitis were confirmed by other diagnostic procedures, but 
abdominal CT did not show any abnormalities of the spleen. In one patient with 
endocarditis, PET showed increased FDG-uptake around a vascular prosthesis of the 
abdominal aorta. Infection of his vascular prosthesis was supported by clinical signs 
and favorable reaction to antibiotic therapy, but was not confirmed otherwise. In 
this case, surgery was not possible because of his deteriorated cardiovascular 
condition. The histories of tree patients with Candida lung abscesses diagnosed 
with FDG-PET have been described in a research note [11]. In three patients, FDG-PET 
results were false positive. The first patient was diagnosed with a urinary tract 
infection and abdominal CT showed extensive thrombosis of both femoral veins, 
iliac veins and the inferior caval vein extending from a caval filter, which was 
suspected to be infected. PET showed increased FDG-uptake in the thrombosed 
blood vessels, but also in several mediastinal lymph nodes. On chest CT, however, 
no pathologically enlarged lymph nodes were found.  In the second patient, PET 
demonstrated increased FDG-uptake in the right hip and the left femur. Arthritis of 
the right hip was confirmed by 111Indium-labeled polyclonal immunoglobulin G 
(IgG)-scintigraphy, but no abnormal IgG-uptake in the left femur was found.  In the 
third patient who was treated with azathioprine and prednisone because of a renal 
transplant, PET showed right-sided retroperitoneal FDG-uptake, but abdominal 
ultrasound was normal. In the remaining 7 patients treated with immunosuppres-
sive drugs, FDG-PET was true positive. In the 40 cases studied, positive predictive 
value of FDG-PET was 91% and negative predictive value was 100%.
The median duration of follow-up was 12 months (range 3 to 51 months). The 
duration of hospitalization was significantly longer in the patients with metastatic 
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complications (median 47 vs. 23 days, Table 6). The patients with metastatic 
complications were also treated with antibiotics for a longer time period (median 75 
vs. 35 days). The duration of fever, the percentage of patients admitted to the ICU, 
and the duration of ICU stay, however, did not differ significantly between patients 
with and patients without metastatic complications. In the group with metastatic 
infection, five patients died of complicated infection and four patients had 
persisting infection (one patient with a mycotic aortic aneurysm with a follow-up of 
36 months and three patients with infected vascular prostheses, who could not be 
treated surgically, with a follow-up of 3, 6, and 23 months, respectively). One patient, 
who had been treated because of a S. aureus psoas abscess, was diagnosed with a 
relapse after discontinuation of antibiotic therapy. The cure rate was significantly 
lower in the group with metastatic infection than in patients without metastatic 
complications (67% vs. 100%). 
Discussion
In this study, the utility of FDG-PET in patients suspected of metastatic infectious 
disease was evaluated. Even after a median number of four conventional diagnostic 
tests, FDG-PET revealed clinically relevant new infectious foci in 45% of all patients. 
In these cases, the results of FDG-PET led to a change of treatment. This study 
represents the largest patient population ever screened for metastatic infectious 
foci by FDG-PET. No comparable studies are available at this time. In several previous 
studies, the accuracy of FDG-PET for diagnosing primary, mostly orthopedic, 
infections ranged from 80 to 100% [12-14]. Although FDG-PET is able to detect 
infection of joint prostheses, it is less accurate than, and is not a suitable replacement 
for, leukocyte imaging or labeled IgG for this indication [15,16]. In three prospective 
studies, FDG-PET enabled correct visualization of spondylodiscitis and proved to be 
superior to MRI, 67Gallium-citrate scintigraphy and bone scan [17-19]. In two studies, 
FDG-PET reliably identified septic thrombophlebitis in cancer patients with CVCs 
suspected of infection and was able to distinguish septic thrombophlebitis from 
deep venous thrombosis leading to significant therapeutic changes [20,21]. PET 
revealed increased FDG-uptake at the site of the CVC even in patients without signs 
of infection and in several patients with severe neutropenia. It is obviously 
impossible to compare these studies because of different study designs and 
different patient characteristics, but the results of these studies and our results 
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suggest that FDG-PET is a sensitive method to detect various infectious foci in 
different organ systems with a reasonable specificity. 
A weakness of this study is its retrospective nature. A high percentage of patients 
had metastatic disease, underscoring that this group of patients had been selected 
on the basis of their high risk of metastatic complications. The results of this study, 
therefore, should not be applied to all patients with blood stream infection. 
Furthermore, since a rigid investigation protocol for the diagnostic work-up of these 
patients was not applied, the number and the kind of diagnostic tests performed 
differed considerably between individual patients. For a period of at least three 
months after admission, follow-up data were available from the medical charts of all 
patients. However, it cannot be excluded that relapses have occurred, which 
remained unnoticed by the attending physicians. 
Calculation of sensitivity and specificity of FDG-PET in patients suspected of focal 
infection is difficult for several reasons. First, the interpretation of this procedure is 
hampered due to a lack of a gold standard, especially in case of a normal 
FDG-PET-scan. When additional diagnostic procedures were negative and a 
follow-up of at least three months did not reveal new infectious foci or a relapse 
after discontinuation of therapy, it was considered appropriate to presume that 
other infectious foci were indeed absent. Second, FDG-PET cannot exclude cerebral 
disease or meningitis, because physiologic uptake in the cerebral cortex in most 
cases obscures any pathological uptake. Besides physiologic uptake of FDG in the 
brain, normal activity in the heart, the kidneys and the bladder severely hampers 
the delineation of disease in these organs. Variable physiologic FDG-uptake in the 
bowel is possible [22] and can thus lead to a false positive interpretation, although 
this problem was not encountered in our group of patients. 
Detection of infectious foci by CT, MRI and ultrasonography is difficult in an early 
phase because of the lack of substantial anatomical changes at that time. Also, 
discrimination of active infectious lesions from residual changes due to cured 
processes or surgery remains difficult. FDG-PET shows functional changes caused 
by activation of inflammatory cells and does not depend on anatomical changes. In 
addition, advantages of FDG-PET in suspected metastatic infection, compared to 
CT and MRI, are whole body screening, high contrast resolution, absence of 
disturbance by metallic implants and absence of contrast-related side effects (CT). 
Conventional radiopharmaceuticals routinely used in clinical practice (67Ga-citrate 
and 111In-labeled or 99mTc-labeled leucocytes or IgG) have several disadvantages, 
such as normal accumulation in liver and spleen, handling of potentially infected 
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blood products, and high radiation burden (67Ga) [23]. Advantages of FDG-PET are 
early imaging (one hour vs. up to 48 hours), higher resolution, high target-to-back-
ground ratio (24), sensitivity in chronic low-grade infections [25-27], high accuracy 
in the central skeleton, liver, spleen and vascular system, and high interobserver 
agreement [25]. Obvious disadvantages are the relatively high cost and the currently 
limited availability. However, when FDG-PET performance for this indication is 
confirmed in larger prospective studies and the number of PET-systems further 
increases, the high diagnostic yield of FDG-PET may well become a clinically 
significant and also cost-effective modality, since adequate early diagnosis limits 
the number of non-contributing (invasive) tests required and the time to diagnosis 
and thus facilitates adequate antibiotic and/or local (surgical) therapy. A further 
potential application, that needs to be investigated, is the contribution of FDG-PET 
in determining the duration of antimicrobial treatment in patients with metastatic 
infection.
Conclusion
FDG-PET is a valuable imaging technique in patients at high risk of metastatic 
infectious disease even when the results of other diagnostic procedures show no 
signs of infection. However, for a validation of FDG-PET for this indication and for 
determination of its exact position in the order of diagnostic tests, prospective 
studies in a larger number of patients are warranted.
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Fluorodeoxyglucose positron emission tomography in detecting metastatic infectious disease
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Abstract
Timely detection of metastatic infectious foci in Gram-positive bacteraemia is 
crucial, because these foci often require prolonged antibiotic treatment or drainage. 
Diagnosis of metastatic infectious foci is difficult since localizing symptoms are 
often absent. We investigated whether FDG PET/CT scanning is able to detect such 
foci and if detection influences clinical outcome.
Methods
115 non-neutropenic patients with Gram-positive bacteraemia were prospectively 
included. Patients with positive blood cultures growing Staphylococcus aureus, 
Streptococcus species or Enterococcus species were eligible when a risk factor for 
developing metastatic infectious foci was present. FDG PET/CT  was performed 
within 2 weeks after the first positive blood culture. Abnormal FDG-uptake had to 
be confirmed by either radiological, microbiological, or pathological studies. Results 
were compared  with a matched historical control group of 230 patients in whom no 
FDG PET/CT was performed. 
Results
Significantly more patients were diagnosed with metastatic foci in the study group 
(67.8% versus 35.7%). FDG PET/CT was the first to delineate infectious foci in 35 
patients (30%). Sensitivity, specificity, NPV and PPV of FDG PET/CT were 100%, 87%, 
100%, and 89%. Relapse rates decreased from 7.4% to 2.6 % among study patients 
(p=0.09), and from 8.9% to 1.4% in patients with S. aureus (p=0.04). Overall mortality 
after 6 months decreased from  32.2% to 19.1% in the FDG PET/CT group  (p=0.014).
 
Conclusion
FDG PET/CT is a valuable technique in the diagnostic work-up of high risk patients 
with Gram-positive bacteraemia that results in lower mortality rates. In patients 
with S. aureus bacteraemia,  relapse rates decreased significantly after addition of 
FDG PET/CT .
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Introduction
Timely detection of metastatic infectious foci in Gram-positive bacteraemia is crucial, 
because these foci require prolonged antibiotic treatment and in some cases drainage. 
Insufficiently eradicated infectious foci result in relapse of infection after cessation 
of antibiotic treatment in 12-16% of cases [1,2]. Mortality rates are significantly 
higher in case of metastatic complications or relapse [3,4]. Diagnosis of complicating 
infectious foci is often difficult since up to 32% of these foci do not have any 
localizing symptoms and signs [5,6]. To date, no guidelines addressing the diagnostic 
workup of patients with Gram positive bacteraemia are available, except for the 
advice to perform echocardiography in patients with S. aureus bacteraemia [7]. 
A sensitive imaging technique suitable for screening of complicating infectious foci 
might be very helpful to identify patients in need of prolonged antibiotic treatment. 
CT, MRI, and ultrasonography are less suitable as screening methods when clues for 
specific sites of infection are absent [8,9]. fluorodeoxyglucose (FDG) accumulates in 
metabolic active cells including activated leucocytes at the site of infection enabling 
imaging of inflammatory processes [10]. Whole body FDG positron emission 
tomography (FDG PET/CT ) is therefore potentially useful to delineate metastatic 
infectious foci. In a retrospective study in a selected patient population with 
bacteraemia, FDG PET/CT diagnosed clinically relevant new infectious complications 
in 45% of patients with a very high negative predictive value [11]. To date there is 
very limited data on infection imaging by FDG PET/CT in deeply neutropenic 
patients. The present prospective study investigated whether FDG PET/CT enables 
early and accurate diagnosis of metastatic infectious complications in patients with 
Gram-positive bacteraemia and risk factors for complicating infectious foci and 
whether detection of metastatic foci influences clinical outcome by enabling early 
and more accurate diagnosis of those foci.
Study design and patients
From November 2005 until January 2008, patients were prospectively recruited 
from the Radboud University Nijmegen Medical Center, a 950-bed university 
hospital. All non-neutropenic (neutrophil count ≥0.5*109) adult patients (≥ 18 y.o.) 
were eligible when at least 1 of the following known risk factors for the presence of 
complicating infectious foci was present: community acquisition, signs of infection 
>48 hours before initiation of appropriate treatment, fever >72 hours after initiation 
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of appropriate treatment, positive blood cultures >48 hours after initiation of 
appropriate treatment [3,5,12]. Patients primarily admitted to the intensive care unit 
(ICU) were included only when transferred to regular patient wards within 14 days 
after the first positive blood culture. Exclusion criteria were polymicrobial infection 
and pregnancy. The records of all patients with positive blood cultures growing S. 
aureus, Streptococcus species (excluding S. pneumoniae) or Enterococcus species 
were reviewed for eligibility as soon as blood culture results were available. The 
protocol was approved by the institutional review board. Written informed consent 
was obtained from all patients. The study has been registered in the ISRCTN data - 
base, number 76425553.
A historical control group was defined using the electronic database of the 
department of microbiology in which all culture results of clinical specimens are 
available. A pool of 456 patients diagnosed with Gram-positive bacteraemia 
between January 2000 and December 2004 in whom FDG PET/CT was not performed 
was identified. Patients having at least 1 of the known risk factors for developing 
complicating infectious foci were eligible for inclusion in the control group. For 
every prospectively included patient, 2 control patients were matched for the type 
of microorganism, site of acquisition of the infection, and the presence or absence 
of additional risk factors (treatment delay, persistent fever, or both). Presence of 
persistently positive blood cultures >48 hours after initiation of treatment was not 
included as a risk factor in the matching strategy as blood cultures had not been 
obtained in a standardized way in the retrospective cohort.
Clinical features
The portal of entry was defined as a localized site of infection preceding bacteraemia. 
A central venous catheter (CVC) was considered a portal of entry if there was 
evidence of inflammation at the insertion site or if culture of the catheter tip grew 
the same microorganism as the blood culture in the absence of evidence for another 
source of infection. Respiratory or urinary tract infections were diagnosed as portal 
of entry only when specific symptoms and signs were present in addition to positive 
culture results. Phlebitis due to peripheral intravascular catheters and cellulitis, 
categorised as skin infections, were considered as portals of entry.
Bacteraemia was considered to be nosocomial if only blood cultures taken after >48 
hours of hospitalization were positive and clinical signs of the infection were absent 
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at the time of admission. All other infections were considered community-acquired. 
Both infectious foci without anatomic relation to the portal of entry and direct 
extension of the infection beyond the primary focus of infection were defined as 
complicating infectious foci. Endocarditis was defined according to the Duke criteria 
[7]. 
Metastatic infectious foci, which were not diagnosed during the first period of 
infection, or a second period of bacteraemia with the same micro-organism, both 
within 3 months of the first positive blood culture, were defined as relapse of 
infection. Patients were considered cured if no symptoms or signs of infection were 
present 3 months after discontinuation of antibiotic treatment. Infection was 
considered contributory to death using the criteria described elsewhere [12,13]. The 
outcome was assessed in a blinded fashion, independent of knowledge of the 
predicting variables and imaging results. 
Diagnostic workup
FDG PET/CT was performed as soon as possible after inclusion. The maximum time 
between the first positive blood culture and FDG PET/CT was 2 weeks. Since 
antibiotic treatment can be stopped after 2 weeks in uncomplicated bacteraemia, 
the decision to prolong treatment because of infectious complications should be 
made within those 14 days.  
An integrated PET/CT scanner (Siemens Biograph, Knoxville, TN, USA) was used for 
data acquisition. Prior to FDG-injection, patients fasted and glucose or insulin-con-
taining intravenous infusions were discontinued for at least 6 hours. Glucose was 
below 12.0 mmol/l in all diabetic patients at the time of FDG injection. One hour 
after intravenous injection of 200-220 MBq FDG (Covidien, Petten, The Netherlands), 
a low-dose CT, without contrast enhancement, of the area between the proximal 
femora and the base of the skull was made for anatomical correlation and 
attenuation correction of the PET data. Subsequently, emission images of the same 
area were acquired. FDG PET/CT images were evaluated without knowledge of prior 
clinical evaluation and imaging results. Abnormal FDG-uptake was a trigger to 
perform conventional radiological, microbiological or pathological studies when 
possible to confirm the diagnosis. All confirmed infectious focus were reported to 
the attending physician.
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Except for FDG PET/CT and the diagnostic procedures needed for confirmation of 
abnormal FDG PET/CT results, standard diagnostic and therapeutic procedures 
were followed. Conventional radiological techniques before FDG PET/CT were only 
performed at the discretion of the attending physician. Transthoracic echocardiog-
raphy, followed by transoesophageal echocardiography was to be performed in all 
patients. In the study group, additional blood cultures were taken 24, 48, and 72 
hours after the first positive blood culture and 48 hours thereafter when subsequent 
blood cultures were positive. C-reactive protein and leukocyte counts were ordered 
twice weekly. FDG PET/CT results were considered  abnormal if focal accumulation 
of FDG was detected. Results were considered to be true positive when abnormal 
FDG-uptake pointed to the organ or tissue in which infection was eventually 
diagnosed. Abnormal results were categorized as false positive when the 
abnormality could not be confirmed. Normal test results were true negative when 
no complicating infectious foci were diagnosed within 2 weeks following FDG PET/
CT . Abnormal test results not related to metastatic infection that were caused by a 
confirmed alternative diagnosis (i.e. cancer) were also considered true negative. 
Antibiotic treatment was not influenced by these foci. Normal test results were 
considered false negative when a localised infectious focus was diagnosed. AsFDG 
PET/CT is unsuitable for detection of infectious foci within the brain, the heart and 
kidney due to high physiological FDG uptake, FDG PET/CT was not evaluated for 
metastatic foci in those organs. Within the study period (2000-2008) the diagnostic 
work-up or treatment of patients with Gram-positive bacteraemia remained 
unchanged in our hospital. If no complicating infectious foci were detected, 
standard duration of treatment was 14 days. Treatment was prolonged to 6-12 
weeks in case of complicating infectious foci depending on the site of infection and 
clinical response according to clinical practice. Endocarditis was treated according 
to international guidelines [14].
Diagnosis and patient follow-up
The final diagnosis served as a standard of reference and was based on microbio-
logical and pathological results. If these results were not available, the probable 
final diagnosis was based on conventional radiological procedures and clinical 
follow-up. The final diagnosis was never based on the results of the FDG PET/CT 
scan alone. Patient follow-up was performed for 6 months after the first positive 
blood culture (FJV). Epidemiological data, number, type, and results of all diagnostic 
tests, and treatment data were registered in a structured database (Microsoft 
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Access). Mortality data were obtained for all patients at three and 6 months after 
diagnosis.
Outcome parameters
The primary outcome parameter was relapse of infection. Secondary outcome 
measures were overall and attributable mortality after 3 and 6 months, duration of 
antibiotic treatment, number of diagnostic procedures performed to confirm FDG 
PET/CT results.
Statistical analysis
The study was designed to detect a statistically significant difference of 10% 
between the study group and a historic control group (alpha 0.05, power 0.80; 
2 group Chi-square test, 2-sided). This design required 115 evaluable study patients 
and 230 patients in the historic control group. An intention to treat analysis was 
performed. Differences between groups were tested with Fisher’s exact tests for 
categorical variables. Differences were considered to be statistically significant at p 
less than 0.05 (2-sided). Cox  proportional-hazards models were used to analyze  the 
relationship between durations (survival, duration of therapy) and exploratory 
variables after adjustment for  potential confounding variables. In case no statistical 
significant confounding variables were detected Kaplan-Meier curves were 
estimated. We used SPSS, version 16.0 for the analyses.
Results
115 study patients and 230 control patients were included in the study (Figure 1). 
For 102 of 115 (89%) study patients, 2 perfectly matching controls were found 
(Table 1). The remaining 13 study patients were always matched with control 
patients with the same type of micro-organism. Overall, the control patients had 
fewer additional risk factors than the study patients (89% vs. 80%, p< 0.05). 
Treatment delay was added as a covariate in the final analysis, but showed to be an 
insignificant covariate (confounder) in all the analysed Cox proportional-hazards 
models, therefore Kaplan-Meier analyses were performed. Identification of the 
portal of entry of infection was similar for study and control patients. 
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Figure 1 Enrolment of prospectively included study patients and historical control patients 
from the database of the department of medical microbiology.
A false positive FDG PET/CT scan was found in 7 patients: 
•  Localised colonic uptake followed by normal colonoscopy was seen in 2 patients. 
•  In 1 patient, shoulder uptake was not accompanied by hydrops on ultrasound, but no 
puncture was performed. 
•  Confirmed mediastinal lymfadenopathy on CT-scanning was seen in 1 patient, but no 
further diagnostic tests were performed. The lymphadenopathy had disappeared after 6 
months of follow-up. 
•  Pleural uptake without pleural effusion on chest X-ray was seen in 1 patient. She died 
before further investigations could be performed. 
•  In 1 patient, uptake in the psoas was suggested to be due to a recent bleeding on CT 
scanning. No cultures were taken. She was treated for 6 months because of an infected 
knee prosthesis. Abnormalities on Ct scanning  disappeared. 
•  In 1 patient, FDG uptake was present at the site of a pacemaker lead. He refused trans-
oesophageal echocardiography. He was treated for 6 weeks until a presumed infected 
kidney stone was removed. No relapse of infection appeared occurred. 
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FDG PET/CT was performed in 111 of 115 study patients at a median of 7 (mean 6.8) 
days after the first blood culture became positive. Significantly more metastatic foci 
were identified in study patients as compared to control patients: 67.8% vs. 35.7% 
(p<0.05, Table 2). Almost 40% of the study patients with metastatic foci had more 
than one localisation, as compared to 27% in the controls. More than half of the 
patients with endocarditis in both groups also had another metastatic localisation. 
Figure 2 shows an example of a CT confirmed mycotic aneurysm that was 
asymptomatic. In 50% of all patients eventually diagnosed with metastatic infection, 
no signs and symptoms suggesting metastatic complications were present before 
FDG PET/CT  was performed. FDG PET/CT was the first to delineate 44 (35%) of all 
124 metastatic infectious foci in 35 patients (30% of all patients). In 26 of these 35 
patients the metastatic foci were not associated with clinical signs, guiding the 
attending physician. Nevertheless, in 7 of those patients prior investigations were 
performed (5 ultrasounds, 1 CT scan and 1 MRI). In 5 of the 9 remaining patients who 
did have guiding symptoms, prior diagnostic procedures (4 CT scans, and 1 MRI) 
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 Table 1   Localization of metastatic infectious foci in 30 patients eventually 
diagnosed with metastatic disease.
Study patients 
(n=115)
Control 
patients 
(n=230)
P value
Male 56% 52% 0.57
Mean age (years ± SD) 59 ± 16 58 ± 16
Matching criteria
      Microorganism: S. aureus
                                 Strep. spp
                               Enterococcus spp
      Community acquisition
      Additional risk factors
                               Treatment delay
                               Persistent fever
n=73 (64%)
n=30 (26%)
n=12 (10%)
70%
27%
46%
n=146 (64%)
n=60 (26%)
n=24 (10%)
68%
45%
37%
1.0
1.0
1.0
0.71
0.01
0.13
Remaining possible risk factors
     Portal of entry unknown
     CVC not removed within 48 hrs
     Persistent positive blood cultures
     Immune suppression
52%
5%
16%
22%
46%
8%
6%*
17%
0.30
0.50
0.006
0.30
* not routinely obtained in the control group
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had not revealed the focus of infection. In the remaining 4 patients with guiding 
symptoms, conventional diagnostic procedures were delayed due to logistic 
reasons in 2 patients and syptoms had not led to ordering additional imaging in the 
remaining 2 patients. To confirm FDG PET/CT findings, 24 ultrasounds, 16 CT scans, 
and 7 MRI scans were performed. Echocardiography was performed significantly 
more often in the study group (83% vs. 29%, p=0.001). The difference in patients 
with metastatic foci between both groups remains significant (p<0.001), when 
patients with endocarditis alone are excluded from the analysis. For delineating 
metastatic infectious foci, FDG PET/CT had a sensitivity of 100%, a specificity of 87%, 
Chapter 4
 Table 2   Localisation of metastatic foci and number of foci first detected by FDG 
PET/CT.
Metastatic foci Study patients 
(n=115)
Control patients 
(n=230)
total number first detected  
by FDG-PET
total number P value
Patients with foci identified 78 67.8%  82 35.7% <0.01
Total number of foci 124 113
Organ system  
    Endocarditis 21 18.3% 0 19 8.3% 0.01
    Endovascular 20 17.4% 12  9 3.9% <0.01
    Lung 12 10.4% 6  8 3.5% 0.01
    Liver 1 0.9% 0 1 0.4% 1.0
    Spleen 1 0.9% 1 0 0% 1.0
    Arthritis 10 8.7% 3 28 12.2% 0.37
    Spondylodiscitis 11 9.6% 8 10 4.3% 0.09
    Osteomyelitis 6 5.2% 1 3 1.3% 0.06
    Psoas abscess 3 2.6% 2 1 0.4% 0.11
    Soft tissue 11 9.6% 4 12 5.2% 0.18
    Central nervous system 11 9.6%  3*  7 3.0% 0.02
    Eye 3 2.6% 0  0* 0% 0.04
    Joint prosthesis 9 7.8% 3  5 2.2% 0.02
    Intra-abdominal 4 3.5% 1 6 2.6% 0.74
    Kidney 1 0.9% 0 4 1.7% 0.67
In 30 study patients and 22 controls more than one metastatic localisation was identified.
* Epidural extension of FDG uptake in 3 patients with spondylodiscitis, confirmed by MRI.
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a negative predictive value of 100%, and a positive predictive value of 89%. 
Information regarding the 7 patients with false positive FDG PET/CT results is shown 
in Figure 1.
Relapse rate was 7.4% in controls and 2.6% in the study group (Table 3). In the 
S. aureus subgroup, however, significantly fewer study patients had a relapse of 
infection than controls (p=0.04). Overall mortality rate was 16.6% in the study group 
at 3 months of follow-up and 25.7% in the control group (p=0.06). Eight patients 
had died after relapse of infection in the control group versus 2 study patients. The 
difference in overall mortality rate remained significant during 6 months of follow 
up (19.1% vs. 32.2%, p=0.014) in the Kaplan-Meier models (Figure 3). Infection 
contributed to death in 80% of study patients and 74% of controls (P=0.7). After 6 
months of follow-up, infection-related mortality decreased from 24.3% in controls 
to 14.8% in study patients (p=0.049). In all but 2 patients in each group, 6-month 
follow-up data were available. In the study group, the median duration of treatment 
was longer. Median duration of treatment of patients without metastatic foci of 
infection was 14 days in both groups (Figure 4) . When metastatic infectious foci 
were present study patients as well as control patients were treated significantly 
longer in both groups (median 45 and 36 days, respectively). In the study group, 
73 of the 78 patients with metastatic foci were treated for more than 14 days. After 
the diagnosis of infectious complications, percutaneous or surgical drainage was 
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Figure 2  FDG PET/CT of a patient with community acquired S. aureus bacteraemia and 
proven endocarditis, presenting with fever, heart failure, and a new cardiac murmur 
(aortic valve insufficiency).
FDG PET/CT detected accumulation in the left common iliac artery (arrow) due to a 
clinically silent mycotic aneurysm. This finding resulted in prolonged treatment with 
antibiotics and monitoring of aneurysm size. A-C : coronal sections  (A: FDG PET/CT; B: CT; 
C: integrated FDG PET/CT). 
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 Table 3   Clinical endpoints at 3 and 6 months follow-up.
Study patients Control patients P Value*
Total group (at 3 mo) n=115 n=230
   Cure 72 (62.6%) 151 (65.6%) 0.63
   Relapse 3 (2.6%) 17 (7.4%) 0.09
   Persisting infection 21 (18.2%) 3 (1.3%) 0.001
   Mortality 19 (16.6%) 59 (25.7%) 0.06
S.aureus subgroup (3 mo) n=73 n=146
   Relapse 1 (1.4%) 13 (8.9%) 0.04
Total group (at 6 mo)† n=115 n=230
   Cure 83 (72.2%) 154 (66.9%) 0.26
   Persisting infection 8 (7%) 0 <0.001
   Overall mortality
   Infection related mortality
22 (19.1%)
17 (14.8%)
74 (32.2%)
56 (24.3%)
0.007
0.049
   Lost to follow up 2 (1.7%) 2 (0.9%) 0.60
* P values are estimated by Fisher-exact tests.
†  At 6 months follow up 8 patients had died after relapse of infection in the control group versus  
2 study patients.
Figure 3  Kaplan-Meier curve for survival at 6 months follow-up in the study and the 
control group.
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performed in 30 of these patients. Another 6 patients underwent cardiac valve 
replacement. In 5 patients treatment was not prolonged. Three of those patients 
died. Six of the study patients were still being treated at the end of follow-up.
Discussion
This prospective study with matched historical controls showed that relapse rate 
and mortality decreased when FDG PET/CT is performed in patients with 
Gram-positive bacteraemia and at least 1 risk factor for developing complicating 
infectious foci. With the use of FDG PET/CT, metastatic foci were found in a larger 
proportion of study patients compared to control patients (p<0.001). In previous 
studies investigating Gram positive bacteraemia, the reported incidence of 
complicating foci varies between 16 and 35%, which is comparable to the percentage 
of complicating foci in the control group (36%) [1,3,12,15]. The percentage of 
complicating infectious foci delineated in the FDG PET/CT group, however, is much 
higher: 68%. In 35 patients (30% of all patients), metastatic infectious foci were first 
revealed by FDG PET/CT, despite the fact that FDG PET/CT was considered 
experimental: priority was given to other clinically indicated diagnostic procedures 
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Figure 4  Kaplan-Meier curves for the duration of treatment.
Panel A : duration of treatment between the study and control group when metastatic foci 
were present. 
Panel B : duration of treatment between the study and control group when metastatic foci 
were absent. 
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and FDG PET/CT was sometimes postponed, as long as the 14 days time limit was 
not reached. FDG PET/CT delineated significantly more endovascular, pulmonary, 
and spine infections in comparison with the control patients in whom no FDG PET/
CT was performed, which is not surprising since these infections often lack localising 
symptoms. These sites of infection, however, should not be missed because 
treatment should be prolonged, and surgical intervention is indicated in a 
proportion of these patients. Remarkably, duration of treatment in six of the 22 
patients with endocarditis was dictated by a second complicating infectious foci 
requiring prolongation of antibiotic treatment. As expected, endocarditis was not 
detected by FDG PET/CT due to physiological uptake in the myocardium [16]. In line 
with international guidelines, echocardiography was strongly advocated both in 
our protocol, as it was in clinical practice in previous years [7,14]. Nevertheless, echo-
cardiography was performed significantly more often in the study group, resulting 
in a more frequent diagnosis of endocarditis. However, when patients with 
endocarditis alone were excluded, still metastatic foci were found significantly 
more often in the study  group. This indicates that the higher incidence of patients 
with metastatic infections in the study group was not caused by the increased use 
of echocardiography, as significantly more metastatic infections at other anatomical 
sites were also diagnosed. 
The early detection of metastatic infectious foci facilitated the adaptation of 
treatment in patients at high risk of relapse. In the study group, the overall relapse 
rate was only 2.6%. This did not differ significantly from the 7.4% among controls. 
The study was designed to detect a 10% decrease in relapse rate. In the subgroup 
with S. aureus bacteraemia, however, a significant improvement in relapse rate from 
8.9% to 1.4% was found. Compared to literature our historic relapse rate in S. aureus 
bacteraemia is low (8.9 vs. 12-16%), possibly due to the low number of Meticillin 
resistant S.aureus (MRSA) infections (<2%) and concomitant vancomycin use in our 
study [17]. It was hypothesized that early mortality due to sepsis cannot be 
prevented by early detection of metastatic infection, so total mortality was only 
regarded as a secondary outcome parameter. However, overall and infection related 
mortality proved to be significantly lower in the study group after follow up of 6 
months.
A limitation of our study is the use of a historical control group. However, the control 
group was both large in size and matched for the risk profile for developing 
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metastatic infectious complications [3,5,12,18,19]. Furthermore, the study patients 
had more additional risk factors than the control patients taking into account the 
larger number of persisting positive blood cultures. Thus, the overall risk for relapse 
of infection should have been higher in the study group. As treatment delay might 
have been an important confounder being significantly more present among 
control patients, this was added as a covariate in the final analysis. This did not 
influence the outcome on survival at 6 months of follow-up. There were no 
differences in the management of patients with Gram positive infections as 
protocols for diagnostic evaluation and treatment did not change within the period 
2000-2008. The median duration of treatment was significantly longer in the 
presence of metastatic infectious foci with a difference between study and control 
patients. This difference was probably due to the fact that more endovascular 
infections (17% vs 4%) were found in the study group, which require prolonged 
antibiotic treatment. As stated, most of these infections were delineated first by 
FDG PET/CT due to lack of guiding symptoms. Therefore, it is highly likely that the 
difference in the number of metastatic foci  and the reduced relapse rate and 
mortality rates can be attributed to the addition of FDG PET/CT to the diagnostic 
regimen.
Conclusion
FDG PET/CT detected clinically relevant new complicating infectious foci in 30% of 
all study patients with a very high negative predictive value. The addition of FDG 
PET/CT to the diagnostic work-up led to a decrease of relapse rates and overall and 
infection-related mortality of Gram-positive bacteraemia by early detection and 
treatment of metastatic infectious foci.  FDG PET/CT is thus a valuable technique in 
the diagnostic work-up of all patients with Gram positive bacteraemia and at least 
one risk factor for developing metastatic complications.
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Abstract
Gram-positive bacteraemia has a high morbidity and mortality rate of approximately 
30%. Delayed diagnosis of clinically silent metastatic infectious foci is an  important 
indicator for complicated outcome. FDG-PET/CT allows detection of focal infection, 
resulting in lower relapse rates and mortality. Here, we present a cost-effectiveness 
analysis associated with introduction of FDG-PET/CT in patients with Gram-positive 
bacteraemia.
 
Methods  
A cost effectiveness analysis in a prospective FDG-PET/CT group (n=115) and 
matched control group (n=230) was performed alongside the clinical study 
published before (JNM 2010;51:1234-40) . Mortality at 6 months was considered the 
final effect outcome and used in the denominator of the incremental cost-effective-
ness ratio (ICER).
 
Results  
Mortality in the FDG-PET/CT group was 19% compared to 32% in the control group 
(p<0.01). Incremental costs of FDG-PET/CT were €6,303 (95%CI €2,642-9,965), mainly 
due to admission (mean €4,421; 95%CI €966-7,876). Additional costs were related to 
echocardiography (p<0.01), not to FDG-PET/CT (p=0.8). The mean incremental costs 
of the FDG-PET/CT strategy estimated by stratification for endocarditis were €3,518 
per patient (95%CI €286-6,749), p=0.03. The point estimate of the ICER is €48,325 
per mortality case prevented (95% CI €7,592-215,586).
 
Conclusion 
Introduction of a diagnostic regimen including routine FDG-PET/CT decreases 
morbidity and mortality. The cost increase is due to in-hospital treatment of 
metastatic infectious foci. Costs per mortality case prevented of €48,325 are within 
the range that is considered to be efficient by Dutch guidelines. Patients with high 
risk Gram-positive bacteraemia therefore should have easy access to FDG-PET/CT to 
enable early detection of metastatic infectious disease.
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Introduction
Gram-positive bacteraemia is a serious and growing health care problem known for 
its high morbidity and a mortality rate of approximately 30% [1-5]. In several 
European studies, the incidence of Staphylococcus aureus bacteraemia (SAB) 
increased to 17-19 per 100.000 inhabitants in the past decades [6,7]. In the same 
time frame, both community acquired and nosocomial SAB increased more than 2-3 
fold to approximately 250 per 100,000 hospital discharges in the US [8,9]. Among 
survivors of nosocomial bloodstream infections at a surgical ICU, median hospital 
stay of surgical patients was extended by 14-24 days once admission was 
complicated by a bloodstream infection [10,11]. Delayed diagnosis of disease activity 
and subsequent treatment is one of the most important indicators for complicated 
outcome [12]. Incomplete eradication of either the primary infection or secondary 
metastatic infectious foci appears to be the most important contributor to worse 
outcome and relapse of infection specifically in Gram positive bacteraemia [13]. 
A substantial part of metastatic infectious foci (32%) are clinically silent as they 
lack guiding symptoms [14]. To date, diagnostic strategies after Gram-positive 
bacteraemia are mainly symptom based, even though metastatic infectious foci are 
described in 16-36% of patients in daily clinical practice [2-5]. Extra costs attributable 
to infection averaged $30,000 to $40,000 in the 1990s and may be higher at present 
[10,11]. Routine echocardiography in SAB to assess endocarditis is the only imaging 
technique that has been studied extensively. Routine echocardiography proved to 
be cost effective and is recommended in international guidelines to rule out 
infective endocarditis in patients with high risk bacteraemia [15,16]. 
It has been hypothesized that scintigraphic whole body imaging techniques are 
helpful in detecting clinically silent infectious foci other than endocarditis [17]. 
In an earlier study, FDG-PET/CT proved to reveal clinically relevant metastatic foci, 
despite the fact that a median of three conventional imaging techniques had 
been performed before FDG-PET/CT had been ordered [18]. As uncomplicated 
bacteraemia can be cured with 2 weeks of antibiotic treatment, metastatic foci 
ideally should be revealed within the first 2 weeks after admission in order to enable 
the physician to adjust treatment, e.g. either to prolong antibiotic treatment or 
perform surgical drainage [19-21]. Most metastatic foci require at least 6 weeks or 
longer of antibiotic treatment to be cured.
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In a prospective matched control study published before in this journal, we have 
shown that introduction of FDG-PET/CT for detection of metastatic infectious foci in 
patients with SAB or Streptococcus spp. bacteraemia (SSB) reduced both relapse 
rates and mortality due to SAB and SSB [1]. In the present study, performed alongside 
the aforementioned clinical study, we assessed costs associated with the 
introduction of FDG-PET/CT for this indication. This results in information about the 
efficiency or cost-effectiveness of the addition of FDG-PET/CT in high risk patients 
with Gram-positive bacteraemia. The cost-effectiveness analysis was performed 
from a health care perspective, meaning only direct medical costs related to 
diagnosis, treatment and admission were analysed. We hypothesized that early 
detection and treatment of metastatic foci would be cost effective as fewer patients 
would be re-admitted and treated for relapse of infection, or delayed cure.
Methods 
Design
The methodology of the clinical study was published earlier [1]. In brief, between 
2005 and 2008 FDG-PET/CT was performed in the first 2 weeks after admission in 
111 of 115 prospectively included study patients with Gram-positive bacteraemia 
and at least one risk factor for the development of metastatic infectious foci: 
community acquisition, signs of infection >48 hours before initiation of appropriate 
treatment, fever >72 hours after initiation of appropriate treatment, or positive 
blood cultures >48 hours after initiation of appropriate treatment. Study patients 
were matched on micro-organism and their risk profile for the presence of metastatic 
infectious foci with 230 historical control patients in the same hospital in the 4 years 
preceding the prospective study in whom no FDG-PET/CT was performed. Echocar-
diography was facilitated routinely in the FDG-PET/CT group and was only 
performed at the discretion of the attending physician in the historical control 
group. Metastatic infectious foci included those localized infectious foci without 
anatomical relation to the portal of entry of bacteraemia (i.e. hematogenous 
spreading), or direct extension beyond the anatomical borders of the primary 
source of infection (e.g. abscess formation following wound infections). Endocarditis 
was defined according to the DUKE criteria [22].
Next to clinical data, cost data were collected based on the principals of a cost 
effectiveness analysis. An electronic case record form was used to collect resource 
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consumption data (Microsoft Access 2003). Both in the prospectively acquired study 
population as well as in the historical control group only health care variables and 
medical costs were collected, using a micro-costing approach, meaning all relevant 
cost components are defined at the most detailed level [23]. 
Effect measures that were collected and considered relevant to the cost effectiveness 
analysis were relapse rate, defined as confirmed relapse of infection within 3 months 
after completion of antibiotic treatment and mortality at 6 months of follow-up. 
Mortality is considered the final outcome (together with costs) and is used in the 
denominator of the incremental cost-effectiveness ratio. Differences in relapse rate 
are reported as consequence of the comparison between both the FDG-PET/CT 
group and the historical controls. The cost-effectiveness ratio is expressed as costs 
per mortality case prevented. Potential confounders between both study groups in 
the clinical study were taken into account in the analysis by sub-stratification or by 
adding as a covariate to the linear regression model.
Cost analysis
All medical costs associated with the experimental strategy were collected 
prospectively. Also, the costs related to more accurate diagnostics resulting in more 
appropriate treatment of patients were collected. Direct costs related to the 
diagnosis and treatment of patients with complicated blood stream infection 
included admission days in the ICU and general ward, all imaging techniques, 
antibiotic treatment, specialist consultation, and surgical interventions. Costs of the 
primary visit to the emergency room department, routine blood examinations, 
blood cultures and chest X-rays were not included in the analysis as they belong to 
regular care and there were no differences on a per patient basis in both study 
groups. The cost analysis had two main parts. First, at the patient level, the duration 
of hospital admission, length of antibiotic treatment, and numbers and types of 
procedures were considered in both the historic control group and the prospective 
study group. In the second part of the cost analysis, prices were determined for 
each unit of health care consumed. Subsequently, these were used for multiplying 
the volumes registered for each patient. In case of relapse of infection, the same set 
of items was collected and costs were added to the total costs of the first admission. 
The prices per item were retrieved from various sources (Table 1).The costs of 
antibiotic treatment were assessed using a standardized method of full cost 
calculation (including administration and monitoring costs) as published before 
[24,25]. The Dutch guidelines for conducting pharmaco-economic studies and the 
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guidelines for cost analyses were used [26,27]. Costs were adjusted to the price level 
of the first quarter of 2007 based on the consumer price index (CPI) as presented by 
the Central Bureau of Statistics (CBS, www.statline.nl). Mean, median, range and 
standard deviation of the total medical costs per patient were determined for each 
of the two  groups. Depending on the skewness of the distribution, costs were 
either log-transformed or not. On costs, parametric statistical testing was done. 
The incremental costs of FDG-PET/CT alone were estimated by excluding all patients 
with endocarditis. The reason for this was the fact that echocardiography is the 
preferred imaging technique to detect endocarditis. Due to physiological 
FDG-uptake in the myocardium FDG-PET/CT was not analysed for possible 
endocarditis. Therefore  FDG-PET/CT and echocardiography both should considered 
as a potential but  independent improvement in patient management, detecting 
clinically relevant infectious metastatic foci.   In the FDG-PET/CT group, besides 
FDG-PET/CT, also echocardiography had been performed significantly more often 
compared to the control group (P<0.01), resulting in the detection of significantly 
more patients having endocarditis
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 Table 1   Clinical endpoints at 3 and 6 months follow-up.
Unit parameter Costs in € Source
Hospital day Oostenbrink25, NZA*
          General ward 513
          Intensive Care Unit 1817
Specialist consultation 36 NZA
Imaging techniques NZA
          CT 146
          Ultrasound 47
          MRI 179-227
          FDG-PET/CT 1212
          Echocardiography 36
Antibiotic treatment per day, mean (range) 37.6 (0.29-106) CVZ†
Surgical intervention 125-1684 NZA
* Dutch Healthcare Authority (www.nza.nl)
† Care Insurance Board (www.cvz.nl)
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Cost-effectiveness analysis
Uncertainty surrounding the incremental cost-effectiveness ratio (ICER), expressed 
as costs per percentage mortality prevented was determined with the bootstrap 
method resulting in a mean and confidence interval, which are presented in a cost-
effectiveness plane. The 95% confidence interval is estimated using the percentile 
method. Finally a cost-effectiveness  acceptability curve (CEAC) was derived 
enabling to evaluate efficiency  by exploring a range of thresholds (willingness to 
pay for a percentage mortality prevented). The graph shows how many of the 
bootstrap replications fall to the right of some line with the slope equal to the ICER, 
given a certain willingness to pay for a percentage mortality prevented. It reads as 
follows: for an increasing willingness to pay for a percentage mortality prevented, 
the probability that the addition of PET-scan becomes cost-effective increases 
according to the shape of the acceptability curve.
Results 
Clinical trial
Patient characteristics and results of the clinical trial have been reported earlier [1]. 
The main results of the clinical study are presented in table 2. Both relapse rate 
(2.6% vs. 7.4%, P=0.07) and mortality (19% vs. 32% , p<0.01) were favorable in the 
FDG-PET/CT group compared to the matched historical control group (1). 
The length of hospital stay was similar in both the FDG-PET/CT and control group; 
27 and 28 days respectively in the presence of metastatic infection and 14 days in 
both groups in the absence of metastatic infection. Duration of treatment also 
depended on the presence or absence of metastatic infectious foci in both groups. 
During follow-up, no additional foci became apparent in the study group, indicating 
that no clinically relevant lesions were missed. To confirm FDG PET/CT findings, 24 
ultrasounds, 16 CT scans, and 7 MRI scans were performed.
Echocardiography, however, was a potential confounder as it was performed in 29% 
in the control group and in 83% in the FDG-PET/CT group. Due to this difference, 
endocarditis was diagnosed significantly more often in the FDG-PET/CT group 
(P=0.01). Endocarditis was never diagnosed by FDG-PET/CT. After correction for the 
effect of echocardiography, the mortality of the FDG-PET/CT group was still 
favorable as compared to the control group (P<0.01). 
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Cost analysis
Mean total costs per patient were higher in the FDG-PET/CT group, €21,140 (95%CI 
€17,303-24,977) vs. €14,837 (95%CI €13,082-16,592) in the control group. The 
incremental costs of the FDG-PET/CT group were €6,303 (95%CI €2,642-9,965). 
Mean total costs of relapse of infection were €15,986 per patient in the 3 patients 
with a relapse in the FDG-PET/CT group and €13,786 per patient in 17 patients with 
a relapse in the control group.  Admission days accounted for the largest part of the 
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 Table 2   Main results of the clinical study.
Study group 
n=115
Control group
n=230
p-value
Age, y (mean) 59 58 1.0
Matching criteria
      Micro-organism    SAB 73 (64%) 146 (64%) 1.0
                                   SSB 30 (26%) 60 (26%) 1.0
                                   Ent 12 (10%) 24 (10%) 1.0
      Community acquisition 70% 68% 0.71
      Treatment delay >48hrs 27% 45% 0.01
      Fever > 72 hrs 46% 37% 0.13
      Portal of entry unknown 52% 46% 0.30
      CVC not removed > 48hrs 5% 8% 0.50
      Blood cultures >72 hrs* 16% 6% <0.01
      Immunosuppression 22% 17% 0.30
Echocardiography performed 83% 29% <0.01
Metastatic foci (no of patients) 68% 36% <0.01
      Endocarditis 18% 8% 0.01
Relapse of infection 2.6% 7.4% 0.09
Overall mortality 19% 32% <0.01
Treatment days (median)
      Metastatic infection present 45 36 <0.01
      Metastatic infection absent 14 14 0.38
Length of hospital stay
      Metastatic infection present 27 28 0.51
      Metastatic infection absent 14 14 0.61
* not routinely obtained in the control group
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incremental costs with a mean of  €4,421 per patient (95%CI €966-7,876) (Table 3). 
When echocardiography was analysed as a potential confounder, costs in the 
FDG-PET/CT group were not related to FDG-PET/CT (p=0.8), but to echocardio-
graphy (p<0.01). The mean incremental costs due to FDG-PET/CT estimated by 
stratification for endocarditis were €3,518 per patient (95%CI €286-6,749), p=0.03.  
Cost-effectiveness analysis
Figure 1 shows the cost-effectiveness plane where 1000 bootstrapped incremental 
cost-effectiveness ratios “cost per percentage mortality prevented” are presented . 
The estimated ICER is €48,325 per mortality case prevented  (95% CI €7,592 – 
215,586), indicating that prevention of a single fatality by the addition of FDG-PET/
CT requires an additional investment in health care of €48,325. 
Figure 2, shows the acceptability curve based on the analysis described above. 
Figure 2 indicates that, given an 80% chance on being cost-effective, the willingness 
to pay for a case fatality prevented approaches €75.000, indicating that the costs to 
prevent a mortality case due to the addition of FDG-PET/CT (€48,325) is within the 
generally accepted limit of the willingness to pay. 
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 Table 3   Mean incremental costs of the FDG-PET group compared to the control 
group per volume.
Mean incremental costs in € 95% CI  in €
Total costs 6303 2642-9965
      Hospital days 4421 966-7876 (p<0.01)
      Antibiotic treatment 350 130-569 (p<0.01)
      Imaging techniques 1285 1216-1354 (p<0.01)
      Specialist consultation 16 5-27 (p=0.05)
      Surgical intervention 132 -1-266 (p=0.05)
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Figure 2  Willingness to pay for a percentage mortality prevented.
The acceptability curve can be interpreted as the probability of FDG-PET/CT being cost 
effective for a certain willingness to pay for a percentage mortality prevented.
Figure 1  Cost-effectiveness plane with the bootstrap replicates of the incremental cost-
effectiveness ratio (ICER): cost per percentage mortality prevented.
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Discussion 
This study reports on cost-effectiveness of routine performance of FDG-PET/CT for 
reason of infection, i.e. in patients with high-risk Gram-positive bacteraemia. We 
demonstrated this strategy identified significantly more clinically relevant infectious 
foci, enabling early adjustment of treatment, resulting in a decrease of mortality 
rates. Associated costs resulted in a point-estimate per mortality case prevented of 
€48,325 which is well within the acceptable range [26]. In-hospital treatment, 
prolongation of antibiotic treatment and surgical procedures are the most important 
cost drivers. 
To date, no direct comparison is available on this subject. In patients with 
pneumococcal pneumonia, in whom disease burden is considered high (0.82), 
acceptable costs per QALY were estimated at €64,000 [26]. In the present study, 
however, we did not measure QALYs, which hampers a comparison with the 
point-estimate of costs per mortality case prevented in the present study (€48,325) 
is not possible. In-hospital treatment is not needed for a substantial part of patients 
with pneumococcal pneumonia, in contrast to SAB and SSB in which the vast 
majority of patients are admitted to the hospital [1,14,26]. Disease burden and the 
related impact on QALY therefore might be higher in SAB and SSB. Following this 
line of reasoning it seems appropriate to state that FDG-PET/CT is an efficient 
modality. 
In the FDG-PET/CT group both echocardiography and FDG-PET/CT had been 
performed more often resulting in an increase in the number of patients with 
metastatic infectious foci. The  number of patients diagnosed with endocarditis 
doubled in the FDG-PET/CT group. As patients were carefully matched for their risk 
for infectious complications, the incidence of endocarditis can be considered to be 
equal in both groups. The increase in the number of patients diagnosed  with 
endocarditis in this group therefore was explained by the performance of echocar-
diography. Treatment of endocarditis seemed to be the main driver of costs when 
echocardiography was added in the cost-effectiveness analysis. The consequence 
of excluding all patients with endocarditis from the analysis is a decrease in 
incremental costs from €6,303 (95%CI €2,642-9,965) to €3,518 (95%CI €286-6,749). 
This figure can not be translated in to real costs contributed by FDG-PET/CT as in a 
subgroup of patients both endocarditis and other clinically relevant metastatic 
infectious foci requiring prolonged antibiotic treatment were present. It shows 
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however, that both echocardiography and in a lesser part FDG-PET/CT are cost 
drivers. 
Although confirmation of FDG-PET/CT findings is still daily clinical practice, it might 
be reasonable to anticipate on making decisions solely on FDG-PET/CT, resulting in 
lower incremental costs than in the present study group, where confirmation 
FDG-PET results by conventional techniques was required per protocol. The positive 
predictive value of FDG-PET/CT for the detection of localized infectious foci when 
performed in patients at high risk for metastatic infectious foci was around 90% in 
previous studies [1,18]. This leads to efficiency gains, as conventional radiological 
techniques may subsequently be restricted to delineate the extent of infection if 
necessary, e.g. epidural extension in patients with spondylodiscitis. 
Conclusion
Routine FDG-PET/CT in patients with high risk Gram-positive bacteraemia is an 
important tool to reduce morbidity and mortality. Introduction of a diagnostic 
regimen that incorporates routine FDG-PET/CT results in an increase in costs due to 
more in-hospital treatment of clinically relevant metastatic infectious foci. Still, the 
costs per mortality case prevented of €48,325 are considered to be well within the 
range that is generally accepted as efficient. Cost effectiveness would further 
improve if patient management would be based on FDG-PET/CT abnormalities 
without ordering non-contributing confirmatory tests. Patients with high risk 
Gram-positive bacteraemia therefore should have easy access to FDG-PET/CT when 
available in order to enable early detection of metastatic infectious disease. 
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Cost-Effectiveness of routine FDG-PET/CT in high risk patients with Gram-positive bacteraemia
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Abstract
Early detection of metastatic infection in patients with Gram-positive bacteraemia 
is important as morbidity and mortality are higher in the presence of these foci, 
probably due to incomplete eradication of clinically silent foci during initial 
treatment.
We performed a prospective study in 115 patients with S. aureus or Streptococcus 
species bacteraemia with at least one risk factor for the development of metastatic 
foci, e.g.: community acquisition, treatment delay, persistently positive blood 
cultures >48h, and persistent fever >72 h after initiation of treatment. An intensive 
search for metastatic infectious foci was performed including FDG-PET/CT and 
echocardiography in the first 2 weeks of admission. 
Metastatic infectious foci were detected in 84 of 115 (73%) patients. Endocarditis (22 
cases), endovascular infections (19 cases), pulmonary abscesses  (16 cases) and 
spondylodiscitis (11 cases) were diagnosed most frequently. The incidence of 
metastatic infection was similar in patients with Streptococcus spp. and those with S. 
aureus bacteraemia. Symptoms guiding the attending physician in the diagnostic 
work-up were only present in a minority of cases (41%). An unknown portal of entry, 
treatment delay >48h and the presence of foreign body material were significant 
risk factors for developing metastatic foci. Mean CRP levels on admission were 
significantly higher in patients with metastatic infectious foci (74 vs. 160 mg/L). 
FDG-PET/CT was the first to localise metastatic infectious foci in 35/115 (30%) 
patients. As only a minority of foci were accompanied by guiding symptoms, the 
number of foci revealed by symptom guided CT, ultrasound and MRI remained low. 
Mortality tended to be lower in patients without complicated infection (25% vs. 
16%). Five of 31 patients without proven metastatic foci died (16%). In retrospect, of 
these 5 patients three likely had metastatic foci that could not be diagnosed during 
life. In patients with Gram-positive bacteraemia and a high risk for development of 
complicated infection a structured protocol including echocardiography and 
FDG-PET/CT aimed at detection metastatic infectious foci contribute to improved 
outcome.
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Introduction
An important complication of Gram positive bacteraemia is the presence of 
complicating metastatic infectious foci both by haematogenous and local spreading 
beyond the anatomic boundaries of the primary source of infection. Reported 
incidence of complicating foci varies between 16 and 36% [8,9,17,20,26]. Early 
detection of metastatic foci is important as morbidity and mortality are higher in 
the presence of these foci, probably due to incomplete eradication during initial 
treatment17. However, metastatic foci are often asymptomatic. In up to one third of 
patients with Gram positive bacteraemia and metastatic foci, localising signs and 
symptoms are absent [7]. In a Danish study, more than half of all patients admitted 
with S. aureus spondylodiscitis did not have any symptoms pointing at this diagnosis 
at the time of admission [16]. 
Treatment delay and community acquisition, which is probably a surrogate marker 
of delayed treatment, are the most important risk factors for the development of 
metastatic infection [9,10,24]. Persistently positive blood cultures and fever despite 
appropriate antibiotic treatment have a predictive value for the presence of such 
complicating foci [9,22]. It has been suggested earlier that an intensive search for 
the presence of metastatic foci reduces relapse rates of infection and mortality [18]. 
However, conventional radiological techniques would require the presence of 
guiding symptoms as only a fixed part of the body is visualised. Nuclear imaging 
techniques, such as whole body Fluorodeoxyglucose-positron emission tomography 
in combination with low-dose Computer Tomography scanning for optimizing 
anatomical correlation (FDG-PET/CT), might overcome this problem [28,29]. 
FDG-PET/CT is able to visualise localised foci of infectious and non-infectious 
inflammation and has proven to contribute to the diagnosis in patients with fever of 
unknown origin or blood stream infections [3,4,30]. In a retrospective study of 40 
patients with bloodstream infection and a high risk of complications, FDG-PET 
diagnosed a clinically relevant new focus in 45% of cases, while, on average, four 
conventional diagnostic tests had already been performed previously. To date, 
there are no guidelines describing a diagnostic protocol for the detection of 
metastatic infectious foci in patients with Gram-positive bacteraemia, except for 
the recommendation to perform echocardiography in patients with Staphylococcus 
aureus bacteraemia.
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Here we present a prospective study in patients with S. aureus or Streptococcus 
species bacteraemia with at least one risk factor for the development of metastatic 
foci. Based on previous studies, FDG-PET/CT was routinely added to the diagnostic 
work-up including  echocardiography. The outcome and contribution of all diagnostic 
procedures were evaluated, risk factors for developing metastatic infection were 
identified, and the relation between the presence of metastatic infection and clinical 
outcome was assessed. 
Patients and Methods
Patients
This study was part of a prospective matched case control study evaluating the  utility 
of FDG-PET/CT for the detection of metastatic infectious foci in high-risk patients with 
Gram positive bacteraemia (ISRCTN 76425553). From November 2005 until January 
2008, patients were recruited from the Radboud University Nijmegen Medical Centre, 
a 950-bed university hospital. Charts of all subsequent adult patients were reviewed 
within the first working day after a blood culture showed growth of S. aureus or 
Streptococcus species (excluding S. pneumoniae). Patients were eligible when a 
systemic inflammatory response syndrome was present at the time the blood culture 
was taken1. Besides at least one of the known risk factors for the development of 
complicating infection had to be present, i.e. community acquisition, signs of infection 
>48 hours before initiation of appropriate treatment (treatment delay), fever >72 
hours after initiation of appropriate treatment, or positive blood cultures >48 hours 
after initiation of appropriate treatment. Patients with chemotherapy-induced 
neutropenia and pregnant women were excluded. The study was approved by the 
local ethics committee. Written informed consent was obtained from all patients.
Clinical features
The portal of entry was defined as a localized site of infection preceding bacteraemia. 
A central venous catheter (CVC) was considered a portal of entry if there was 
evidence of inflammation at the insertion site or if culture of the catheter tip grew 
the same microorganism as the blood culture in the absence of evidence for another 
source of infection. Respiratory or urinary tract infections were diagnosed as portal 
of entry only when specific symptoms and signs were present in addition to positive 
culture results. Phlebitis due to peripheral intravascular catheters and cellulitis, 
categorised as skin infections, were considered as portals of entry, if present.
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Bacteraemia was defined to be nosocomial if only blood cultures taken after >48 
hours of hospitalization were positive and clinical signs of the infection were absent 
at the time of admission. All other infections were considered community-acquired. 
Both infectious foci without anatomic relation to the portal of entry and direct 
extension of the infection beyond the primary focus of infection were defined as 
complicating infectious foci. Endocarditis was defined according to the Duke criteria 
[23]. Prednisone ≥ 10mg, or its equivalent dose of corticosteroids was considered as 
immunosuppressive treatment.
Metastatic infectious foci, that were not diagnosed during the first period of 
infection, or a second period of bacteraemia with the same micro-organism, both 
within 3 months of the first positive blood culture, were defined as relapse of 
infection. Patients were considered cured if no symptoms or signs of infection were 
present 3 months after discontinuation of antibiotic treatment. 
Diagnostic workup
All patients were visited by an infectious diseases specialist for physical examination. 
Echocardiography was recommended. Transthoracic echocardiography (TTE) was 
used as a first line screening technique, except for those patients with prosthetic 
valves, in whom transesophageal echocardiography (TEE) was the first line 
technique. A TEE, however, was advocated in all patients in whom TTE was 
unremarkable, especially when imaging was hampered due to technical, or 
anatomical problems. FGD-PET/CT was performed within 2 weeks after the first 
positive blood culture in all patients who gave written informed consent. Further 
diagnostic procedures like ultrasound, CT and magnetic resonance imaging (MRI) 
were only requested in the presence of guiding signs or symptoms, or for 
confirmation of FDG-PET/CT findings. For treatment monitoring, C-reactive protein 
(CRP) and leucocyte counts were performed twice weekly. Blood culture samples 
were taken daily until 3 days after appropriate treatment had started and continued 
every other day as long as blood culture results remained positive. 
Diagnosis and patient follow-up 
Patient follow-up ended 6 months after the first positive blood culture. Standard 
duration of antibiotic treatment in patients with uncomplicated bacteraemia was 14 
days. Treatment duration was extended to 6-12 weeks in case of infectious 
complications, depending on the localisation and guidelines. Endocarditis was 
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treated according to AHA guidelines5. The final diagnosis was established by the 
attending physician and the first and last author. The presence of metastatic 
infectious foci was based on the combination of clinical findings and results of 
conventional radiological techniques. Wherever possible, samples were taken for 
culture and/or pathology and served as final prove. As FDG-PET/CT is not an 
established imaging technique for some types infectious foci that were diagnosed, 
a final diagnosis was never based on FDG-PET/CT findings alone. 
Data collection and statistical analysis
All epidemiological data as well as diagnostic procedures and treatment data were 
collected in a structured database (Microsoft Access). Descriptive statistics for 
continuous variables are presented as means ± standard deviations. Differences 
between groups were tested with unpaired Student t-tests for continuous variables 
and with Fisher exact tests for categorical variables. Differences were considered to 
be statistically significant at p < 0.05. Sensitivity and specificity were calculated with 
95% confidence intervals. A parameter was considered to be a significant predicting 
factor when the 95% confidence interval of the relative risk was >1. 
Results
A total of 177 patients with either S. aureus, or Streptococcus spp. bacteraemia were 
identified during the study period. Of these patients, 53 did not have any of the 
pre-defined risk factors for the presence of metastatic infection. Nine patients 
refused informed consent, and 115 patients were included in the study (85 S.aureus, 
13 hemolytic Streptococci, 17 viridans Streptococci). Most infections were community-
acquired (72%, Table 1). Characteristics of patients with S. aureus, or Streptococcus 
spp. differed in several aspects. In the  S. aureus group, patients were more often 
primarily admitted to the ICU (24% vs. 0%, p=0.02), blood cultures remained positive 
for >48h after initiation of therapy  more often (25% vs. 7%, p=0.03), and significantly 
more patients suffered from persistent fever >72 hours after start of therapy (61% 
vs. 33%,Table 1). The portal of entry was unknown in more than half of all patients 
(61/115, 53%), significantly more often in patients with Streptococcus spp. (70% vs. 
47%, p=0.04, Table 2). Skin infections were most often diagnosed as the portal of 
entry, especially in patients with S. aureus bacteraemia. 
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Metastatic infectious foci were detected in 84 of 115 (73%) patients (Table 3). The 
portal of entry was known in only 38% of patients and an unknown portal of entry 
was a significant risk factor for developing metastatic foci (Odds Ratio 5.6 (95%CI 
2.3-13.8) ) (Table 3). Mean CRP levels on admission were significantly higher in 
patients with metastatic infectious foci, 74 (95%CI 45-103mg/ml) vs. 160mg/ml 
(95%CI 132-188mg/ml), p<0.01. The maximal CRP levels during admission did not 
differ significantly between both groups (172mg/ml (95%CI 127-217) vs. 224mg/ml 
(95%CI 197-251), p=0.53). Treatment delay >48h was a strong predictor for 
developing metastatic infectious foci, p<0.01. In total, 131 metastatic infectious foci 
were diagnosed in 84 patients (Table 4). The incidence of metastatic infection was 
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 Table 1    Baseline characteristics of high risk patients with Gram-positive 
bacteraemia.
Characteristic
All 
patients
(n=115)
No. (%)
Staphylococcus 
aureus
(n=85)
No. (%)
Streptococcus 
spp.
(n=30)
No. (%)
p-value
Mean age (years ± SD) 59 ± 15 59 ± 15 59 ± 15
Male 67 (58) 52 (61) 15 (50) 0.29
Community acquisition 83 (72) 58 (68) 25 (83) 0.15
Primary ICU admission 20 (17) 20 (24) 0 (0) 0.02
Treatment delay >48 hrs* 83 (72) 59 (69) 24 (80) 0.35
Positive blood cultures 
>48 hrs after treatment
23 (20) 21 (25) 2 (7) 0.03
Fever > 72 hrs 62 (54) 52 (61) 10 (33) 0.01
CVC present on admission 12 (10) 6 (7) 6 (20) 0.08
Diabetes mellitus 29 (25) 21 (25) 8 (27) 0.81
Malignancy 14 (12) 11 (13) 3 (10) 1.0
Immunosuppression 22 (19) 17 (20) 5 (17) 0.79
Dialysis 4 (3) 3 (4) 1 (3) 1.0
Alcohol abuse 6 (5) 4 (5) 2 (7) 0.65
Joint prosthesis 16 (14) 14 (16) 2 (7) 0.23
Cardiac valve prosthesis 9 (8) 7 (8) 2 (7) 1.0
Vascular prosthesis 14 (12) 11 (13) 3 (10) 1.0
Pacemaker 7 (6) 4 (5) 3 (10) 0.38
* delay between first clinical signs of infection and initiation of treatment
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 Table 2   Portal of entry of bacteraemia.
Portal of entry Total  
group
(n=115)
No. (%)
Staphylococcus 
aureus
(n=85)
No. (%)
Streptococcus 
spp.
(n=30)
No. (%)
p-value
Unknown 61 (53) 40 (47) 21 (70) 0.04
Known 54 (47) 45 (53) 9 (30)
     CVC 7 4 3 0.37
     Skin infection 16 14 2 0.23
     Pulmonary infection 5 5 0 0.32
     Urinary tract 
infection
4 4 0 0.57
     Wound infection 11 10 1 0.59
     Other* 11 8 3 1.0
*  manipulation urinary tract (2), colitis (2), endometritis (2), cholangitis, puncture carinal nodes, 
steroid injection bursa trochanterica, known fistula osteomyelitis, meningitis
 Table 3  Possible risk factors for the presence of metastatic infectious foci.
Risk factor Metastatic focus
present
(n=84)
No. (%)
Metastatic focus 
absent
(n=31)
No. (%)
p-value Odds Ratio 
(95%CI)
Community acquisition 63 (75) 20 (65) 0.35 1.6 (0.6-4.0)
Treatment delay >48 hrs 68 (81) 14 (45) <0.01 5.6 (2.3-13.8)
Blood cultures >48 hrs 20 (24) 3 (10) 0.12 2.9 (0.8-10.6)
Fever >72hrs 50 (60) 12 (39) 0.06 2.3 (1.0-5.4)
CVC present on 
admission
6 (7) 6 (19) 0.08 0.3 (0.1-1.1)
Portal of entry unknown 52 (62) 9 (29) 0.03 4.0 (1.6-9.7)
Diabetes mellitus 22 (26) 7 (23) 0.81 1.22 (0.5-3.2)
Malignancy 8 (10) 6 (19) 0.2 0.4 (0.1-1.4)
Immunosuppression 16 (19) 6 (19) 1.0 1.0 (0.4-2.8)
alcoholism 3 (4) 3 (10) 0.34 0.4 (0.1-1.8)
Foreign body material 31 (37) 5 (16) 0.04 3.0 (1.1-8.7)
Staphylococcus aureus 64 (76) 21 (68) 0.47 1.5 (0.6-3.7)
Age > 60 years 47 (56) 18 (58) 0.83 1.1 (0.5-2.6)
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similar in patients with Streptococcus spp. and those with S. aureus bacteraemia. 
Endocarditis, endovascular infections, pulmonary abscesses and spondylodiscitis 
were diagnosed most frequently (Table 4) (Figure 1). Pulmonary foci were 
significantly more often found in patient with S. aureus bacteraemia (p=0.01). In 30 
patients (26%), more than one complicating focus of infection was present. In 13/22 
(59%) of patients with endocarditis, another metastatic focus of infection was 
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 Table 4   Localisation of metastatic infectious foci and presence of guiding 
symptoms.
Localisation Total 
group
(n=115)
No. (%)
Guiding 
symptoms
No.
Staphylococcus 
aureus
(n=85)
No. (%)
Streptococcus 
spp.
(n=30)
No. (%)
p-value
Not present (nr of 
patients)
31 (27) 21 (25) 10 (33)
Present (nr of patients) 84 (73) 64 (75) 20 (67) 0.47
     Endocarditis 22 0 13 9 0.1
     Endovascular* 19 5 11 8 0.09
     Lung 16 5 16 0 0.01
     Liver 2 1 1 1 0.46
     Spleen 3 0 3 0 0.57
     Joint 9 8 8 1 0.44
     Osteomyelitis 6 4 5 1 1.0
     Spondylodiscitis 11 8 10 1 0.28
     Psoas 4 1 3 1 1.0
     Soft tissue 11 6 11 0 0.06
     Central nerve system 11 11 8 3 1.0
     Eye 3 3 1 2 0.17
     Prosthetic joint 10 8 8 2 1.0
     Intra-abdominal 3 1 2 1 1.0
     kidney 1 1 1 0 1.0
Total number of 
metastatic foci
131 54 101 30
* Bentall prosthesis aortic arch (2), aortic  prosthesis (3), mycotic aneurism aorta (3), mycotic aneurism 
femoral artery (2), subclavian vein after line removal (4), pacemaker lead (1), mycotic aneurism iliac 
artery (1), septic thrombophlebitis femoral vein (2), pylephlebitis (1).
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detected (Figure 2). All 22 endocarditis cases were proven according to the Duke 
criteria. Symptoms guiding the attending physician in the diagnostic work-up were 
only present in a minority of cases (41%). Fifty-six foci were diagnosed by either 
culture or pathology results. The remaining 53 foci were diagnosed using a 
combination of clinical examination and conventional radiological techniques. 
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Figure 1  A 65 year old male with SAB and persistent fever despite antibiotic therapy.
Top to bottom FDG-PET, CT and fusion: left transverse, right sagital slices. FDG-PET/CT 
shows pathological FDG uptake (arrows) compatible with C6-7 spondylodiscitis and 
spreading inside the spinal canal compatible with an epidural abscess. The latter was 
confirmed on CT myelography. MRI was not possible due to his intracardial defibrillator.
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FDG-PET was performed in 102 patients, echocardiography in 85, CT in 60, 
ultrasound in 56, and MRI in 20 patients (Table 5). FDG-PET was the first to localise 
metastatic infectious foci in 35/115 (30%) patients, most of whom did not have 
guiding symptoms. In 4 patients FDG-PET was false positive, resulting in a positive 
predictive value of 96% (Table 5). In one patient with endocarditis, pathological 
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Figure 2  Mycotic aneurysm of the a. femoralis profunda in a 49 year old male with SAB 
and endocarditis.
Top to bottom FDG-PET, CT and fusion: left coronal, right transverse slices.
FDG-PET/CT shows pathological FDG uptake (arrows) compatible with vascular infection.
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uptake in the right shoulder was due to tendinitis. Pathological FDG-uptake was 
caused by  a sterile haemorrhage in the psoas muscle during anticoagulant use in a 
second patient. False positive uptake in the colonic wall was seen in one patient, 
and one patient died before further investigations could have been performed to 
confirm pathological pleural FDG-uptake. She had possible endocarditis and pleural 
effusion with persistently positive blood cultures. The negative predictive value 
was 98% when only those foci were counted which were situated inside the area 
scanned by FDG-PET (Table 5). In one patient, a pacemaker lead infection was 
missed by FDG-PET. Another 10 foci were not revealed, these foci however, were 
situated inside the central nervous system in five patients, and in the distal 
extremities in another five other patients These areas are not captured by routine 
PET-scanning. In all 10 patients in whom FDG-PET did not reveal metastatic 
infectious foci, guiding signs and symptoms directed the attending physician to 
perform further investigations.
Routine echocardiography, performed in 86 patients, supported the presence of 
endocarditis in 22 cases (26%). A TTE was performed in 77 patients of which 43 were 
followed by TEE.  A primary TEE was performed in 9 patients. Symptom guided CT, 
ultrasound and MRI reached excellent specificity and positive predictive values with 
high sensitivity and negative predictive values (Table 5). As only a minority of foci 
were accompanied by guiding symptoms, the number of foci revealed by CT, 
ultrasound and MRI remained low.
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 Table 5   Diagnostic utility of imaging techniques contributing to diagnosis of 
metastatic infectious foci.
Technique No of 
examinations
Contributory
No. (%)
Sensitivity
%
Specificity
%
PPV
%
NPV
%
FDG-PET 102 61 (60) 99 92 96 98
CT-scan* 60 32 (53) 94 100 100 93
Ultrasound* 56 19 (34) 95 100 100 96
MRI* 20 12 (60) 92 100 100 88
* CT, ultrasound and MRI were only performed in case of guiding symptoms and when suitable for the 
area to be investigated, e.g.: Chest CT in 21, abdominal CT in 24, Central nervous system (CNS) CT in 11, 
soft tissue CT in 4, abdominal US in 30, soft tissue US in 25, CNS MRI in 13 and soft tissue MRI in 8 
patients. FDG-PET was the only diagnostic technique routinely performed for screening purposes.
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Risk factors for mortality are listed in table 6. Persistently positive blood cultures 
>48h after starting treatment, nosocomial infection and age above 60 years were 
associated with increased mortality. Treatment delay was not associated with 
mortality (Table 6). Median duration of treatment differed significantly between 
patients with or without metastatic infectious foci (44 vs. 15 days) (Table 7). Mortality 
tended to be lower in patients without complicated infection (25% vs. 16%), albeit 
not significantly. Five of 31 patients without proven metastatic foci died (16%). In 
retrospect, of these 5 patients three likely had metastatic foci that could not be 
diagnosed during life. The first patient had a possible endocarditis (persistently 
positive blood cultures, continuing fever, Janeway lesions, and  changed systolic 
murmur). He died before echocardiography was performed. The second patient 
had persistently positive blood cultures during 72 hours despite high dose flucloxa-
cilline and persistent pyuria growing S. aureus. This patient refused any further 
investigations. Antibiotic treatment was stopped on his request after 15 days. He 
died 2 weeks after discharge in a nursing home having documented high fevers 
during the weeks before his death. The third patient had positive blood cultures 
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 Table 6   Risk factors for mortality at 6 months of follow-up.
Risk factor Survivors
(n=89)
No. (%)
Died
(n=26)
No. (%)
p-value
Community acquisition 69 (78) 14 (54) 0.03
Treatment delay >48h 63 (71) 20 (77) 0.63
Positive blood cultures >48h 14 (16) 9 (35) 0.05
Fever >72h 47 (53) 15 (58) 0.82
CVC present on admission 9 (10) 3 (12) 1.0
Portal of entry unknown 44 (49) 10 (38) 0.38
Diabetes mellitus 19 (21) 10 (38) 0.12
Malignancy 11 (12) 3 (12) 1.0
Immunosuppression 13 (14) 9 (35) 0.43
alcoholism 5 (6) 1 (4) 1.0
Foreign body material 26 (29) 10 (38) 0.47
S. aureus 63 (71) 23 (88) 0.08
Age > 60 years 44 (49) 21 (81) <0.01
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with S. aureus and splinter haemorrhages, three days after a pacemaker implantation. 
Only transthoracic echocardiography was performed not showing any signs of 
endocarditis or pacemaker lead infection. Transesophageal echocardiography was 
refused by the patient and the pacemaker was not removed. This patient died while 
on antibiotic treatment 36 days after admission due to cardiac failure. Autopsy was 
refused. When these patients are presumed to have metastatic foci, only 2 patients 
died in the absence of metastatic infectious foci. One of these patients died on day 
2 because of septic shock and the other patient died day 24 after admission with 
end stage laryngeal carcinoma. 
Discussion
In this prospective cohort study the vast majority of high-risk patients with Gram- 
positive bacteraemia developed metastatic infectious foci (73%), of which more 
than 40% were clinically silent. Mortality rates might be decreased by an active 
search and treatment for clinically silent foci as mortality tended to be higher in the 
presence of metastatic infectious foci. 
Earlier studies that not specifically addressed high-risk patients, have reported an 
incidence of metastatic foci ranging from 16 to 36% (Table 8) [7,17,20,21,26,27]. 
Patients in our study were selected on the presence of 4 well known clinical risk 
factors for the development of complicated infection [9,10,21,24]. These differences 
in patient characteristics may hamper a direct comparison, but the active search in 
our study aimed at early identification of metastatic foci most likely contributes to 
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 Table 7  Patient outcomes at 6 months follow up.
Outcome             Total 
    Metastatic foci 
Present     Absent
  (n=84)      (n=31)
  No. (%)     No. (%)
Staphylococcus aureus
       Metastatic foci
Present         Absent
  (n=64)           (n=21)
  No. (%)         No. (%)
   Streptococcus spp.
      Metastatic foci
Present         Absent
  (n=20)          (n=10)
  No. (%)         No. (%)
Median treatment 
duration (days)
44 15 42 15 48 13
Mortality 21 (25) 5 (16) 19 (30) 4 (19) 2 (10) 1 (10)
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the much higher yield of metastatic infections. The active approach utilising 
FDG-PET/CT and echocardiography in the first 2 weeks of admission in high risk 
patients with Gram-positive bacteraemia revealed significantly more metastatic 
foci compared to a matched control group in whom the diagnostic regime was 
symptom-guided and led to significantly lower mortality rates [30]. Three earlier 
studies have described that significantly fewer metastatic foci could be diagnosed 
in patients in whom recommendations of an infectious disease specialist were 
not followed [8,23,26]. Most importantly, this was due to the failure to perform 
supplementary investigations such as echocardiography and surveillance blood 
cultures. 
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 Table 8  Comparison of previous series of Gram positive bacteraemia.
First author  
(Country)
Design Micro-
organism
No of patients 
(recruitment 
period)
Metastatic 
foci %
Lautenschlager 
(Switzerland)[20]
Retrospective, hospital 
based, 1 UH, ID 
consultancy 
SAB 281  
(1980-1986)
27
Lesens  
(France)[21]
Retrospective, dpt Internal 
Medicine, 1 UH,
SAB 109  
(1992-1999)
25
Jensen  
(Denmark)[17]
Prospective, hospital 
based, 4 CH, ID consultancy
SAB 186  
(1994-1996)
16
Fowler  
(USA)[8]
Prospective, hospital 
based, 1 UH, ID 
consultancy
SAB 244  
(1994-1996)
30
Verhagen  
(Netherlands)[27]
Retrospective, hospital 
based, 1 UH
SAB 79  
(1999-2000)
38
Cuijpers  
(Netherlands)[7]
Retrospective, hospital 
based, 1 UH
SAB+SSB 180  
(2002-2004)
34
Rieg  
(Germany)[26]
Retrospective/prospective, 
hospital based, 1 UH, ID 
consultancy
SAB 521  
(2002-2007)
36
Vos  
(present study)[30]
Prospective, hospital 
based, high risk patients 
selected, 1 UH, ID 
consultancy, routine 
FDG-PET/CT and 
echocardiography
SAB+SSB 115  
(2005-2008)
73
UH= University Hospital, CH= Community Hospital, ID consultancy= infectious diseases specialist 
consultancy, SAB= S. aureus bacteraemia, SSB= Streptococcus spp. bacteraemia
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Positive blood cultures during follow-up after start of antimicrobial therapy have 
been found to be a predictor of metastatic infectious disease [22]. In the present 
study we identified delayed initiation of treatment, the presence of foreign body 
material and an unknown portal of entry for infection as risk factors for the 
development of metastatic foci. Of patients with an unknown portal of entry, 52/61 
(82%) developed proven metastatic infection, versus 32/54 (59%) of patients 
admitted with a known portal of entry. CRP levels on admission tended to be higher 
in patients with metastatic foci; however, the maximal CRP level during admission 
did not differ between patient groups Most likely, the  CRP level on admission 
reflects the duration of illness on admission and therefore is a surrogate marker for 
treatment delay. As some overlap in CRP levels on admission was found between 
groups with and without metastatic infectious foci, CRP levels should only be 
interpreted in relation to the patient’s history, for example regarding treatment 
delay which probably leads to a higher CRP upon admission. 
It is important to realise that only 41% of metastatic foci were associated with clear 
signs or symptoms guiding the physician towards a diagnosis. Especially deep soft 
tissue infections, endovascular, and pulmonary foci lacked guiding symptoms. 
When ordered based on symptoms, predictive values of CT, MRI and ultrasound are 
high. However, as only a minority of patients did have guiding signs or symptoms 
only a minority of foci (9-24%) could be identified using CT, ultrasound and MRI. In 
contrast, routinely performed FDG-PET revealed 69% of all metastatic infectious 
foci that were identified. In approximately  30% of patients, FDG-PET/CT revealed at 
least 1 clinically silent infectious metastatic focus. This is in line with studies on fever 
of unknown origin in which whole body FDG-PET proved to be superior when 
compared to routinely performed combined chest and abdominal CT [3,6]. In a 
retrospective study on detection of metastatic foci, FDG-PET revealed a significant 
number of new relevant foci even after a total of 4 conventional imaging techniques 
had been performed [2]. Not only due to whole body imaging, but also the fact that 
FDG-PET provides functional information in contrast to CT, and in a lesser extend to 
MRI contributes to superiority of FDG PET/CT. Previously, FDG-PET also proved to be 
superior in post operative wound infections and vascular graft infections when 
compared to CT scanning and in spondylodiscitis when compared to MRI 
[11,13,19,25,31]. The most important technical drawback in FDG-PET compared to CT 
and MRI is the lower spatial resolution (3-5mm compared to 1-2mm). In suspected 
epidural extension accompanying spondylodiscitis, MRI might be contributory. CT, 
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ultrasound and MRI therefore are not suitable as a screening technique in the 
detection of metastatic infectious foci, in patients with a high prior probability 
having these infectious complications because only a limited part of the body is 
scanned [12]. Routine echocardiography showed vegetations in approximately a 
quarter of patients who underwent echocardiography. 
Mortality rates in patients with Gram-positive bacteraemia are high. We speculated 
that a more rigorous search for metastatic infection could influence outcome, i.e. 
decrease relapse rates and mortality rates, and this has indeed been confirmed in 
our prospective matched case control study [30]. Relapse rates in patients with S. 
aureus bacteraemia were significantly lower in the study group (8.9% vs. 1.4%, 
p=0.04) as  was mortality (30% vs. 19%, p<0.01).This underlines that appropriate and 
early diagnosis of metastatic infectious foci is important for adequate treatment of 
these patients, for example by timely initiation of antibiotic treatment, prolongation 
of antibiotic treatment or drainage of abscesses. The extra costs related to the 
treatment of the increased number of metastatic infectious foci in high risk patients, 
however are balanced by the reduction of re-admissions due to relapse of infection 
or protracted cure (in press). To date, there are no guidelines describing a diagnostic 
protocol for the detection of metastatic infectious foci in patients with Gram-positive 
bacteraemia, except for the recommendation to perform echocardiography in 
patients with S. aureus bacteraemia. It has been shown before that metastatic 
infectious foci can be detected in most parts of the body by FDG-PET-scanning, and 
therefore FDG-PET was included on a routine base in the diagnostic protocol of our 
study [3,30]. 
Earlier studies in patients with Gram-positive bacteraemia have also reported high 
mortality rates, especially in patients with S. aureus bacteraemia, varying between 
9 and 38% [8,9,17,20,26,27]. Only sparse information on mortality rates among 
patients with Streptococcal bacteraemia is available. In patients with bacteraemia 
due to haemolytic group A and G streptococci, mortality rates varied between 14 
and 23 % [2,14]. In a recent series of 53 patients with Streptococcus spp. bacteraemia, 
mortality was 11% [7]. 
In the present study among patients with Gram-positive bacteraemia persistently 
positive blood cultures and older age were associated with increased mortality 
rates, as were nosocomial infections. In contrast to other studies, treatment delay 
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and community acquisition were not associated with increased mortality. Two 
possible explanations come in mind. First patients were selected using a set of four 
known clinical parameters predicting complicated infection, amongst which 
treatment delay and community acquisition both were present in approximately 
75% of patients. The study therefore was not designed to identify risk factors for 
complicated outcome. Treatment delay, on the other hand, was a strong predictor 
for the presence of metastatic infectious foci, which were treated accordingly and 
death might have been prevented. Since an intensive search for the presence of 
metastatic foci was performed, it is possible that no relation between treatment 
delay and mortality was found. Lautenschlager already described that complicated 
infection was associated with increased mortality rates, which was confirmed in 
other studies [8,17,20]. In these studies, complicated infection was defined as a 
combination of metastatic foci of infection, relapse, or the inability to remove the 
primary focus of infection. An important explanation for treatment failure in these 
studies was the delayed start of appropriate treatment in patients without an 
identifiable focus of infection. In a retrospective survey of 281 patients with S. aureus 
bacteraemia, bacteraemia was judged insignificant in 19% until a metastatic focus 
of infection was detected [20]. Treatment delay for more than 45 hours was 
associated with increased mortality in a retrospective cohort of 167 patients with 
hospital acquired S. aureus bacteraemia [24]. Finally, inappropriate focus eradication 
was associated with relapse of infection and mortality in other studies [7,17]. These 
studies suggest that identifying metastatic foci of infection may be an important 
tool to improve treatment outcome in patients with Gram positive bacteraemia. 
In conclusion, the present study has demonstrated two important issues, first after 
an intensive search aimed at the detection of metastatic infectious foci the majority 
of high risk patients with Gram-positive bacteraemia did have metastatic foci. 
Secondly, the majority of these metastatic foci did not have guiding signs, or 
symptoms, which can lead to incomplete focus eradication. Thus in patients with 
Gram-positive bacteraemia and a high risk for development of complicated 
infection (community acquisition, treatment delay, persistently positive blood 
cultures >48h, and persistent fever >72h after initiation of treatment), a structured 
protocol including echocardiography and FDG-PET aimed at detection of metastatic 
infectious foci may contribute to improved outcome.
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Abstract
Background
Despite firm recommendations to perform echocardiography in high-risk patients 
with Gram-positive bacteraemia, routine echocardiography is not embedded in 
daily practice in many settings. The aim of this study was to evaluate whether a 
regime including routine echocardiography results in better outcome.
Methods 
115 patients with Gram-positive bacteraemia and at least one risk factor for 
developing metastatic infection were prospectively included. Routine echocardi-
ography was advocated and facilitated in these patients. Results were compared to 
a matched historical control group of 230 patients in whom echocardiography was 
performed at the discretion of the attending physician. Endocarditis was diagnosed 
according to the Duke criteria.
Results
Echocardiography was performed more often in the study group (82% vs. 27%, 
p<0.001). Endocarditis was diagnosed more often among study patients, 22/115 
(19%) versus 17/230 (7%) in the control group (p=0.002). In the study group echocar-
diography revealed vegetations in 22 of 94 (23%) patients, compared to 17 of 64 
(27%) control patients (p=0.7). In the absence of  heart murmurs, 70% of patients 
underwent echocardiography in the study group against 21% in the control group 
(p<0.001). No differences in adherence to AHA guidelines concerning treatment of 
endocarditis were noticed. In patients with endocarditis, overall mortality was 23% 
in study patients and 59% in controls (p=0.04).
Conclusion
Routinely performed echocardiography in patients with Gram-positive bacteraemia 
resulted in diagnosing endocarditis in a larger proportion of patients which was 
associated with a significant decrease of mortality rates. In the past endocarditis 
probably was detected in a more advanced stage.
Chapter 7
129
Introduction
Timely recognition of infective endocarditis is the first step in successful 
management and improved outcome of this potentially devastating disease. 
However, classical signs of endocarditis, such as new onset heart murmurs and skin 
lesions are absent in up to 57% of patients [1,2]. The importance of echocardiogra-
phy to reveal cardiac sequelae has been emphasized in several studies [3]. In the 
AHA and ESC guidelines, echocardiography is recommended for all patients with 
high risk Staphylococcus aureus bacteraemia to reveal disseminated disease [4,5]. 
Although the recommendations from the literature are clear, routine echocardiog-
raphy is not performed in a substantial part of  patients with S. aureus bacteraemia 
in many clinical settings: in several studies, patients with S. aureus bacteraemia 
underwent echocardiography in only 27%-59% of cases [2,6-9].
We performed a unique prospective case control study in patients with Gram- 
positive bacteraemia and at least one risk factor for the presence of metastatic 
infection comparing two echocardiographic regimes [10-12]. We added patients 
with Gram positive bacteraemia as risk factors predicting the presence of metastatic 
infection were suggested to be identical to those in S. aureus bacteraemia [13]. In 
this prospective study, routine echocardiography was facilitated in all patients 
within two weeks after admission in the study group and was compared to a 
matched historical control group in the same hospital in whom echocardiography 
was performed at the discretion of the attending physician. The aim of the study 
was to evaluate whether routine performance of echocardiography in a high risk 
patient group with Gram-positive bacteraemia leads to an increased incidence of 
the diagnosis of endocarditis and a better outcome when compared to clinically 
driven requests for echocardiography.
Patients and Methods
Study design
This study is part of a prospective case-control study in which patients with a 
positive blood culture growing Staphylococcus aureus, Streptococcus species 
(excluding S. pneumoniae), or Enterococcus species at high risk for developing 
secondary metastatic foci between November 2005 and January 2008 were 
assigned to undergo an FDG-PET-scan  within 14 days after their first positive blood 
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culture. Echocardiography was advocated and facilitated in all patients. High risk 
bacteraemia was defined as the presence of at least one of the known risk factors 
for metastatic infectious disease, i.e., community acquisition, treatment delay for 
more than 48 hours after the onset of symptoms, persisting fever for more than 72 
hours after initiation of antibiotic treatment, or the presence of persistently positive 
blood cultures for more than 48 hours after starting appropriate treatment. The 
original study was registered in the ISRCTN database, number 76425553. The 
protocol was approved by the institutional review board. Written informed consent 
was obtained from all patients.
All charts of subsequent adult, non-neutropenic patients with positive blood 
cultures were revised within the first working day in order to check for eligibility. 
Patients primarily admitted to the ICU were only included when they were 
discharged from the ICU within 14 days. Exclusion criteria were polymicrobial 
infection and pregnancy.
A historical control group was assigned by revising all charts of patients with the 
same type of bacteraemia during the 4 years before the study started. For this 
purpose, the database of the department of medical microbiology was used. Only 
patients with the same risk profile were eligible, including an ICU stay of less than 14 
days. Matching criteria were the micro-organism, community acquisition, and the 
presence or absence of one of the remaining risk factors. For every study patient, 
two of the best matching controls were included. 
Endocarditis and metastatic infection 
Endocarditis was defined according to the modified Duke criteria [14]. The AHA 
guidelines were used for the treatment of infective endocarditis. Choice and timing 
of starting antibiotics were evaluated in all patients diagnosed with endocarditis. 
No relevant changes were noticed between subsequent AHA guidelines throughout 
the study period [4,15]. The portal of entry of bacteraemia was defined as a localised 
focus of infection preceding bacteraemia. A central venous catheter (CVC) was 
considered a portal of entry if there was evidence of inflammation at the insertion 
site or if culture of the catheter tip grew the same microorganism as the blood 
culture in the absence of evidence for another source of infection. Metastatic 
infection was discriminated from the portal of entry of infection. Metastatic 
infection was defined as true haematogenous spreading of infection, e.g.. endo - 
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carditis or spondylodiscitis. In addition, infectious foci without anatomic relations 
to the portal of entry or direct spreading outside the anatomic borders of the portal 
of entry were  defined as metastatic infection e.g., deep tissue abscess complicating 
a surgical wound infection. 
Echocardiography
Echocardiography was strongly recommended and facilitated in all study patients 
by the principal investigator. Transthoracic echocardiography (TTE) was performed 
first only in the absence of prosthetic valves, but had to be followed by transesoph-
ageal echocardiography (TEE) when no signs of vegetations were visualized. An 
echocardiogram was judged to be positive for endocarditis when vegetations, 
defined as oscillating intracardiac structures, were visualised on valves or their 
adjacent structures or in the path of a regurgitant jet, or on implanted material in 
the absence of an alternative anatomic explanation [4]. The outcomes of TTE and 
TEE were compared.
Patients
The side of acquisition of infection was determined in all patients. Bacteraemia was 
considered to be nosocomial if only blood cultures taken after >48 hours of hospi-
talization were positive and clinical signs of the infection were absent at the time of 
admission. All other infections were considered community-acquired. Blood 
cultures were routinely taken during the first three days of admission and every 
second day as long as blood cultures remained positive. Except for echocardiogra-
phy and FDG-PET, which were routinely performed in all study patients, other 
diagnostic tests were ordered at the discretion of the attending physician. Special 
attention was paid to the presence of heart murmurs, immunological or vascular 
skin features, and the presence of guiding symptoms and signs supporting possible 
metastatic infectious foci. Patient follow-up ended 6 months after admission. 
Mortality data, epidemiological data, number, type and results of all diagnostic 
tests and treatment data were registered in a structured database (Microsoft 
Access). 
Endpoints
The primary endpoint was the incidence of endocarditis as defined by the Duke 
criteria [14]. Secondary outcome measures were overall mortality, other metastatic 
foci of infection, and outcome of TTE and TEE.
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Statistical evaluation
Differences between groups were tested with Fisher’s exact tests for categorical 
variables. Differences for continuous variables were tested with unpaired Student 
t-tests. Differences were considered to be statistically significant at p less than 0.05 
(two-sided). Cox proportional Hazard models were performed to analyze outcome 
after adjustment for potential confounding differences between both groups. SPSS, 
version 17.0, was used for the analyses. 
Results
A total of  148 eligible patients with Gram positive bacteraemia were identified 
during the study period. Of those, 22 were excluded because of prolonged ICU stay, 
and 11 refused informed consent. The remaining 115 patients were included in the 
study. A matched control group of 230 patients was identified out of a pool of 294 
eligible patients. Baseline characteristics did not differ significantly between both 
groups except for treatment delay for more than 48 hrs, which was found 
significantly more often in the control group on one side, persistently positive 
blood cultures and diabetes mellitus that were found significantly more often in the 
study group on the other side (Table 1). Treatment delay was not a significant 
confounder for survival in a Cox proportional-hazards model (not shown, p=0.9). 
Follow-up blood culture samples had not been routinely drawn in the control 
group.  
Echocardiography was performed significantly more often in the study group (82% 
(94/115) vs. 27% (64/230), p<0.001, Table 2). In the study group 2 patients died before 
echocardiography took place, 6 patients refused echocardiographic evaluation and 
in 13 patients echocardiographic evaluation was not performed for various other 
reasons. . The mean time between the first positive blood culture and echocardio-
graphy was 6.4 vs. 6.8 days in the study and control group respectively, with a 
median of 5 days in both groups. Endocarditis was diagnosed significantly more 
often among study patients, 22/115 (19%) vs. 17/230 (8%) in the control group 
(p=0.002). In the control group, endocarditis was first detected by autopsy in 
another two patients. Echocardiography revealed vegetations in 22 of 94 (23%) 
study patients in whom echocardiography was performed, compared to 17 of 64 
(27%) patients in the control group (p=0.7). A negative TTE was followed by TEE in 
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50% of study patients (36/72) vs. 11 of 48 control patients (23%, p=0.26). In 6 of 22 
patients with definite endocarditis (27%), TTE did not show any signs of endocarditis 
while only TEE did. This was also the case in 3 of 17 (18%) control patients with 
endocarditis. 
S. aureus was the causative microorganism in 13 patients with endocarditis (59%) in 
the study group and in 8 patients (42%) in the control group (Table 3). Seven patients 
in the study group had a prosthetic valve (6.1%) compared to 9 patients in the 
control group (3.9%, p=0.42). In the study group, 4/7 of these patients were 
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 Table 1  Baseline characteristics of study and control patients.
Study patients
% (n)
Control patients
% (n)
Total number of patients (115) (230)
Male 56% (65) 52% (120)
Mean age (y) 59 ± 16 58 ± 16
Blood culture results: S.aureus * 64% (73) 64% (146)
         Strep. spp: haemolytic 11% (13) 13% (29)
                      viridans 15% (17) 13% (31)
         Enterococcus spp 10% (12) 10% (24)
Community acquisition 70% (81) 68% (156)
Treatment delay > 48 hrs 27% (31) 45% # (104)
Persistent fever > 72 hrs 46% (53) 37% (86)
Portal of entry unknown 52% (60) 46% (106)
CVC not removed within 48 hrs 5% (6) 8% (18)
Persistently  positive blood cultures † 16% (18) 6% (14)
Prior ICU admission 11% (13) 10% (24)
Diabetes mellitus 29% (33) 13%b (31)
malignancy 14% (16) 17% (39)
Immune suppression 23% (26) 17% (39)
Prosthetic heart valves 6% (7) 4% (9)
* All S. Aureus isolates were methicillin-susceptible
# p<0.05 (Treatment delay was not a significant confounder for survival in a Cox proportional-
  hazards model (not shown))
†  p<0.05 (Repetitive blood cultures were not routinely taken in the control group) 
No iv drug use was noticed in both groups.
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diagnosed with prosthetic valve endocarditis versus 3/9 in the control group 
(p=0.6). Only a minority of patients had vascular or immunological skin phenomena 
supporting a diagnosis of endocarditis (3.5% (n=4) in the study group vs. 0.9% (n=2) 
in the control group (p=0.1). Of the patients diagnosed with endocarditis, 64% had 
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 Table 2  Number of patients in whom echocardiography was performed.
Study patients
(n=115)
Control patients
(n=230)
TTE only 34% (39) 18% (43)* 
TEE only 9% (10) 3% (7)*
TEE following TTE 39% (45) 6% (14)*
Total percentage of echocardiography 82% (94) 27% (64)*
* p<0.05
 Table 3  Baseline characteristics of patients with endocarditis*.
Study patients
(n=22)
Control patients
(n=19)
Median age (y) 58 59
Community acquisition 91% (20) 63% (12)
Duration of symptoms prior to blood 
culture results (mean number of days) 
16 26
Unknown portal of entry 82% (18) 63% (12)
Cardiac murmur 64% (14) 79% (15)
Skin phenomena 18% (4) 11% (2)
Prosthetic valve 14% (3) 21% (4)
Microorganism: S. aureus 59% (13) 42% (8)†
        Strep. Spp: haemolytic 9% (2) 5% (1)
                      viridans 27% (6) 42% (8)
         Enterococcus spp 5% (1) 11% (2)
Adherence to AHA guideline 100% (22) 95% (18)
* Endocarditis was found in 22/115 (19%) of study patients and in 19/230 (8%) of matched historical 
controls, p=0.005. In 2 of 19 control patients endocarditis was only diagnosed post-mortem. No right 
sided endocarditis was detected.
† p=0.006
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a new or existing heart murmur in the study group versus 79% among controls 
(p=0.32, Table 3). Of the patients without a heart murmur, 71% (46/65) underwent 
echocardiography in the study group against 21% (39/190) in the control group 
(p<0.001). 
In patients with endocarditis, relevant metastatic foci of infection requiring 
supplementary therapy were found in 13 (59%) of study patients and in 8 patients 
(42%) in the control group (p=0.54, Table 4). In some of these patients a truly 
haematogenous focus of infection was the first presentation on admission, leading 
to repetitive echocardiography in order to identify the source of persistently 
positive blood cultures.
American Heart Association (AHA) guidelines concerning the choice of antibiotic 
treatment were followed in all study patients compared to 18 of 19 (95%, p=0.46) in 
the control group. Seven patients in both groups underwent valve replacement 
(p=0.25). The mean duration of symptoms in patients diagnosed with endocarditis 
before blood culture results were present was 16 days in the study group vs. 26 in 
the control group. The median duration of treatment among study patients 
diagnosed with endocarditis was 42 (range 15-140) days compared to 38 (range 
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 Table 4  Other metastatic infectious foci in patients with endocarditis.
Study patients
(n=22)
Control patients
(n=19)
Patient without metastatic foci 9 9
Patients with metastatic foci 13 10
          Lung 0 1
          CNS 3 2
          Endovascular 4 1
          Soft tissue 2 1
          Spondylodiscitis 3 3
          Arthritis 6 2
          Psoas abscess 1 0
          Spleen 1 0
          Eye 1 0
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1-182) days in the control group. Two patients in the study group and 6 patients in 
the control group died within one month after admission while on antibiotic 
treatment.  When these patients are excluded, median duration of treatment was 44 
(range 13-140) and 42 (range 7-182) days, respectively. In patients without definite 
endocarditis or other complicating infectious foci, median treatment duration was 
14 days in both groups.
Mortality rates at 6 months of follow-up differed significantly between both groups 
in favour of the study group. Overall mortality was 19% (22/115) in study patients 
compared to 32% (74/230) in control patients (p=0.011). This difference was also 
found regarding infection related mortality (14/115 vs. 56/230, p=0.049). In the 
patients diagnosed with endocarditis during life, mortality was 23% (5/22) in the 
study group and 59% (10/17) in controls (p=0.04). 
Discussion
This is the first study directly comparing two echocardiographic regimes. Routinely 
facilitating echocardiography in patients with Gram-positive bacteraemia resulted 
in the detection of significantly more patients with definite endocarditis compared 
to a matched historical control group in the same hospital in whom echocardiogra-
phy was ordered at the discretion of the treating physician. This was associated with 
significantly reduced mortality rates at 6 months follow-up in the study group. 
Although the recommendations to perform echocardiography have been clear for 
a long time, the percentage of control patients in whom echocardiography was 
performed (27%) was low, completely in agreement with other population based 
studies (22%-59%) [3,6,16]. The incidence of definite endocarditis in our control 
group (8%) is comparable with those studies (5%-13%) [6,8,9,16]. Reported incidence 
rates are higher (25%-32%) in studies on selected populations in whom echocardi-
ography was routinely performed [17,18]. No previous study, however, has directly 
compared two echocardiographic regimens in two identical groups, as was done in 
the current study. In a study on patients with S. aureus bacteraemia, the impact of 
recommendations of an infectious disease consultant were studied [6]. In patients 
not treated according to these recommendations (n=132), relapse rate and mortality 
were higher compared to patients in whom the recommendations of an infectious 
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disease consultant were followed. In half (65/132) of patients in that study 
noncompliance to the recommendations concerned the failure to perform any form 
of echocardiography. 
Although the recommendation to perform echocardiography in all patients with S. 
aureus bacteraemia is supported by both treatment guidelines and previous studies, 
the decision to perform echocardiography in clinical practice appears to be largely 
driven by the presence of certain symptoms [1,3-5,18]. This might be the most 
important caveats explaining the proportion of patients (18%) who did have echo-
cardiographic examination even in our study group. This is, however, favourable 
compared to other studies evaluating the effects of  infectious disease specialist 
consultation recommending echocardiographic evaluation in patients with S. 
aureus bacteraemia. Echocardiographic evaluation was not performed in  27%-34% 
of patients in those studies [6,9,19]. In our historical control group, echocardiogra-
phy was mainly restricted to patients with cardiac murmurs. Cardiac murmurs, 
however, were only present in 64% of patients with definite endocarditis in our 
prospective study group. Also, endocarditis associated vascular and immunological 
phenomena of the skin and mucosa were only found in a very small minority of 
cases in our study group. This is in line with several other studies [2,3,20]. Patients 
with possible endocarditis therefore cannot be selected by the presence of clinical 
findings alone. Our findings support recommendations to perform echocardiogra-
phy in all patients with S.aureus bacteraemia [4,5]. In previous studies, risk factors 
for metastatic infection in patients with other Gram positive bacteraemia were 
identical to those in patients with S. aureus bacteraemia [13]. The present study 
suggests that routine echocardiography should also be performed in  patients with 
bacteraemia caused by other Gram positive micro-organisms and at least one risk 
factor for metastatic complications. In 27% (6/22) of patients, infective endocarditis 
was only revealed by TEE following normal TTE. This is comparable with other 
studies (14%-19%) comparing both echocardiographic techniques [17,20,21]. 
An important difference between the present study and previous studies is that a 
matched control group was included in order to compare two strategies of a 
diagnostic approach in high risk patients with Gram-positive bacteraemia. The use 
of a historical control group might have introduced potential bias. Patients were, 
however, accurately matched regarding risk profiles and microorganisms. In 
addition, the control group was large and within the timeframe of this study, no 
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changes in diagnostic work-up  or therapy regarding Gram-positive bacteraemia or 
endocarditis had occurred in our hospital. It is therefore most likely that endocarditis 
remained undetected in many control patients, as the incidence of endocarditis was 
significantly lower in the control group. This was also supported by the fact that 
endocarditis was first diagnosed by autopsy in two patients in the control group 
and that mortality rates were significantly higher in the control group. Autopsy had 
only been performed in a minority of patients in both patient groups. The antibiotic 
regimens for diagnosed endocarditis were similar in both groups, regarding both 
choice and timing of antibiotic treatment. However, more patients in the study 
group underwent valve replacement. In the absence of definite endocarditis or 
metastatic infectious foci, no differences in treatment duration were found, 
suggesting that the percentage of patients with prolonged antibiotic treatment 
due to suspected, but unproven endocarditis or metastatic foci did not differ 
between patient groups. Most likely early detection and intervention has led to the 
lower mortality in patients with endocarditis in the study group, resulting in 
favourable mortality rates (23%) in line with previous studies (22%-46%) [3,22]. In 
contrast, in the past endocarditis presumably was diagnosed in an advanced stage 
in most patients. This was further supported by the difference in duration of 
symptoms prior to diagnosis. This may also be an important explanation for higher 
mortality rates in endocarditis patients in the past in studies on the positive effects 
of infectious diseases specialist consultation. An increase in the number of patients 
with S. aureus bacteraemia  who underwent echocardiographic evaluation as a 
result of infectious disease specialist consultation was described in some of these 
studies [6,9,19]. Overall mortality rates (32%) in the control group was in line 
(17%-43%) compared to studies who introduced consultation of an infectious 
disease (ID) consultant in order to improve diagnostics and treatment [6,19]. No 
details on mortality in patients with endocarditis are provided in those studies. 
Mortality (59%) in patients with endocarditis in the control group in the present 
study is in line with mortality (71%-74%) in patients with advanced stages of 
endocarditis, including those with metastatic disease and congestive heart failure 
and patients with a contraindication to surgery [3,22]. The fact that a retrospective 
control group was included makes it impossible to evaluate in detail if the non-sig-
nificant difference in patients who underwent valve replacement reflects contrain-
dications for surgery due to  the advanced stage alone, or a change in acceptance 
for cardiothoracic surgery in the timeframe of the study. No such changes, however, 
were noticed in internal guidelines in our hospital. 
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Relevant additional infectious foci were found in more than half of patients with 
endocarditis. Several of these foci, such as spondylodiscitis and mycotic aneurisms, 
required prolonged antibiotic treatment or surgical interventions. This underscores 
the possibility of metastatic infectious foci being the cause of treatment failure and 
thus the need for a directed search for these complicating foci in addition to echo-
cardiography. FDG-PET appears to be a valuable diagnostic technique for this 
purpose [13,23].
Conclusion
Routine performance of echocardiography in all patients with Gram-positive 
bacteraemia and at least one risk factor for complicated infection is associated with 
the detection of a significantly higher percentage of endocarditis cases when 
compared to a strategy in which echocardiography was performed based on signs 
and clinical suspicion of endocarditis. Patients selected by a clinically driven echo-
cardiographic regime were characterised by higher mortality rates. This probably 
reflects the fact that only advanced cases of endocarditis are detected relying on 
clinical signs and symptoms of endocarditis alone. Our results also support the 
finding by others that TEE is more sensitive than TTE in a substantial proportion of 
endocarditis patients. Therefore, transthoracic echocardiography should be 
performed routinely in all patients with Gram positive bacteraemia and at least one 
risk factor for complicated infection. If transthoracic echocardiography does not 
reveal signs of endocarditis, transesophageal echocardiography should be 
performed.
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Abstract
Purpose
Between 30-50% of febrile neutropenic episodes are accounted for by infection. 
C-reactive protein is a non-specific parameter for infection and inflammation but 
might be employed as a trigger for diagnosis. The aim of the study was to evaluate 
whether FDG-PET/CT can be used to detect inflammatory foci in neutropenic 
patients with elevated CRP and helps to direct treatment.
Methods
Twenty-eight consecutive patients with neutropenia as a result of intensive 
chemotherapy for hematologic malignancies or myeloablative therapy for hema -
topoietic stem cell transplantation were prospectively included. FDG-PET/CT was 
added to the regular diagnostic work-up once the C-reactive protein level rose 
above 50 mg/L. 
Results
Pathological FDG-uptake was found in 26 of 28 cases despite peripheral neutrophil 
counts less than 0.1x10-9/L in 26 patients: in the digestive tract in 18 cases, around 
the tract of the central venous catheter in 9, and in the lungs in 7 cases. FDG-uptake 
in the CVC tract was associated with coagulase-negative staphylococcal bacteraemia 
(p<0.001) and deep venous thrombosis (p=0.002). The number of patients having 
Streptococcus mitis bacteraemia appeared to be higher in patients with grade 3 
oesophageal FDG-uptake (p= 0.08). Pulmonary FDG-uptake was associated with 
the presence of invasive fungal disease (p=0.04).
Conclusions
FDG-PET/CT-scanning during chemotherapy-induced febrile neutropenia and 
increased CRP is able to detect localized foci of infection and inflammation despite 
the absence of circulating neutrophils. Besides its potential role in detecting CVC 
related infection during febrile neutropenia, the high negative predictive value of 
FDG-PET/CT is important for avoiding unnecessary diagnostic tests and therapy.
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Introduction
Fever frequently develops during the profound neutropenia induced by intensive 
chemotherapy but is not always related to infection. It has long been the standard 
of care to start treatment with broad-spectrum antibiotics promptly once fever is 
observed because infection can be life-threatening. Between 30-50% of febrile 
episodes are caused by infection. Most cases are caused by bacteraemia but invasive 
fungal pulmonary disease (IFD) also occurs and this is the most important infectious 
cause of death in stem cell recipients with mortality rates varying between 50 and 
90% [1-3]. Inflammation of the mucosa of the digestive tract induced by cytotoxic 
treatment of hematologic malignancies manifests itself as mucositis and also leads 
to elevated C-reactive protein levels (CRP) and fever, often preceding certain types 
of bacteraemia typically with Streptococcus mitis [4,5].
Coagulase negative staphylococcal-bacteraemia (CoNS) is seen in 30% of recipients 
of hematologic stem cell transplantation (HSCT) and the central venous catheter 
(CVC) usually implanted to manage most of patients is assumed to be the source of 
this bacteraemia. Transient bacteraemia secondary to mucosal barrier injury, 
however, may also lead to infection of the CVC and to catheter related thrombi [6-8].
Early recognition of infection contributes to better patient outcomes [2,9]. 
Unnecessary treatment, on the other hand, is associated with side effects, the 
development of resistant micro-organisms, and increased costs [10-12]. Hence it is 
important to attempt to distinguish fever due to mucosal barrier injury and fever 
caused by infection whenever possible. fluorodeoxyglucose (FDG) positron 
emission tomography (PET) (FDG-PET) proved capable of detecting localized 
infectious and non-infectious inflammatory foci in immunocompetent patients 
often before any anatomical changes could be detected by conventional radiological 
techniques [13-16]. Since FDG-PET/CT depends not only on neutrophils, it was 
hypothesized that this technique can also be used in severely neutropenic patients 
[17-19].
We therefore performed a prospective observational study among patients given 
myeloablative chemotherapy for hematologic malignancies. The aim of the study 
was to determine whether FDG-PET/CT allows detection of inflammatory foci in 
patients with severe neutropenia. We also explored the possibility of using FDG-PET/
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CT to direct treatment of infectious complications in patients with elevated 
CRP-levels during neutropenia. FDG-PET/CT was also evaluated for pathological 
FDG-uptake in the digestive tract because of expected mucosal barrier injury.
Methods
This was a prospective, descriptive study in which the relationship between clinically 
defined infection (CDI) and microbiologically defined infection (MDI) with FDG-PET/
CT findings was defined. The Regional Ethics Committee granted approval (CMO nr 
11231).
Patients
All consecutive patients admitted between November 2006 and June 2007 to the 
Department of Haematology for remission induction or consolidation chemotherapy 
for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS), or for a 
hematologic stem cell transplantation (HSCT) following myeloablative therapy 
were eligible provided treatment was expected to result in neutropenia of more 
than 7 days duration. CRP levels (upper limit of normal 10 mg/L) were determined 
twice weekly and an FDG-PET-CT scan was made as soon as the CRP concentration 
exceeded 50 mg/L. Patients were withdrawn from the study when there was 
evidence of hemodynamic instability, diabetes mellitus if insulin had to be 
administered within 4 hours before the FDG-PET/CT scan, or when glucose levels 
exceeded 15 mmol/L at the time of FDG-PET/CT. The study ended when the patient 
was discharged. All patients gave written informed consent. 
FDG-PET/CT
An integrated PET/CT scanner (Siemens Biograph, Knoxville, TN, USA) was used for 
data acquisition. FDG-PET/CT was performed according to the EANM guideline [20]. 
Before FDG-injection, patients fasted and glucose or insulin-containing intravenous 
infusions were discontinued for 6 hours. One hour after intravenous injection of 3.5 
MBq/kg FDG (Covidien, Petten, The Netherlands), a low-dose CT of the area between 
the proximal femora and the base of the skull was made for anatomical correlation 
and attenuation correction of the PET data. Subsequently, emission images of the 
same area were acquired. FDG-uptake in the digestive tract was compared to liver 
uptake. The digestive tract was divided into 3 anatomical regions: oesophagus, 
small bowel and colon. Lack of FDG-uptake was graded as 0, FDG uptake less than 
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that in the liver was designated grade 1, equal to liver uptake as grade 2, and as 
grade 3 when uptake was more than that in the liver (21). 
Low dose-CT versus High-Resolution-CT of the thorax (HRCT)
FDG-PET/CT was combined with a HRCT of the thorax when a HRCT of the thorax 
was indicated because of suspected invasive pulmonary fungal disease [10,22-24]. 
The trigger for ordering a HRCT for high risk patients included the following: signs 
or symptoms of pulmonary disease, abnormal chest X-ray, a plasma galactomannan 
index of >0.5, or fever persisting  for >4 days despite broad-spectrum antibiotic 
treatment.
Regular patient monitoring
Monitoring of patients was performed according to standard clinical practice. CRP 
determination was the only additional test to the regularly scheduled laboratory 
tests. FDG-PET/CT was included in the regular diagnostic work-up when CRP 
exceeded 50 mg/L. Additional investigations to confirm FDG-PET/CT findings were 
only performed when clinically justified. Epidemiological data, the number, type, 
and results of all diagnostic tests, and treatment data were registered in an 
electronic case record form (FileMaker Pro 9.0). 
Confirmation of FDG-PET/CT findings
FDG-PET/CT reading was performed by 2 nuclear medicine physicians. The 
low-dose-CT provided anatomical reference for FDG-PET abnormalities and was 
not used for diagnostic purposes. On the same day, this was reported to the 
attending physician. To be included in patient management, FDG-PET/CT findings 
had to be supported by clinical evidence, microbiologic tests and routine radiology. 
Invasive techniques such as biopsy, bronchoscopy or endoscopy were only 
performed when clinically indicated. 
The FDG-PET/CT assessments were independently re-evaluated (F.V. and W.O.) 
without knowledge of the final diagnosis or the outcome. At a later stage, a 
differential diagnosis of febrile neutropenia was made independently without 
knowledge of the FDG-PET/CT assessment by an infectious disease specialist (F.V.) 
and a specialist in infectious diseases in haematology (P.D.). 
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Clinical features
Bacteraemia was defined by the recovery of a microorganism from a single 
percutaneous blood culture except for members of the skin commensal flora such 
coagulase-negative staphylococci (CoNS) or coryneforms in which case an identical 
isolate had to be recovered from two simultaneous sets of percutaneous blood 
cultures, or from each lumen of a 3 or 4 lumen central venous catheter (CVC). 
Bacteraemia was deemed persistent when blood cultures drawn on at least 2 
separate days yielded growth of the same isolate.
Catheter exit site infection was defined by the development of any of the following 
manifestations within 2 cm of the exit site:- erythema or tenderness or induration or 
seropurulent discharge (clinically defined infection). When any potential pathogen 
was isolated from a specimen of the exit site or >15 colony forming units (cfu) were 
isolated in pure culture from segment A (the external catheter) or segment B (the 
subcutaneous part of the catheter), the infection was deemed a microbiologically 
defined infection. Tunnel infection was defined by the development of any of the 
following along the subcutaneous tract: cellulitis, erythema or tenderness or 
induration with or without an exit site infection. In the absence of a specimen of the 
tunnel infection, the cause was assumed to be the same as that of an exit site 
infection when one existed. Septic thrombophlebitis at the site of a CVC was defined 
as persistent bacteraemia, and deep venous thrombosis as diagnosed by ultrasound 
or venography, and no other source of infection explaining the persistence of 
bacteraemia [25]. No specific testing for mucosal bowel injury was performed. 
Citrulline levels however have shown to be a reproducible measure for intestinal 
villous mass [26].  Measurement of citrulline levels had been performed in the 
majority of the patients. Citrulline levels below 10 µmol/L have been interpreted as 
severe mucosal bowel injury in other studies and replaces other indirect functional 
tests to assess cytotoxic effects of chemotherapy [27]. Invasive fungal disease (IFD) 
was classified as, possible, probable and proven according to EORTC/MSG guidelines 
[10].
Outcome parameters
The primary outcome parameter was the ability of FDG-PET/CT to locate an 
inflammatory (infectious or non-infectious) focus during neutropenia. Secondary 
outcome parameters were the ability of FDG-PET/CT to be used to direct treatment 
of infectious complications in patients with elevated CRP-levels during neutropenia 
and the ability of FDG-PET/CT to depict mucosal barrier injury.
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Statistical analysis
Descriptive statistics were done to compare FDG-PET/CT with current practice 
regarding identification of infectious or inflammatory foci explaining fever or other 
potential signs of infection. Per anatomical area patients with or without 
pathological FDG-uptake were assessed for the presence of a clinical and microbio-
logical  defined illness. Differences between patients with or without pathological 
FDG-uptake  were tested using Fisher’s exact tests for categorical variables. 
Differences were considered to be statistically significant when the p value was less 
than 0.05 (2-sided).  
Results
A total of 37 eligible patients provided written consent. CRP levels remained below 
50 mg/L in 6 cases, one patient who experienced clinical deterioration withdrew 
consent before FDG-PET/CT could be performed, and FDG-PET/CT could not be 
performed in a further 2 cases due to technical problems. Hence 28 cases were 
evaluated (Table 1). 
On average, CRP reached 50 mg/L on day 12 after starting chemotherapy. In 26 of 28 
(93%) patients this was accompanied by fever. FDG-PET/CT was performed a mean 
of 14 days after starting chemotherapy when all patients were still profoundly 
neutropenic:  26 had peripheral neutrophil counts less than 0.1x10-9/L. Pathological 
FDG-uptake was found in 26 of 28 cases (93%) (Table 1). Grade 3 uptake was found 
in the digestive tract in 18 cases, uptake in the CVC tract was seen in 9 cases, and 
abnormal pulmonary uptake was found in 7 cases. In 1 case, localized FDG-uptake 
in the right thyroid lobe was found during the neutropenic phase (Figure 1) although 
the patient had no localizing symptoms. He deteriorated one week later due to 
persistent candidemia. A second FDG-PET/CT scan, made 3 weeks after the first 
scan, indicated abscess formation in the right thyroid lobe, which was confirmed by 
surgical drainage and culture. 
FDG-uptake in the CVC tract and CoNS bacteraemia
26/28 patients included in the study had a central venous catheter. FDG-uptake in 
the CVC tract was only seen in 9 patients, all of whom had persistent CoNS 
bacteraemia (p<0.001). The presence of FDG-uptake in the CVC tract was not related 
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 Table 1  Patient Characteristics.
Patient Clinical, microbiological and radiological diagnoses Citrulline FDG-uptake
Sex, age (yr), 
hematological 
disease
Persistent  
CoNS
bacteraemia
Strep mitis
bacteraemia
DVT
 subclavian 
vein
IFD Other (µmol/L) CVC tract Lung Colon  
(Grade 3)
Oesophagus 
(Grade 3)
Other
1.   M, 66, AML Yes N/A* Typhlitis No CVC Yes
2.   F, 63, MM N/A 4.4 Yes Yes
3.   F, 33, AML Yes Yes 4.3 Yes Yes
4.   M, 54, AML Yes Yes 7.0 Yes
5.   F, 42, AML Yes No Yes (possible) Typhlitis 6.9 Yes Yes
6.   M, 62, NHL N/A 4.5
7.   M, 48, NHL Yes N/A 4.9 Yes Yes
8.   M, 59, MM Yes N/A 4.4 Yes Yes
9.   M, 41, MM N/A Yes (probable) No CVC Yes
10.  M, 50, MDS N/A Candida abscess 
thyroid gland
6.9 Thyroid 
lesion
11.  M, 58, NHL N/A
12.  F, 57, MDS Yes N/A Yes (possible) Typhlitis 2.9 Yes Yes
13.  M, 54, MDS Yes Yes Yes (possible) 6.6 Yes Yes
14.  M, 44, NHL Yes No Yes (possible) 6.3 Yes Yes
15.  M, 52, NHL N/A Yes (possible) 18.7 Yes
16.  M, 40, ALL Yes Yes 6.0 Yes Yes
17.  M, 59, AML Yes N/A 3.5 Yes Yes
18.  M, 31, HL N/A 9.3 Yes
19.  F, 49, AML N/A 7.1 Yes
20.  F, 48, CMMOL Yes Yes 5.8 Yes
21.  F, 59, MDS Yes Yes 10.7 Yes Yes
22.  F, 45, AML Yes No 8.1 Yes Yes
23.  M, 45, MDS Yes N/A 11.6 Yes Yes
24.  M, 55, AML Yes N/A typhlitis Yes Yes
25.  M, 36, ALL Yes No Yes (probable) Yes Yes
26.  M, 62, MM N/A Yes
27.  M, 52, MM Yes N/A Yes
28.  F, 44, AML Yes Yes Yes Yes
*  N/A= ultrasound not performed, no clinical signs of thrombosis, IFD=Invasive Fungal Disease, 
AML=acute myeloid leukaemia, MM=multiple myeloma, NHL=Non-Hodgkin Lymphoma, 
MDS=myelodysplastic syndrome, ALL=acute lymphatic lymphoma, HL=Hodgkin lymphoma
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27.  M, 52, MM Yes N/A Yes
28.  F, 44, AML Yes Yes Yes Yes
*  N/A= ultrasound not performed, no clinical signs of thrombosis, IFD=Invasive Fungal Disease, 
AML=acute myeloid leukaemia, MM=multiple myeloma, NHL=Non-Hodgkin Lymphoma, 
MDS=myelodysplastic syndrome, ALL=acute lymphatic lymphoma, HL=Hodgkin lymphoma
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to clinical signs of exit site or tunnel infection. Ultrasounds were only performed in 
the presence of local complaints, such as swelling of the arm, to exclude deep 
venous thrombosis. An ultrasound of the subclavian vein was performed in 11/26 
(42%) of patients, amongst whom all 9 patients with FDG-uptake in the CVC tract. In 
case of deep venous thrombosis alone without concomitant persistent CoNS 
bacteraemia, FDG-uptake in the CVC tract was never seen (see Table 1). Confirmed 
deep venous thrombosis in combination with persistent CoNS bacteraemia (septic 
thrombophlebitis) was present in 7 patients. Increased FDG-uptake in the subclavian 
tract was found in 6 of these 7 cases with confirmed septic thrombophlebitis. 
In 3 patients FDG-uptake in the CVC-tract was present without confirmed septic 
thrombophlebitis. Persistent CoNS bacteraemia was present in all 3 of them, but 
an ultrasound ruled out in 2 of them and was not performed in the last patient.
In the patients without FDG-uptake in the CVC-tract septic thrombosis was ruled 
out either by an ultrasound ruling out thrombosis in 1 patient, or the absence of 
persistent bacteraemia in 14 patients. In only 1 patient septic thrombophlebitis 
could not be ruled out definitely as despite the presence of persistent CoNS 
bacteraemia no ultrasound was performed. However, no clinical signs of thrombosis 
were present. The positive predictive value of FDG-PET/CT for the presence of septic 
thrombophlebitis was 67% and the negative predictive value 94%. 
In 4 of these 6 cases with septic thrombophlebitis delineated by FDG-PET/CT the 
first ultrasound was negative and thrombosis could only be confirmed by a second 
ultrasound, whereas FDG-PET/CT had been positive at the time of the first ultrasound 
(Figure 2). 
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Figure 1  Patient #10 with a Candida abscess in the right thyroid lobe, already present on 
the first (left) FDG-PET/CT-scan and increased on a second scan (right).
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FDG-uptake in the intestinal wall 
and Streptococcus mitis bacteraemia
FDG-uptake grade 2 or more was found 
in the digestive tract, irrespective of 
the localization, in 24 of 28 (86%) cases. 
Citrulline levels were known in 20 of 
28 patients (see Table 1). In 2 of the 
4 patients in whom no pathological 
FDG-uptake was found in the digestive tract citrulline levels were measured and 
below 10 µmol/L. FDG-uptake grade 2 or more in the oesophagus and colon were 
not concomitant (p=1.0). Grade 3 FDG-uptake in the wall of the oesophagus was 
seen in 11 cases. Endoscopy was not performed in these patients. Seven of these 11 
patients (64%) had retrosternal complaints consistent with oesophagitis (Figure 3). 
Only 1 of the patients with retrosternal complaints did have Streptococcus mitis 
bacteraemia. On the other hand there appeared to be an association, between 
Streptococcus mitis bacteraemia and grade 3 oesophageal FDG-uptake (p=0.08), as 
5 out of 7 patients with Streptococcus mitis bacteraemia did have grade 3 FDG-uptake 
in the oesophagus (Table 2). Grade 3 FDG-uptake in the wall of the colon was found 
in 13 cases, but there was no correlation with Streptococcus mitis bacteraemia 
(p=0.2). Four patients had severe abdominal complaints consistent with typhlitis 
and grade 3 colonic FDG-uptake was found in each case (Figure 4). 
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Figure 2  Patient # 4 with a swollen arm 
showed FDG-uptake in the left subclavian 
tract.
Figure 3  Grade 3 FDG-uptake in the 
oesophagus in patient # 8. He developed 
Streptococcus mitis bacteraemia during 
the neutropenic phase.
Thrombosis of the subclavian vein was 
rejected by normal ultrasound and he 
was discharged from the hospital 4 days 
later. Two days later, the patient was 
readmitted for progressive swelling of his 
arm. Deep venous thrombosis was con- 
firmed by a repeat ultrasound and blood 
cultures after removal of the CVC remained 
positive for CoNS. The diagnosis of septic 
thrombophlebitis of the subclavian vein 
was further supported by CT.
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Pulmonary FDG-uptake and invasive fungal disease
Proven invasive pulmonary fungal disease was not found, but 5 patients had 
possible and 2 patients had probable invasive fungal disease (Figure 5). Pulmonary 
FDG-uptake was present in both cases of probable invasive fungal disease and in 
3 of the 5 cases with possible invasive fungal disease and in only 2 out of 21 patients 
without invasive fungal disease. Pulmonary FDG-uptake therefore is associated 
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 Table 2  Number of patients in whom echocardiography was performed.
S. mitis bacteraemia 
present
(n=7)
S. mitis bacteraemia 
absent
(n=21)
FDG uptake oesophagus gr 3 5* 6
FDG uptake oesophagus < gr3 2 15
FDG uptake colon gr 3 5 8
FDG uptake colon < gr 3 2 13
*p=0.076 Strep mitis bacteraemia is most often found in patients with grade 3 oesophageal FDG- 
uptake
Figure 4  FDG-PET/CT  images of patient # 1 during severe right sided abdominal pain, 
diarrhoea and signs of local peritonitis on physical examination, showing grade 3 FDG 
uptake in the entire colonic wall.
155
with the presence of invasive fungal disease (p=0.04). Probable invasive fungal 
disease was never present in absence of pulmonary FDG-uptake.
Discussion
This study shows that localized foci of infection or inflammation can be visualized 
by FDG-PET/CT during severe neutropenia. It has been shown before that FDG-PET/
CT is capable of visualizing localized areas of inflammation by using the accelerated 
metabolism of different activated inflammatory cells, other then neutrophils, such 
as macrophages and monocytes [17-19,28]. This suggests that not only activated 
neutrophils, but also other inflammatory cells play a  role in visualizing localized 
infection or inflammation by FDG-PET/CT. Some retrospective studies have reported 
the possibility to visualize infectious foci by FDG-PET/CT in neutropenic patients, 
but only a minority of these patients were deeply neutropenic at the time FDG-PET/
CT was performed in contrast to all of our study patients [25,29,30]. In the largest 
study so far among patients with multiple myeloma (n=248), FDG-PET/CT was 
performed for disease staging in most patients (n=199) and for infection work-up in 
FDG-PET/CT during severe neutropenia
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Figure 5  FDG-PET/CT images during the neutropenic phase after Allogeneic Stem Cell 
Transplantation of patient # 9 treated for multiple myeloma.
The FDG-PET/CT scan shows extensive pulmonary FDG-uptake in both lungs (image 
shows pathological uptake in the right lung). A chest X-ray made because of fever during 
the neutropenic phase was unremarkable 3 days earlier. The HR-CT scan performed on the 
same day as the FDG-PET/CT showed bilateral consolidations, with a surrounding halo of 
ground glass supporting probable invasive fungal disease.
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the remaining 49 patients [29]. In total, 165 infectious foci were detected in that 
study. Neutropenia  (<1.0x10-9 /L) was present in only 27 of 248 (11%) patients, 
however. Most probably FDG-uptake in other activated inflammatory cells is the 
explanation for the visualization of inflammatory foci on FDG-PET/CT in the vast 
majority of patients in our study despite neutrophil counts below 0.1 x 109/L [17,18]. 
We found a clear correlation between FDG-uptake in the CVC tract and septic 
thrombophlebitis of the subclavian vein. This supports the results of another study 
on the value of FDG-PET/CT in the diagnosis of septic thrombophlebitis in which 
FDG-PET/CT was prospectively conducted in patients with suspected septic throm-
bophlebitis [25,30]. FDG-PET/CT showed pathological tracer uptake in all 9 patients 
with proven septic thrombophlebitis. Control patients in that study were collected 
from a retrospective cohort of patients with deep venous thrombosis (DVT), without 
signs of infection in whom a FDG-PET/CT was performed for other reasons. Selection 
bias in that study makes it impossible to calculate positive and negative predictive 
values of FDG-PET/CT regarding detection of septic thrombophlebitis. A caveat in 
our study is, however, that ultrasound was only performed on clinical grounds, so 
we might have missed asymptomatic deep venous thrombosis. The negative 
predictive value of FDG-PET/CT for the presence of septic thrombophlebitis, 
however, can be estimated to be high (94%) as in only 1 patient with persistent 
bacteraemia a deep venous thrombosis was ruled out solely on the absence of 
clinical signs. The positive predictive value (67%) regarding septic thrombophlebitis 
on the other hand might be underestimated in our study, because ultrasound was 
not performed in all patients precluding these patients of fulfilling the definition of 
septic thrombophlebitis. In 3 patients with FDG-uptake in the subclavian tract and 
persistent bacteraemia only 1 ultrasound was performed. This is important as 
strikingly, FDG-PET/CT seemed to precede detection of the abnormalities on 
ultrasound of the subclavian vein in 4 cases of septic thrombophlebitis. Therefore, 
pathological FDG-uptake in the CVC tract in patients with febrile neutropenia 
should not be ignored as they might be have important consequences in  CVC 
management, e.g. line removal, particularly when persistent bacteraemia is 
diagnosed. 
Pulmonary FDG-uptake was frequently seen in this study and was related with 
possible or probable invasive fungal disease. In the absence of pulmonary 
FDG-uptake probable or definite invasive fungal disease was never the cause of 
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fever at the time FDG-PET/CT was performed. An adequate comparison with HRCT, 
which already has an added value in the early recognition of life threatening invasive 
fungal disease, was not possible in our study because FDG-PET/CT and HRCT were 
not performed within a timeframe of several days in enough patients [22-24]. Data 
show, however, that invasive fungal disease can be visualized despite profound 
neutropenia. 
Metastatic infection was diagnosed in only one patient with a Candida abscess in 
the thyroid gland. No other metastatic foci were diagnosed by clinical symptoms or 
signs or other imaging techniques in our study. Consequently, the negative 
predictive value of FDG-PET/CT for excluding clinically relevant metastatic foci of 
infection is likely to be high assuming that these foci reveal themselves due to 
intensive monitoring for symptoms and signs when left untreated. 
Substantial FDG-uptake in the digestive tract was seen in almost every case, but 
digestive tract uptake is contentious as it is known to yield false positive results [31]. 
A visual grading for GI-activity was chosen due to the variability in distribution and 
extent of the enhanced FDG-uptake in the gut. Theoretically, chemotherapy may 
have influenced FDG-uptake in the liver, which was chosen as the organ of reference. 
However, all patients were scanned at approximately the same point in time during 
the course of treatment, thus reducing the possibility of chemotherapy-induced 
variability in liver uptake. Furthermore, none of the patients was on metformin use 
at the time the FDG-PET/CT was performed, excluding another important cause of 
increased FDG-uptake [32]
We specified uptake according to the anatomic region and graded uptake 
comparing it to liver uptake to circumvent this problem as has been done by others 
for staging disease activity in colitis, which then showed a firm correlation with 
disease activity [21,33]. An interesting finding was the possible correlation between 
oesophageal FDG-uptake and Streptococcus mitis bacteraemia, which was not seen 
in colonic FDG-uptake. These findings support the theory that Streptococcus mitis 
bacteraemia originates from oesophageal mucosal barrier injury [34]. Increased 
FGD-uptake may be the result of mucositis with or without infection since this has 
been shown to be associated with thickening of the oesophagus [35]. Besides 
mucosal barrier injury, there may be an additional local factor such as infection due 
to Streptococcus mitis of the mucosa, resulting in increased FDG-uptake [36]. 
Surprisingly no FDG-uptake was found in the digestive tract in some patients 
FDG-PET/CT during severe neutropenia
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despite citrulline levels below 10 µmol/L. Probably this supports the presence of an 
additional inflammatory factor. Further studies on this subject, however should be 
performed.
Conclusion
FDG-PET/CT during chemotherapy induced febrile neutropenia and increased CRP 
is able to visualize localized foci of infection and inflammation despite the absence 
of neutrophils in the peripheral blood. Besides the potential role of FDG-PET/CT in 
early detection and managing specific infectious complications during febrile 
neutropenia, i.e. septic thrombophlebitis and metastatic infection, its high negative 
predictive value may help in avoiding unnecessary diagnostics and therapy. 
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In this thesis, clinical impact of FDG-PET/CT on the treatment of infection is explored.
Only recently FDG-PET/CT has entered the field of infectious diseases. FDG-PET/CT 
has become an established diagnostic tool in oncology. In fever of unknown 
origin, acceptable specificity combined with high sensitivity regarding localised 
inflammatory processes is employed. 
In the first chapter, the expanding number of reports and studies on the use of 
FDG-PET/CT was reviewed. It was concluded that implementation of FDG-PET/CT in 
a diagnostic protocol in selected patients would provide whole body imaging and 
information about disease activity within hours after scanning, encouraging its use 
in localised infectious diseases.
Infection beyond the primary focus of infection is an important complication of Gram 
positive bacteraemia. From chapter 2 it was learned that complicating infectious foci 
occur in approximately one-third of patients with SAB or SSB. Part of these foci lack 
localising signs and symptoms, thereby increasing the risk of remaining undiagnosed 
and therefore untreated, e.g. the omission to perform surgical removal of the focus of 
infection, drainage, or to prolong antibiotic treatment. As infection-related mortality is 
significantly higher among patients with complicating infectious foci, it was 
hypothesised that increased morbidity, like relapse of infection, and mortality might 
be influenced favourably by early recognition and directed treatment of these clinically 
silent metastatic infectious foci. As patients at high risk for the presence of complicated 
disease were easy to identify, the use of FDG-PET/CT in order to reveal clinically silent 
foci of infection in patients with Gram positive bacteraemia was explored. 
From the results in chapter 3, FDG PET appeared to be promising in detecting 
metastatic infectious foci as relevant new foci were revealed even when the results 
of other diagnostic procedures showed no signs of infection. However, for a 
validation of FDG PET for this indication and for determination of its exact position 
in the order of diagnostic tests, a prospective study including a larger number of 
patients was warranted.
In the large prospective study described in chapter 4 it was investigated whether 
FDG-PET/CT enabled early detection of metastatic infectious complications in 
patients with Gram positive bacteraemia and risk factors for complicating infectious 
foci and whether the detection of metastatic foci would influence outcome by 
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enabling early treatment adjustment. A potential caveat of this study evaluating the 
role of FDG-PET/CT in high risk Gram-positive bacteraemia was the fact that echo-
cardiography was performed more often in the study group. However, when echo-
cardiography was added as a confounder in the analysis, mortality was still 
significantly lower in the FDG-PET/CT group. As due to the lack of guiding symptoms 
most of the infectious foci were first delineated by FDG-PET/CT it is highly likely that 
the differences in relapse rate and mortality were attributed to the addition of 
FDG-PET/CT to the diagnostic regimen. 
Not surprisingly, the diagnostic regimen incorporating FDG-PET/CT resulted in an 
increase in costs due to more in-hospital treatment of clinically relevant metastatic 
infectious foci. Still, the costs per mortality case prevented (€48,325) as described in 
chapter 5 are within the range which is generally accepted as efficient. Cost 
effectiveness would further improve when patient management would be based 
on FDG-PET/CT abnormalities alone without the obligatory confirmation of 
abnormalities by conventional radiological techniques in the study.
The fact that metastatic infectious foci were revealed in the vast majority of patients 
in the prospective study in chapter 6 is not surprising for several reasons. First, only 
high risk patients were selected in contrast to the population based retrospective 
study. Secondly this can be attributed to the addition of routine FDG-PET/CT to the 
diagnostic work-up. As was stated above, the presence of clinically silent infectious 
foci in up to 30% of patients in the retrospective study in chapter 2 urged the need 
of whole body imaging techniques in order to enable early detection of metastatic 
infectious foci. Most probably part of these foci were left undetected in our 
retrospective study. This is reflected by the number of relapses and the fact that in 
some patients metastatic infectious foci were only detected post-mortem. 
Another important lesson learned from the prospective study in chapter 4 was the 
fact that routinely performed echocardiography in patients with Gram-positive 
bacteraemia resulted in a twice as many patients diagnosed with endocarditis. 
Results from this analysis were separately described in chapter 7. Correctly 
diagnosing endocarditis in a larger proportion of patients was associated with a 
significant decrease of mortality rates, most probably because  in the past 
endocarditis was diagnosed in a more advanced stage when the decision to perform 
confirmatory examinations, like echocardiography, was mainly symptom based. 
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Finally in chapter 8 the value of FDG-PET/CT in febrile neutropenia was explored. 
Focal infection and inflammation both have a substantial share in the pathophysiol-
ogy of fever during chemotherapy induced neutropenia. FDG-PET/CT might be of 
value once data concerning predictive values in the studies presented in this thesis 
on metastatic infection and on fever of unknown origin. Data show that localized 
foci of infection or inflammation can be visualized by FDG-PET/CT during severe 
neutropenia. This confirms that not only activated neutrophils play a  role in 
visualizing localized infection or inflammation by FDG-PET/CT as was previously 
thought. Besides the potential role of FDG-PET/CT in early detection and managing 
specific infectious complications during febrile neutropenia, i.e. septic thrombo-
phlebitis and metastatic infection, its high negative predictive value may help in 
avoiding unnecessary diagnostics and therapy. 
In conclusion, in patients with Gram-positive bacteraemia thorough history taking, 
physical examination and close observation should delineate those patients at high 
risk for metastatic complications. The studies presented, however, show that in a 
large proportion of patients metastatic infectious foci are clinically silent. In patients 
with Gram-positive bacteraemia and a high risk for development of complicated 
infection therefore, a structured diagnostic protocol including echocardiography 
and FDG-PET/CT aimed at detection of metastatic infectious foci appears to improve 
outcome. Patients with high risk Gram-positive bacteraemia therefore should have 
easy access to FDG-PET/CT when available. Besides the cost-effectiveness analysis 
should open doors for introduction of FDG-PET/CT in infectious diseases also in 
countries (e.g. US) without endorsement at present.  FDG-PET/CT can also be used 
in patients with febrile neutropenia. Further prospective studies, however should 
be performed implementing FDG-PET/CT in a structured protocol in febrile 
neutropenia. Especially predictive values in invasive pulmonary infection should be 
explored in more detail. 
The studies presented show FDG-PET/CT has conquered its place in difficult to 
diagnose localised infectious diseases and opens doors for further studies on 
specific infections. For example focussing on the large number of endovascular and 
foreign body infections, high quality prospective studies on infections of vascular 
prosthesis are needed. Subsequently tailoring duration of treatment in those 
patients with metastatic infection using follow-up scanning is open for further 
exploration.
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Summary
This thesis contains several clinical studies on FDG-PET/CT imaging for early 
detection of (metastatic) infectious foci in patients with serious (bacterial) infections. 
Fluorodeoxyglucose (FDG) labelled with the radiotracer 18F passes the cellular 
membrane via the normal glucose transporters. After entering the cell, FDG is 
phosphorylated similar to glucose. Unlike glucose, no further processing takes 
place resulting in intracellular accumulation. Leucocytes, especially granulocytes 
and macrophages, show enhanced metabolism and glucose uptake upon activation. 
Localised foci of infection therefore can be visualised using a PET-scan within 2 
hours after injection of FDG. The relatively high costs and limited availability may be 
considered drawbacks. However, the number of integrated PET-CT scanners is 
increasing rapidly. Although a PET procedure is relatively expensive as such, this will 
not be a major issue if FDG-PET/CT proves to be cost-effective due to its high 
diagnostic yield. 
In chapter 1, the increasing number of reports in literature on the use of FDG-PET/
CT in infection, inflammation and fever of unknown origin (FUO) were reviewed. A 
total of 35 studies primarily dealing with infection were retrieved, most of which 
addressed case series of patients with fever and suspected infection in a specific 
organ system. FDG-PET was performed apart from standard diagnostic procedures. 
In general, sensitivity of FDG-PET in detecting non-osseous infections compared 
favourably to other diagnostic modalities. Lower specificity due to possible 
malignancies or non-infectious inflammation can be overcome by implementing 
FDG-PET/CT in a diagnostic protocol. FDG-PET/CT provides whole body imaging 
and information about disease activity within hours after scanning. It was stated 
that FDG-PET/CT is emerging as a promising imaging technique in (acute) focal 
infectious diseases. 
In chapter 2, clinical outcome in patients with Staphylococcus aureus and 
Streptococcus spp. bacteraemia (SAB and SSB)  was analysed. Charts of 180 
consecutive patients were retrospectively reviewed. In both SAB and SSB 
approximately one third of patients were diagnosed with complicating infectious 
foci. In one third of complicating foci, guiding signs or symptoms were absent and 
10% of foci were detected only at autopsy. Factors associated with the development 
of complicating infectious foci were a delay in treatment for more than 48 h after 
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the onset of symptoms, community acquisition, persistently positive blood cultures, 
congenital heart disease, and the presence of foreign bodies. Infection-related 
mortality was significantly higher in patients with complicating infectious foci (29 
vs. 9%). 
In chapter 3, the results of a retrospective study on the possible value of FDG-PET 
in detecting metastatic infectious foci were presented. A total of 40 FDG PET scans 
ordered because of suspected metastatic infection were analysed. Metastatic 
complications were diagnosed in 75% of all episodes. A median number of 4, often 
symptom guided, diagnostic procedures to search for metastatic infection had 
been performed before FDG PET was ordered. FDG PET diagnosed a clinically 
relevant new focus in 45% of cases and confirmed abnormalities already diagnosed 
in 30% of cases. The positive predictive value of FDG PET was 91% and the negative 
predictive value was 100%. We concluded that FDG PET might be a valuable imaging 
technique in patients at high risk of metastatic infectious disease, even when the 
results of other diagnostic procedures are normal.
It was hypothesised that early treatment adjustment in the presence of clinically 
silent infectious foci might lead to a decrease in relapse rate, due to the fact that less 
infectious foci would remain untreated. In chapter 4, the concept of early detection 
of metastatic infectious foci using FDG-PET was evaluated in a large prospective 
study. 115 non-neutropenic patients with Gram-positive bacteraemia were 
prospectively included. Patients with positive blood cultures growing Staphylococcus 
aureus, Streptococcus species or Enterococcus species were eligible when a risk factor 
for developing metastatic infectious foci was present. FDG PET/CT  was performed 
within 2 weeks after the first positive blood culture. Results were compared  with a 
matched historical control group of 230 patients in whom no FDG PET/CT was 
performed. Significantly more patients were diagnosed with metastatic foci in the 
study group (68% versus 36%). Again, FDG PET/CT was the first to delineate 
infectious foci in approximately one third  of patients. Relapse rates decreased from 
7.4% to 2.6 % among study patients (p=0.09), and from 8.9% to 1.4% in patients with 
S. aureus (P=0.04). Overall mortality after 6 months decreased significantly from 
32% to 19% in the FDG PET/CT group. It was concluded that addition of FDG-PET/CT 
in the work-up of high risk patients with Gram-positive bacteraemia is a valuable 
technique that results in lower mortality rates.
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In chapter 5, a cost effectiveness analysis on the use of FDG-PET/CT in patients with 
Gram positive bacteraemia was performed. Alongside the clinical study, healthcare 
related costs were collected influencing total costs due to the addition of FDG-PET/
CT. Incremental costs of FDG-PET/CT were €6,303, however, mainly due to admission 
(mean €4,421). Costs per mortality case prevented of €48,325 are within the range 
that is considered to be efficient by Dutch guidelines. It was concluded that costs 
should not be a drawback for patients at high risk for metastatic infectious disease 
to undergo FDG-PET/CT.
In chapter 6, outcome of a prospective cohort in which patients with SAB and SSB 
were included was presented. In this cohort, a thorough search for detection of 
metastatic infectious foci was performed using routine FDG-PET/CT and echocardi-
ography in the majority of patients. Study patients were derived from our 
prospective study presented in chapter 4, including those patients who had been 
excluded due to the fact they had been admitted primarily to the intensive care 
unit. Results of 115 consecutive patients with at least one risk factor for the presence 
of metastatic infectious foci were analysed. Metastatic infectious foci were detected 
in approximately 70% of patients. Endocarditis, endovascular infections, pulmonary 
abscesses and spondylodiscitis were diagnosed most frequently. The incidence of 
metastatic infection was similar in patients with Streptococcus spp. and those with S. 
aureus bacteraemia. Symptoms guiding the attending physician in the diagnostic 
work-up were only present in a minority of cases (41%). Again, an unknown portal of 
entry, treatment delay >48h, and the presence of foreign body material were 
significant risk factors for developing metastatic foci. Mean CRP levels on admission 
were significantly higher in patients with metastatic infectious foci, probably as a 
surrogate marker for advanced disease and therefore treatment delay. FDG-PET was 
the first to localise metastatic infectious foci in 35% of patients. As only a minority 
of foci were accompanied by guiding symptoms, the total number of foci revealed 
by symptom guided CT, ultrasound and MRI remained low. Mortality tended to be 
lower in patients without complicated infection. Five of 31 patients without proven 
metastatic foci died (16%). In retrospect, however, of these 5 patients, three most 
likely did have metastatic foci that were not diagnosed during life. 
In chapter 7, we had a unique chance to evaluate impact of two echocardiographic 
regimes on patient outcome, as despite the firm recommendation to perform echo-
cardiography in high-risk patients with Gram-positive bacteraemia, routine echo-
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cardiography is not embedded in daily practice in many clinical settings. Differences 
between patients in the prospective cohort in chapter 4 in whom echocardiogra-
phy had been routinely performed were compared with the retrospective control 
group derived from the same study in which echocardiography had been performed 
only at the discretion of he attending physician. In the past, echocardiography was 
performed in only 20% of patients without a heart murmur, versus 70% of study 
patients, while a murmur was only present in 64% of patients with definite 
endocarditis. Endocarditis was diagnosed in 19% among study patients, versus 7% 
in the control group. Correctly diagnosing endocarditis in a larger proportion of 
patients was associated with a significant decrease of mortality rates from 59 % to 
23%. Most probably endocarditis was diagnosed in a earlier stage of disease leading 
to early treatment and treatment adjustment in some of the patients. 
In chapter 8, the ability of FDG-PET to visualise localised foci of infection or 
inflammation in the absence of neutrophils in the peripheral blood was explored in 
28 patients. Fever frequently develops during profound neutropenia induced by 
intensive chemotherapy for hematologic malignancies or myeloablative therapy for 
hematopoietic stem cell transplantation, but is not always related to infection. Early 
recognition and treatment of infection, however, contributes to better patient 
outcome. FDG-PET was performed as soon as CRP reached 50 mg/ml. In the vast 
majority (93%) of patients, this was accompanied by fever. Pathological FDG-uptake 
was found in 26 of 28 cases. A clear correlation was found between FDG-uptake in 
the CVC tract and septic thrombophlebitis of the subclavian vein. Also FDG-uptake 
was found significantly more often in patients with possible and probable invasive 
fungal disease. Inflammation of the mucosa of the digestive tract induced by 
cytotoxic treatment of hematologic malignancies manifests itself as mucositis and 
also leads to elevated C-reactive protein levels (CRP) and fever, often preceding 
certain types of bacteraemia typically with Streptococcus mitis Substantial 
FDG-uptake in the digestive tract was seen in almost every case. Another interesting 
finding was the possible correlation between esophageal FDG-uptake and 
Streptococcus mitis bacteraemia, which was not seen in colonic FDG-uptake. We 
concluded that the absence of neutrophils in the peripheral blood should not be a 
drawback for using FDG-PET/CT in difficult to diagnose infectious complications 
during febrile neutropenia and increased CRP. 
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Chapter 9, contains a general discussion of the results presented in this thesis and 
their possible future implications.
Summary

177
Samenvatting
In dit proefschrift wordt een aantal klinische studies beschreven, waarin wordt 
onderzocht wat de meerwaarde is van de FDG-PET/CT scan bij patiënten met een 
ernstige bacteriële infectie. De belangrijkste achterliggende gedachte hierbij is dat 
de ziektelast en zelfs overlijden van patiënten met bacteriële bloedbaan infecties 
voor een deel wordt bepaald door onopgemerkte en daardoor onvoldoende 
behandelde verspreiding van de bacteriën in zogenaamde strooihaarden. Dit 
probleem zou mogelijk ondervangen kunnen worden door vroegtijdige inzet van 
een gevoelige en nauwkeurige vorm van beeldvormende diagnostiek, zoals de 
FDG-PET/CT scan. De FDG-PET/CT scan werd namelijk in diverse studies met succes 
ingezet om de aanwezigheid van gelokaliseerde infecties op te sporen. 
Het op glucose gelijkende Fluorodeoxyglucose (FDG) is gelabeld met een lage dosis 
van het radioactieve Fluor-18 (18F). Het FDG molecuul wordt net als glucose 
opgenomen in de lichaamscellen. Echter vanwege de kleine anatomische verschillen 
van FDG ten opzichte van glucose, kan het FDG niet snel worden afgebroken voor 
gebruik als brandstof van de cel. Gedurende meerdere uren is er om deze reden een 
ophoping van radioactief geladen FDG in cellen aanwezig. Afweercellen (witte 
bloedcellen/leukocyten, met name neutrofielen en macrofagen) die ter plaatse van 
een infectiehaard helpen bij het bestrijden van de infectie, hebben ten tijde van 
zo’n infectie een duidelijk verhoogde glucose behoefte om goed te kunnen 
functioneren. Deze glucoseconsumptie steekt duidelijk af ten opzichte van het niet 
ontstoken weefsel. Het merendeel van het radioactieve FDG zal zich dan ook in 
deze gebieden met actieve leukocyten ophopen. Binnen 1 uur na injectie van FDG 
in de bloedbaan kan met hulp van een PET-scanner (positron emission tomography) 
een driedimensionale afbeelding van het lichaam worden vervaardigd.  Op deze 
afbeelding is met een nauwkeurigheid van enkele millimeters aan te geven of en 
waar zich gebieden met verhoogde FDG-opname bevinden.
Potentiële beperkingen van het inzetten van PET-scanners zijn echter de beperkte 
beschikbaarheid in de ziekenhuizen en de hoge kosten die aan het onderzoek 
verbonden zijn. In een van de onderzoeken werd geanalyseerd of de vroege opsporing 
van strooihaarden de ziekteduur en ziektelast zoveel zou doen afnemen, dat deze 
aanpak kosteneffectief zou blijken te zijn.
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In hoofdstuk 1 worden allereerst de resultaten gepresenteerd van een analyse van 
de literatuur over het inzetten van de FDG-PET/CT scan om infecties te 
diagnosticeren. In totaal werden 35 studies gevonden over de FDG-PET/CT scan, die 
diagnostiek van infecties als belangrijkste onderwerp hadden. In de meeste 
gevallen ging het echter om zogenaamde “case series”, waarin een klein aantal 
patiënten met dezelfde aandoening beschreven werden. FDG-PET/CT was meestal 
verricht naast standaard diagnostische procedures. In het algemeen was de 
gevoeligheid van de FDG-PET/CT scan vergelijkbaar, of beter dan de standaard 
uitgevoerde onderzoeken. De specificiteit van de FDG-PET/CT scan, die aangeeft of 
een afwijkende testuitslag daadwerkelijk betekent dat de aandoening er ook is, was 
in sommige gevallen minder hoog in vergelijking met andere beeldvormende 
technieken. Een belangrijke verklaring voor deze lagere specificiteit is het feit 
dat niet alleen geïnfecteerd weefsel, maar ook andere ontstekingsziekten en 
kwaadaardige ziekten een afwijkend signaal kunnen geven op de FDG-PET/CT scan. 
Indien de FDG-PET/CT scan echter onderdeel uitmaakt van een diagnostisch 
protocol, waarbij met name geprobeerd wordt patienten met een infectie te 
selecteren, dan zal dat de specificiteit ten goede komen. Daarnaast heeft de 
FDG-PET/CT scan als voordeel dat het gehele lichaam wordt afgebeeld, in 
tegenstelling tot veel andere radiologische technieken, waarbij gericht een 
lichaamsdeel in beeld wordt gebracht op basis van lokaliserende klachten. 
Geconcludeerd wordt dat FDG-PET/CT een veelbelovende nieuwe diagnostische 
techniek is bij acute gelokaliseerde infecties.
Bij patiënten met een levensbedreigende bacteriële infectie van de bloedbaan 
(bacteriëmie) op basis van zogenaamde Gram-positieve bacteriën, zoals Staphylococcus 
aureus en Streptococcus spp (SAB en SSB), is beschreven dat verspreiding van de 
bacteriën in de vorm van strooihaarden geregeld voorkomt. In hoofdstuk 2 werd 
de uitkomst van alle 180 patiënten met een SAB of SSB tussen 2002 en 2004 in ons 
eigen ziekenhuis geanalyseerd. Bij zowel SAB, als SSB werd in circa 30% van de 
patiënten een strooihaard aangetoond. Opvallend was dat 30% van de strooihaarden 
geen symptomen had, die de lokatie prijs gaf. In 10% van de gevallen werd de 
strooihaard pas na het overlijden aangetoond. Factoren die geassocieerd waren 
met de aanwezigheid van strooihaarden waren: het starten van antibiotische 
behandeling meer dan 48 uur nadat de eerste tekenen van infectie aanwezig 
waren, het thuis oplopen van de infectie (waarschijnlijk omdat in die gevallen er 
vaak pas later gestart wordt met antibiotica), de aanwezigheid van bacteriële groei 
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in bloedkweken die meer dan 48 uur na start van antibiotische behandeling zij 
afgenomen, aangeboren hart afwijkingen en de aanwezigheid van kunstmateriaal 
(zoals bijvoorbeeld gewrichtsprothesen). In aanwezigheid van een strooihaard was 
het infectie gerelateerde overlijden significant hoger (29 vs 9%).
Naar analogie van meldingen in de literatuur werden ook in het UMC St Radboud 
FDG-PET/CT scans gemaakt bij patiënten met een onbegrepen infectieus 
ziektebeeld. In hoofdstuk 3 werden de uitslagen en de toegevoegde waarde van 
40 opeenvolgende FDG-PET/CT scans retrospectief geanalyseerd. Al deze FDG-PET/
CT scans waren aangevraagd in verband met een sterke klinische verdenking op de 
aanwezigheid van een strooihaard. Gemiddeld waren er reeds 4 conventionele 
beeldvormende onderzoeken verricht op geleide van mogelijk richtinggevende 
symptomen alvorens de FDG-PET/CT scan was aangevraagd. Bij 75% van de 
patiënten werd een strooihaard aangetoond. Ondanks het feit dat er reeds 
aanvullend onderzoek was verricht toonde de FDG-PET/CT scan als eerste een 
klinisch relevante strooihaard aan in 45% van de patiënten. In de resterende 30% 
van de patiënten met een strooihaard bevestigde de FDG-PET/CT scan deze. De 
positief voorspellende waarde was hiermee 92% en de negatief voorspellende 
waarde 100%. De conclusie van dit onderzoek was dat de FDG-PET/CT scan een 
veelbelovende diagnostische techniek kan  worden bij patiënten met een hoge 
verdenking op de aanwezigheid van strooihaarden.
De uitkomsten van bovengenoemde onderzoeken vormden de basis om de 
hypothese te toetsen dat vroege detectie van strooihaarden met hulp van FDG-PET/
CT scans en daarmee tijdige behandeling van deze infectieuze complicaties zou 
leiden tot afname van ziektelast en overlijden. 
In hoofdstuk 4 worden de resultaten van een grote prospectieve studie beschreven. 
115 Patiënten met een normaal aantal witte bloedcellen (niet neutropenische 
patiënten) en een Gram positieve bacteriëmie op basis van Staphylococcus aureus, 
Streptococcus species of Enterococcus species werden in de studie geïncludeerd. 
Voorwaarde was wel dat er tenminste een bekende risicofactor voor de aanwezigheid 
van strooihaarden aanwezig was. Deze patiënten werden geclassificeerd als hoog 
risico patiënten. Een FDG-PET/CT scan werd binnen 2 weken na de eerste positieve 
bloedkweek verricht. De uitkomsten van deze patiënten werden vergeleken met 
een 230 historische controle patiënten uit het UMC Sint Radboud die eenzelfde 
bacteriëmie hadden doorgemaakt in de 4 jaar direct voorafgaande aan de 
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prospectieve studie. Bij de controle patiënten was geen FDG-PET/CT scan verricht. 
Om 2 vergelijkbare patiëntengroepen te krijgen werden voor elke prospectieve 
studie patiënt 2 historische  controle patiënten geselecteerd, rekening houdend 
met het specifieke microorganisme en het exacte risicoprofiel voor het ontwikkelen 
van strooihaarden. In de studiegroep werd bij significant meer patiënten een 
strooihaard gevonden in vergelijking met de controlegroep (68% vs. 36%). Net als in 
de retrospectieve studie werd ook in deze prospectieve studie circa 30% van de 
strooihaarden als eerste gediagnosticeerd door de FDG-PET/CT scan. Het recidief 
percentage daalde van 7.4% naar 2.6% kijkend naar de totale patiënten populatie 
(p=0.09), en van 8.9% naar 1.4% in de groep patiënten met een SAB (p=0.04). 
De totale mortaliteit na 6 maanden was significant lager in de FDG-PET/CT groep 
(32% vs. 19%). De conclusie van dit onderzoek was dat FDG-PET/CT een waardevolle 
aanvulling is in de diagnostiek van hoog risico patiënten met een Gram-positieve 
bacteriëmie die kan leiden tot een afname van de mortaliteit.
In hoofdstuk 5 wordt een kosteneffectiviteit analyse beschreven over de inzet van 
FDG-PET/CT in de vroeg diagnostiek van strooihaarden bij hoog risico patiënten 
met een Gram-positieve bacteriemie. Ten tijde van de klinische studie die 
beschreven wordt in hoofdstuk 4 werden naast uitkomsten van onderzoeken en 
behandeling, tevens de kosten van al deze onderzoeken, behandelingen en 
ligdagen in het ziekenhuis verzameld. De veranderde totale kosten (incrementele 
kosten) op basis van FDG-PET/CT bedroegen €6,303 euro. Deze toename van kosten 
werd echter met name bepaald door de toename van het aantal ligdagen dat nodig 
was voor de behandeling van de gevonden strooihaarden (gemiddeld €4,421). De 
kosten om een overlijden te voorkomen bedroegen €48,325 per patiënt, hetgeen 
ruim beneden de geaccepteerde grens ligt binnen het Nederlandse gezondheids-
zorg stelsel. De conclusie van deze analyse was dat de relatief hoge kosten van een 
FDG-PET/CT niet moesten leiden tot terughoudendheid van deze onderzoeks-
modaliteit bij patiënten met een hoog risico Gram-positieve bacteriemie. 
In hoofdstuk 6 gaat de aandacht met name uit naar de strooihaarden zelf die 
gevonden werden bij het routinematig uitvoeren van aanvullende diagnostiek. In 
deze studie worden het klinische beloop en de infectieuze complicaties bij 115 
hoog risico patiënten met SAB en SSB beschreven die werden onderworpen aan 
een intensieve diagnostische procedure, bestaande uit een FDG-PET/CT en een 
echo van het hart (echocardiografie). Patiënten in deze studie waren afkomstig uit 
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de prospectieve studie beschreven in hoofdstuk 4, aangevuld met de patiënten die 
eerder geëxcludeerd waren, omdat zij primair op een intensive care afdeling waren 
opgenomen. Strooihaarden werden  bij ongeveer 70% van de patiënten aangetoond. 
Endocarditis (hartklep ontsteking), endovasculaire (bloedvatstelsel) infecties, 
longhaarden en spondylodiscitis (tussenwervelschijf infectie) waren de meest 
voorkomende strooihaarden. Strooihaarden werden even vaak gevonden bij SAB 
en SSB. Slechts 41% van de strooihaarden had symptomen die de behandelend arts 
konden helpen bij het lokaliseren van de infectiehaard. Een onbekende intreeplaats 
(port d’entree) van de infectie, het starten van antibiotische therapie >48 uur na de 
eerste tekenen van infectie en de aanwezigheid van vreemd lichaamsmateriaal 
(zoals bv hartklep-, gewrichts- en vaatprotheses) waren de sterkste risicofactoren 
voor de aanwezigheid van een strooihaard. De gemiddelde CRP waarde (verhoogd 
in het bloed aanwezig bij ontsteking/infectie) was significant hoger bij patiënten 
met een strooihaard. Dit fenomeen kan mogelijk gezien worden als een surrogaat 
marker voor de duur van infectie tot aan start van de behandeling. FDG-PET/CT 
toonde als eerste de strooihaard aan in 35% van de patiënten. Daar CT scans, 
echografie en MRI slechts een beperkt deel van het lichaam afbeelden en derhalve 
gericht op basis van lokaliserende klachten aangevraagd moeten worden, hadden 
deze technieken slechts bij een minderheid van de strooihaarden meerwaarde. 
Hoewel het niet definitief bevestigd kon worden, leek de mortaliteit lager bij 
patiënten zonder strooihaard. Vijf van de 31 (16%) patiënten bij wie geen strooihaard 
was aangetoond waren na 6 maanden overleden. Terugkijkend bleken echter 3 van 
deze 5 patiënten zeer waarschijnlijk wel een strooihaard te hebben gehad. Het was 
tijdens het leven echter niet gelukt om de strooihaard te diagnosticeren, omdat de 
patiënt overleden was voordat de diagnostiek was afgerond.
Bij het analyseren van de strooihaarden studie uit hoofdstuk 4 viel het op dat in 
tegenstelling tot de prospectieve studie groep, waar echocardiografie routinematig 
was aangeboden, er in de historische controlegroep bij veel minder patiënten een 
echo van het hart was gemaakt (82% vs 27%). Hierdoor leek een unieke kans te 
bestaan om twee verschillende echocardiografische regimes met elkaar te 
vergelijken. In hoofdstuk 7 worden de resultaten van deze analyse beschreven. Een 
nieuw ontstane cardiale soufle bij een patiënt met een Gram-positieve bacteriemie 
is een van de belangrijkste klinische afwijkingen bij het lichamelijk onderzoek die kan 
duiden op de aanwezigheid van endocarditis. In het verleden werd een echo van 
het hart slechts bij 20% van de patiënten zonder een cardiale soufle en een 
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Gram-positieve bacteriemie aangevraagd. Bij de prospectieve studie patiënten 
werd een echo van het hart verricht bij 70% van de patiënten zonder cardiale soufle. 
Een cardiale soufle bleek uiteindelijk slechts bij 64% van de patiënten aanwezig in 
de prospectieve studie groep. Het lijkt er derhalve op dat in het verleden de 
beslissing om diagnostiek te verrichten naar de aanwezigheid van endocarditis 
voor een groot deel afhing van de klinische verschijnselen en niet van een risico-
inschatting. In de prospectieve groep werd gedurende het leven bij significant 
meer patiënten endocarditis aangetoond (19% vs. 7%). Opvallend was dat de 
mortaliteit in de prospectieve studiegroep significant lager was dan de in de groep 
waarbij in het verleden endocarditis was aangetoond. De meest waarschijnlijke 
verklaring hiervoor is dat op basis van de klinische beoordeling alleen, slechts de 
meer gevorderde en daardoor ziekere patiënten gevonden worden. Een deel van 
de patiënten komt dan te overlijden als gevolg van een niet ontdekte  endocarditis. 
Het routinematig uitvoeren van echocardiografie zou, net als het routinematig 
uitvoeren van FDG-PET/CT kunnen leiden tot een vroegtijdige behandeling van 
infectieuze complicaties, met een afname van mortaliteit als gevolg. 
Koorts in de neutropenische fase (verlaagd aantal witte bloedcellen, met name 
neutrofielen) direct volgend op chemotherapeutische behandeling is een frequent 
voorkomend fenomeen. In lang niet alle gevallen is dit het gevolg van een 
onderliggende infectie. In hoofdstuk 8 wordt onderzocht of het indicatiegebied 
van FDG-PET/CT verder uitgebreid kan worden naar de groep patiënten die als 
gevolg van chemotherapeutische behandeling een verlaagd aantal witte 
bloedcellen heeft. Dit is belangrijk om te exploreren, omdat de neutrofielen die zich 
in ontstekinghaarden bevinden voor een belangrijk deel de toegediende FDG 
consumeren en derhalve verantwoordelijk worden geacht voor het afwijkende 
signaal op de FDG-PET/CT scan. Hun afwezigheid zou kunnen leiden tot een 
afgenomen gevoeligheid van de FDG-PET/CT scan, daar waar het gaat om het 
aantonen van infecties. In deze studie werd bij 28 opeenvolgende patiënten tijdens 
de neutropenische fase na chemotherapie, die gegeven was in verband met een 
hematologische maligniteit, een FDG-PET/CT scan gemaakt. De scans werden 
gemaakt op het moment dat de ontstekingswaarde CRP in het bloed verhoogd was 
(>50 mg/ml). Op dat moment had 93% van de patiënten inderdaad ook koorts. 
Afwijkende FDG opname was aanwezig in 26 van de 28 patiënten. Een duidelijke 
correlatie werd aangetoond tussen FDG opname ter plaatse van de centraal veneuze 
katheter en de aanwezigheid van een septische tromboflebitis (infectie van een 
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bloedstolsel in een ader). Ook bleek dat FDG opname in de longen in de meeste 
gevallen gepaard ging met een diepe schimmel infectie in de longen. Ontstekings-
reacties van de darm als gevolg van chemotherapie zijn een bekend fenomeen. 
Bekend is dat deze ontstekingsreacties gepaard kunnen gaan met koorts en CRP 
productie. Gedacht wordt dat een aantal darmbacteriën, zoals Streptococcus mitis 
die met name in de mond- en keelholte en slokdarm leeft, als gevolg van de 
beschadigde darmwand in de bloedbaan terecht kunnen komen. Sterk afwijkende 
FDG opname in het maagdarm stelsel werd bij nagenoeg alle patiënten gevonden. 
Een trend werd gevonden tussen afwijkende FDG opname in de slokdarm en het 
optreden van een bloedbaan infectie met Streptococcus mitis. Deze correlatie was er 
niet voor wat betreft FDG opname in de dikke darm. De conclusie van deze studie 
was dat FDG-PET/CT ook gebruikt kan worden om infectiehaarden te detecteren bij 
patiënten met koorts en CRP stijging tijdens de neutropenische fase na 
chemotherapie. 
In Hoofdstuk 9 wordt aan de hand van de uitkomsten van de studies besproken 
wat de plaats van FDG-PET/CT kan worden in de diagnostiek van moeilijk te 
detecteren infecties. Ook worden aanbevelingen gegeven voor eventueel 
toekomstig onderzoek. 
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Dankwoord
En toen was het boekje uit….Weinig zaken zijn echt zeker in ons vak. Een daarvan is 
dat je de tijd moet nemen om het begin en eind van een verhaal te definiëren. 
Een van de belangrijke lessen uit het proefschrift is dan ook, denk ik, dat het verhaal 
van de patiënt niet begint bij de opname in het ziekenhuis, maar al ver daar voor 
toen hij nog thuis was. Die voorgeschiedenis verbergt vaak een eerste aanwijzing 
voor wat er onder het oppervlak kan schuilgaan. Niet alles is precies zoals het op het 
eerste gezicht lijkt. Ook eindigt het verhaal van de patiënt vaak niet bij ontslag. 
Goed, misschien bij bloedvergiftiging door een Gram positieve verwekker kan men 
nu het verhaal met wat meer zekerheid afsluiten bij ontslag als een infectioloog, 
microbioloog en nucleair geneeskundige hebben meegekeken….. 
Tot deze ontdekkingen kwam ik niet alleen de afgelopen  6 a 7 jaar. Ik wil graag een 
ieder bedanken die een bijdrage heeft geleverd aan het tot stand komen van dit 
proefschrift. Volgens goed gebruik wil ook ik natuurlijk een aantal mensen in het 
bijzonder bedanken. 
Professor dr. W.J.G. Oyen, beste Wim, ik mag hier geen lang betoog van je houden 
over, wat jij “gewoon het werk van de promotoren” noemt. Oke….toch veel dank. 
Met name het feit dat je telkens weer zo laagdrempelig en zo snel mij van 
antwoorden kon voorzien, gaf vertrouwen en de wil om door te zetten (moet ik 
toch even kwijt!).
Professor dr. BJ Kullberg, beste Bart Jan, het wachten op jou commentaar (….) blijkt 
altijd meer dan de moeite waard. Met name is jou tekstuele “fine-tuning” onmisbaar. 
Dacht ik, naar aanleiding van de “overige commentaren”, het duidelijk te hebben 
opgeschreven, lukt het jou toch weer om er op sommige punten doorheen te prikken. 
Het slikken uit het begin, heeft al lang plaats gemaakt voor de wetenschap dat je op 
deze manier samen tot het beste resultaat komt. Dank voor het vertrouwen dat je me 
gegeven hebt, sinds je me in 2003 aannam voor de opleiding tot infectioloog.  
Beste Chantal Bleeker, binnen het UMC ben jij diegene bij wie ik altijd terecht kan 
voor de nodige ruggespraak. Zowel inhoudelijk voor wat betreft het onderzoek, 
patiënt gerelateerde zaken, je kennis over opleiding en implementatie van diverse 
protocollen, maar ook niet te vergeten, de niet-vakinhoudelijke bespiegelingen 
over dit alles. Heel veel dank daarvoor.
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Beste Nicole Blijlevens en Peter Donnelly, (en verpleging E00), kan me voorstellen 
dat het af en toe moeilijk was om grip op me te krijgen. Hoorde niet tot de echte 
hematologie groep, werkte vervolgens niet eens meer voltijds in het UMC en toch 
zat ik aan “jullie” patiënten. Ik heb het echter van het begin af aan een hele leerzame 
en leuke onderneming gevonden, om me in “jullie” nest te begeven. Peter speciaal 
ook dank voor je beschouwingen ten aanzien van mijn onderzoek, onderzoek in het 
algemeen en het uitvoeren van onderzoek in het UMC (en de diverse spelers daarin).
Beste medewerkers van de afdeling nucleaire geneeskunde, in het bijzonder de 
laboranten op de PET-afdeling. Altijd vriendelijk en behulpzaam als ik weer “last 
minute” met een aanvraag voor de dag erop kwam.
Beste Paul Krabbe en Eddy Adang van de afdeling epidemiologie, biostatistiek en 
HTA, heel veel dank voor jullie hulp en commentaar bij zowel de oorspronkelijke 
subsidie aanvraag, als de meerderheid van de artikelen, ondanks de radiostiltes van 
mijn kant die telkens tussen de diverse exercities zat.
Beste medefellows infectieziekten die hun bijdrage hebben geleverd bij het zoeken 
naar geschikte kandidaten. Een deel van jullie heeft naast hun hand en spandiensten 
voor het onderzoek, mij ook nog eens geholpen tijdens periodes van personele 
schaarste in de Sint Maartenskliniek, zodat ik op zijn minst de afspraken met mijn 
promotoren kon nakomen in het Radboud. 
Beste Marloes, eigenlijk heb jij in de begindagen, toen er nog nauwelijks iets 
gepubliceerd was, de essentiële bijdrage geleverd, die nodig was om het vliegwiel 
op gang te krijgen, terwijl ik nog bezig was een balans te vinden tussen het chef de 
clinique schap op afdeling EOV en het onderzoek. Jij maakte een belangrijk begin 
met het vullen van de retrospectieve database. Het eerste artikel kreeg vervolgens 
met name dankzij jou zijn vorm. 
Natuurlijk moet ik hier ook alle patiënten bedanken die bereid zijn geweest om, 
ondanks hun ingrijpende ziekte een onderzoek te ondergaan dat best behoorlijk wat 
inspanning vergt, terwijl ze niet wisten of het hen persoonlijk verder zou helpen. 
Beste Patrick Sturm, jij was mijn aanspreekpunt op de afdeling microbiologie waar 
het ging om logistieke zaken. Daarnaast was jou kritische blik en soms net iets 
andere (maar overbrugbare) kijk op de zaak, met name waardevol.
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Beste medeauteurs, voor zover ik jullie niet al genoemd heb, dank ik voor hun 
waardevolle bijdragen aan de diverse artikelen.
Beste Professor J.W.M. van der Meer, beste Jos. Hoewel ik niet uit jou kweekvijver 
kwam, ben jij wel diegene die mij de kans heeft gegeven om aan het UMC St 
Radboud internist te worden. Niet altijd van dichtbij, maar uiteindelijk wel op de 
essentiële momenten heb je me met rake handreikingen de juiste weg gewezen. 
Beste Willem, Lieve Hester, met ieder van jullie heb ik en heeft ons gezin zijn eigen 
verhaal. Verhalen die gelukkig meestal niet over het ziekenhuis gaan, maar over de 
kinderen die elkaar kennen als haver en gort, over samen skiën, samen eten en drinken, 
samen zijn. Wat een eer dat jullie mijn paranimfen willen zijn, dank voor dit alles!
Lieve mama, ik heb nog gekeken of 26 januari beschikbaar was…. Natuurlijk had 
papa (†) hier ook bij willen zijn….Zonder jullie en de laatste (bijna) 11 jaar alleen jou 
onvoorwaardelijke steun op alle fronten was ik/waren we niet zover gekomen. Ik 
dank je daar ongelooflijk veel voor.
Lieve Dagmar, Thymen, Fleur en Gijs, het boekje is af. …… Ja, ik heb ’s avonds wel veel 
achter de computer gezeten, zodat ik niet altijd tijd had om jullie uit een gewoon 
boek voor te lezen. Dat gaat veranderen…en daarnaast…. mogen jullie misschien toch 
nog aan mijn laptop zitten voordat die het helemaal begeeft.
Lieve, lieve Els... en toen was het boekje uit, maar het werk dus nog niet af. Je was er 
wellicht al bang voor... Ja natuurlijk, we zijn het thuis altijd samen blijven doen, maar de 
verhouding was niet altijd evenredig en dat gaat veranderen. Wat heb je ongelooflijk 
veel voor ons gedaan de laatste jaren. Dankzij jou keuze om er ten alle tijden te zijn voor 
ons kost baarste bezit, onze 4 kinderen, waarbij je zelfs een stap terug hebt gedaan in je 
werk, kon ik meeliften, mijn specialisatie afmaken en dat combineren met dit onderzoek. 
Daarnaast ben ik ook ontzettend trots op je. Zonder dat je het zelf altijd door hebt, of beter, 
er echt in durft te geloven, heb je de tijd “waarin je alleen maar thuis zat (jou woorden)” 
dusdanig benut dat je alleen maar verder groeide. Van gastouder bij de hockeyclub ben 
je nu voorzitster van de jeugdcommissie met verantwoordelijkheid over het wel en wee 
van 400 kinderen. De internationale club van 40 eigenaren van het complex bij Parijs 
heeft je gevraagd in hun bestuur en als klap op de vuurpijl heb je nu een overkoepelende 
functie in een Nijmeegs ziekenhuis. Els je was en blijft mijn drijfveer, ik houd van je.
Dankwoord
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List of abbreviations
AHA=  American Heart Association
ALL=  Acute lymphatic lymphoma
AML=  Acute myeloid leukaemia
CAPD=  Continuous ambulatory peritoneal dialysis
CDI=  Clinically defined infection 
CEAC=  Cost-effectiveness  acceptability curve
CGD=  chronic granulomatous disease
CNS=  Central nervous system
CoNS=  Coagulase negative staphylococcal-bacteraemia
CRP=  C-reactive protein
CT=  computed tomography
CVC=  Central venous catheter
EANM=  European Association of Nuclear Medicine
EORTC=  European Organisation for research and treatment of cancer
ERCP=  Endoscopic retrograde cholangiopancreatography
FDG-PET/CT=   18F-Fluorodeoxyglucose-positron emission tomography in combination  
with low-dose Computer Tomography
FUO=  fever of unknown origin 
GLUT1=  Glucose transporter 1
HL=  Hodgkin lymphoma
HRCT=  High-Resolution-CT 
HSCT=  Hematologic stem cell transplantation
ICER =  Incremental cost effectiveness ratio
ICU=  Intensive Care Unit
ID consultancy=  Infectious diseases specialist consultancy 
IFD=  Invasive fungal disease
IV=  Intravenous
MBI=  Microbiologically defined infection
MDS=  Myelodysplastic syndrome
MM=  Multiple myeloma
MRI=  Magnetic resonance imaging
NHL=  Non-Hodgkin Lymphoma
NPV=  Negative predictive value
PPV=  Positive predictive value
SAB=  Staphylococcus aureus bacteraemia 
SSB=  Streptococcus spp. Bacteraemia
SUV=  Standardised uptake value
TEE=  Transesophageal echocardiography
TTE=  Transthoracic echocardiography
UH=  University Hospital 
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Fidel Vos is geboren op 26 oktober 1969 te Voorburg. Vanuit Pijnacker fietste hij 
dagelijks naar het Huygens Lyceum te Voorburg, alwaar hij in 1988 zijn VWO diploma 
haalde. Vanaf 1988 studeerde hij geneeskunde aan de Rijks Universiteit Leiden. In 
1994 haalde hij zijn artsenexamen. In 1992 deed hij gedurende een 3 maanden 
durende stage in Suriname onderzoek naar de parasiet Strongyloides stercoralis. 
Voorafgaand aan de coschappen werkte hij 2 maanden in het ziekenhuis van Aruba 
en tijdens zijn afsluitend coschap werkte hij 4 maanden in een Malawiaans streek-
ziekenhuis. Vanaf zijn eindstage broeide al een voorliefde voor infectieziekten. 
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Breed en later dr Hoorntje in opleiding te komen. Omdat de infectieziekten steeds 
meer lonkte solliciteerde hij in 2002 bij Jos van der Meer en Bart Jan Kullberg, om 
het laatste jaar van de opleiding interne geneeskunde in het cluster Nijmegen te 
mogen afronden en vervolgens in opleiding te komen als infectioloog. Hoewel dus 
niet oorspronkelijk uit de Nijmeegse vijver afkomstig, geschiedde het wel zo. In het 
laatste jaar van de opleiding infectiologie kreeg hij van de hoogleraren Jos van de 
Meer, Bart Jan Kullberg (beide interne geneeskunde) en Wim Oyen (nucleaire 
geneeskunde) de kans om een promotietraject te starten, voortbordurend op de 
ideeën van collega internist Chantal Bleeker. Om overdag de kost te verdienen werd 
al snel een detachering geregeld met de Sint Maartenskliniek in Nijmegen om als 
consulent interne geneeskunde aan het werk te gaan. Deze baan groeide echter in 
korte tijd uit tot bijna voltijds proporties, waarbij de internist in alle geledingen van 
dat ziekenhuis mee is gaan tellen. Inmiddels zijn er 3 internisten werkzaam en wordt 
op diverse fronten, zowel in de patiëntenzorg, als in onderzoek, samengewerkt met 
de Nijmeegse ziekenhuizen. 
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